



## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 5 : <b>C12P 7/64, C12N 5/00 C07K 15/00, C07H 15/12</b>		A1	(11) International Publication Number: <b>WO 92/03564</b> (43) International Publication Date: <b>5 March 1992 (05.03.92)</b>
<p>(21) International Application Number: <b>PCT/US91/05801</b></p> <p>(22) International Filing Date: <b>15 August 1991 (15.08.91)</b></p> <p>(30) Priority data:            568,493 15 August 1990 (15.08.90) US            721,761 26 June 1991 (26.06.91) US</p> <p>(60) Parent Application or Grant            (63) Related by Continuation            US 568,493 (CIP)            Filed on 15 August 1990 (15.08.90)</p> <p>(71) Applicant (for all designated States except US): <b>CALGENE, INC. [US/US]; 1920 Fifth Street, Davis, CA 95616 (US).</b></p>			
<p>(72) Inventors: and            (75) Inventors/Applicants (for US only): <b>KNAUF, Vic. C. [US/US]; 1013 Hillview Lane, Winters, CA 95694 (US). THOMPSON, Gregory A. [US/US]; 5127 Cowell Blvd., Davis, CA 95616 (US).</b></p> <p>(74) Agents: <b>LASSEN, Elizabeth et al.; Calgene, Inc., 1920 Fifth Street, Davis, CA 95616 (US).</b></p> <p>(81) Designated States: <b>AT (European patent), BE (European patent), CA, CH (European patent), DE (European patent), DK (European patent), ES (European patent), FR (European patent), GB (European patent), GR (European patent), IT (European patent), JP, LU (European patent), NL (European patent), SE (European patent), US.</b></p> <p><b>Published</b>  <i>With international search report.            Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i></p>			

(54) Title: **PLANT FATTY ACID SYNTHASES**

**(57) Abstract**

By this invention, compositions and methods of use related to  $\beta$ -ketoacyl-ACP synthase, hereinafter also referred to as "synthase", are provided. Also of interest are methods and compositions of amino acid and nucleic acid sequences related to biologically active plant synthase(s). In particular, synthase protein preparations which have relatively high turnover (specific activity) are of interest for use in a variety of applications, *in vitro* and *in vivo*. Especially, protein preparations having synthase I and/or synthase II activities are contemplated hereunder. Synthase activities are distinguished by the preferential activity towards longer and shorter acyl-ACPs. Protein preparations having preferential activity towards shorter chain length acyl-ACPs are synthase I-type. Synthases having preferential activity towards longer chain length acyl-ACPs are synthase II-type. Of special interest are synthases obtainable from *Ricinus communis*.

**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	ES	Spain	MG	Madagascar
AU	Australia	FI	Finland	ML	Mali
BB	Barbados	FR	France	MN	Mongolia
BE	Belgium	GA	Gabon	MR	Mauritania
BF	Burkina Faso	GB	United Kingdom	MW	Malawi
BC	Bulgaria	GN	Guinea	NL	Netherlands
BJ	Benin	GR	Greece	NO	Norway
BR	Brasil	HU	Hungary	PL	Poland
CA	Canada	IT	Italy	RO	Romania
CF	Central African Republic	JP	Japan	SD	Sudan
CG	Congo	KP	Democratic People's Republic of Korea	SE	Sweden
CH	Switzerland	KR	Republic of Korea	SN	Senegal
CI	Côte d'Ivoire	LI	Liechtenstein	SU+	Soviet Union
CM	Cameroon	LK	Sri Lanka	TD	Chad
CS	Czechoslovakia	LU	Luxembourg	TG	Togo
DE*	Germany	MC	Monaco	US	United States of America

+ Any designation of "SU" has effect in the Russian Federation. It is not yet known whether any such designation has effect in other States of the former Soviet Union.

## PLANT FATTY ACID SYNTHASES

This application is a continuation-in-part of USSN  
07/568,493 filed on August 15, 1990, and a continuation-in-  
part of USSN 07/721,761 filed June 26, 1991.

Field of Invention

The present invention is directed to synthase enzymes relevant to fatty acid synthesis in plants, protein preparations, amino acid and nucleic acid sequences related thereto, and methods of use for such compositions.

## Introduction

15 Background

Plant oils are used in a variety of industrial and edible uses. Novel vegetable oils compositions and/or improved means to obtain oils compositions, from biosynthetic or natural plant sources, are needed. Depending upon the intended oil use, various different fatty acid compositions are desired.

For example, in some instances having an oilseed with a higher ratio of oil to seed meal would be useful to obtain a desired oil at lower cost. This would be typical of a high value oil product. In some instances, having an oilseed with a lower ratio of oil to seed meal would be useful to lower caloric content. In other uses, edible plant oils with a higher percentage of unsaturated fatty acids are desired for cardio-vascular health reasons. And alternatively, temperate substitutes for high saturate tropical oils such as palm and coconut, would also find uses in a variety of industrial and food applications.

One means postulated to obtain such oils and/or modified fatty acid compositions is through the genetic engineering of plants. However, in order to genetically engineer plants one must have in place the means to transfer genetic material to the plant in a stable and heritable manner. Additionally, one must have nucleic acid

sequences capable of producing the desired phenotypic result, regulatory regions capable of directing the correct application of such sequences, and the like. Moreover, it should be appreciated that in order to produce a desired 5 phenotype requires that the Fatty Acid Synthetase (FAS) pathway of the plant is modified to the extent that the ratios of reactants are modulated or changed.

Higher plants appear to synthesize fatty acids via a common metabolic pathway. In developing seeds, where fatty 10 acids attached to triglycerides are stored as a source of energy for further germination, the FAS pathway is located in the proplastids. The first step is the formation of acetyl-ACP (acyl carrier protein) from acetyl-CoA and ACP catalyzed by the enzyme, acetyl-CoA:ACP transacylase (ATA). 15 Elongation of acetyl-ACP to 16- and 18- carbon fatty acids involves the cyclical action of the following sequence of reactions: condensation with a two-carbon unit from malonyl-ACP to form a  $\beta$ -ketoacyl-ACP ( $\beta$ -ketooacyl-ACP synthase), reduction of the keto-function to an alcohol ( $\beta$ -ketoacyl-ACP reductase), dehydration to form an enoyl-ACP ( $\beta$ -hydroxyacyl-ACP dehydrase), and finally reduction of the enoyl-ACP to form the elongated saturated acyl-ACP (enoyl-ACP reductase).  $\beta$ -ketoacyl-ACP synthase I, catalyzes 20 elongation up to palmitoyl-ACP (C16:0), whereas  $\beta$ -ketoacyl-ACP synthase II catalyzes the final elongation to stearoyl-ACP (C18:0). Common plant unsaturated fatty acids, such as oleic, linoleic and  $\alpha$ -linolenic acids found in storage 25 triglycerides, originate from the desaturation of stearoyl-ACP to form oleoyl-ACP (C18:1) in a reaction catalyzed by a soluble plastid  $\Delta$ -9 desaturase (also often referred to as "stearoyl-ACP desaturase"). Molecular oxygen is required 30 for desaturation in which reduced ferredoxin serves as an electron co-donor. Additional desaturation is effected sequentially by the actions of membrane bound  $\Delta$ -12 desaturase and  $\Delta$ -15 desaturase. These "desaturases" thus 35 create mono- or polyunsaturated fatty acids respectively. A third  $\beta$ -ketoacyl-ACP synthase has been reported in *S. oleracea* leaves having activity specific toward very

short acyl-ACPs. This acetoacyl-ACP synthase or "β-ketoacyl-ACP" synthase III has a preference to acetyl-CoA over acetyl-ACP, Jaworski, J.G., et al., *Plant Phys.* (1989) 90:41-44. It has been postulated that this enzyme may be 5 an alternate pathway to begin FAS, instead of ATA.

Obtaining nucleic acid sequences capable of producing a phenotypic result in FAS, desaturation and/or incorporation of fatty acids into a glycerol backbone to produce an oil is subject to various obstacles including 10 but not limited to the identification of metabolic factors of interest, choice and characterization of a protein source with useful kinetic properties, purification of the protein of interest to a level which will allow for its amino acid sequencing, utilizing amino acid sequence data 15 to obtain a nucleic acid sequence capable of use as a probe to retrieve the desired DNA sequence, and the preparation of constructs, transformation and analysis of the resulting plants.

Thus, the identification of enzyme targets and useful 20 plant sources for nucleic acid sequences of such enzyme targets capable of modifying fatty acid compositions are needed. Ideally an enzyme target will be amenable to one or more applications alone or in combination with other nucleic acid sequences, relating to increased/decreased oil 25 production, the ratio of saturated to unsaturated fatty acids in the fatty acid pool, and/or to novel oils compositions as a result of the modifications to the fatty acid pool. Once enzyme target(s) are identified and qualified, quantities of protein and purification protocols 30 are needed for sequencing. Ultimately, useful nucleic acid constructs having the necessary elements to provide a phenotypic modification and plants containing such constructs are needed.

35

#### Brief Description of the Figures

Figure 1 shows the time course of inactivation of synthase activities in the first peak of synthase activity from ACP-affinity chromatography by 5 μM cerulenin. At the

outset of the experiment, the activity with C16:0-ACP is approximately twice that with C10:0-ACP, indicating an enrichment for type-II synthase in the sample. The graph shows that activity with C16:0-ACP, representing type-II synthase is virtually insensitive to cerulenin, while activity with C10:0-ACP is inhibited by greater than 80% after 10 minutes. The remaining activity with C10:0-ACP is probably low activity of type-II synthase in the sample with the C10:0-ACP substrate (approximately 10% of the activity with C16:0-ACP); this means that type-I synthase is completely inactivated at this cerulenin concentration by 15 min. (heavy dotted line).

Figure 2 provides partial amino acid sequence of peptides from the *R. communis* 50 kD  $\beta$ -ketoacyl ACP synthase protein listed in order found in cDNA clone. Each fragment represents amino acid sequence obtained from an HPLC purified fraction resulting from digestion of the 50 kD protein with trypsin or endoproteinase gluC. F1 shows amino terminal protein sequence obtained from the undigested 50 kD protein. A lower case x represents a sequence cycle where it was not possible to identify the amino acid residue. The positions with two amino acids represents sequences of two nearly identical peptides with a clear difference in sequence at the indicated position, suggesting microheterogeneity of the 50 kD protein.

Figure 3 provides partial amino acid sequence of peptides from the *R. communis* 46 kD  $\beta$ -ketoacyl ACP synthase protein. Each fragment labeled with a KR represents amino acid sequence obtained from an HPLC purified fraction resulting from digestion of the 46 kD protein with trypsin. Amino terminal protein sequence obtained from the undigested 46 kD protein is also shown (NT). "x" is as defined in Fig. 2.

Figure 4 provides the oligonucleotide primers used in PCR from the *R. communis*  $\beta$ -ketoacyl-ACP synthase 50 kD peptides KR4 and KR16. Primers are shown in one orientation only. Oligonucleotides in both orientations

were used as the order of peptides KR4 and KR16 in the synthase protein was not known.

Figure 5 provides cDNA and translated amino acid sequences of a 50 kD *R. communis* synthase factor B gene. 5 Figure 5A provides preliminary cDNA sequence and the corresponding translational peptide sequence derived from the cDNA clone, pCGN2765 (2-8), which encodes the 50 kD synthase protein. The cDNA includes both the postulated transit peptide sequence (amino acids 1-42) and the 10 sequence encoding the mature protein. Figure 5B provides the 2-8 sequence with additional 3' untranslated sequence.

Figure 6 provides amino acid sequence comparisons of the 50 kD protein sequence with other known synthase sequences. Figure 6A shows protein sequence homology of 15 the translated amino acid sequence of the 50 kD clone with the FabB synthase gene from *E. coli*. The top line is translated amino acid sequence from the cDNA encoding the 50 kD synthase protein and the bottom line is translated amino acid sequence of the *E. coli* synthase encoded by 20 FabB. Figure 6B shows protein sequence homology of the translated amino acid sequence of the 50 kD clone with "ORF-1" of the polyketide synthesis gene from *Streptomyces*. The top line is ORF-1 translated amino acid sequence and the bottom line is translated amino acid sequence from the 25 cDNA encoding the 50 kD synthase protein.

Figure 7 provides approximately 2 kb of genomic sequence of Bce4.

Figure 8 provides a cDNA sequence and the corresponding translational peptide sequence derived from 30 *C. tinctorius* desaturase. The cDNA includes both the plastid transit peptide sequence (amino acids 1-33) and the sequence encoding the mature protein.

Figure 9 provides preliminary partial cDNA sequence of *Brassica campestris* desaturase. Figure 4A represents 35 partial DNA sequence of a 1.6 kb clone, pCGN3235, from the 5' end of the clone. Figure 4B represents partial DNA sequence of a 1.2 kb clone, pCGN3236, from the 5' end of the clone. Initial sequence from the 3' ends of the two

*Brassica campestris* desaturase clones, indicates that pCGN3236 is a shorter clone from the same gene as pCGN3235.

Figure 10 provides cDNA and translated amino acid sequences of a *R. communis* 46 kD synthase factor A gene.

5       Figure 11 provides cDNA and translated amino acid sequences of *Brassica* synthase factor B genes. Figure 11A provides sequences of the cDNA insert of pCGN3248. Figure 11B provides sequences of clone 4A.

10      Figure 12 provides a comparison of synthase amino acid sequences. "RC46" is a portion of the translated amino acid sequence of the *Ricinus communis* synthase factor A gene. "RC50" is a portion of the translated amino acid sequence of the *R. communis* synthase factor B gene. "BC50" is a portion of the translated amino acid sequence of the 15 *Brassica* factor B gene of pCGN3248. "fabB" represents translated amino acid sequence of an *E. coli* synthase I gene (Kauppinen et al., Carlsberg Res. Commun. (1988) 53:357-370).

20

#### Summary of the Invention

By this invention, compositions and methods of use related to  $\beta$ -ketoacyl-ACP synthase, hereinafter also referred to as "synthase", are provided. Also of interest are methods and compositions of amino acid and nucleic acid 25 sequences related to biologically active plant synthase(s).

In particular, synthase protein preparations which have relatively high turnover (specific activity) are of interest for use in a variety of applications, *in vitro* and *in vivo*. Especially, protein preparations having synthase 30 I and/or synthase II activities are contemplated hereunder. Synthase activities are distinguished by the preferential activity towards longer and shorter acyl-ACPs. Protein preparations having preferential activity towards shorter chain length acyl-ACPs are synthase I-type. Synthases having preferential activity towards longer chain length 35 acyl-ACPs are synthase II-type. Of special interest are synthases obtainable from *Ricinus communis*.

Nucleic acid sequences encoding a synthase biologically active in a host cell may be employed in nucleic acid constructs to modulate the amount of synthase present in the host cell, especially the relative amounts 5 of synthase I-type and synthase II-type proteins when the host cell is a plant host cell. A synthase may be produced in host cells for harvest or as a means of effecting a contact between the synthase and its substrate. Host cells include prokaryotes and/or eukaryotes. Plant host cells 10 containing recombinant constructs encoding a synthase, as well as plants and cells containing modified levels of synthase protein(s) are also provided.

By this invention, methods of catalyzing the condensation reaction between an acyl-ACP having a chain 15 length of C<sub>2</sub> to C<sub>16</sub> and malonyl-ACP is effected by contacting an acyl-ACP and malonyl-ACP substrates with a synthase obtainable from *R. communis* under conditions which permit the condensation of the reactants. Although the reaction employs a *R. communis* synthase, this reaction may 20 occur outside of a *R. communis* cell. Using various techniques, this reaction can be conducted *in vitro* or in other plant cell hosts *in vivo*. For example, one may grow a plant cell having integrated in its genome an expression construct having, in the 5' to 3' direction of 25 transcription, a plant expressible promoter, a DNA sequence encoding a synthase obtainable from *R. communis* and a transcription termination region. Of interest is the modulation of synthases alone and in conjunction with each other. For expression in plants, the use of promoters 30 capable of preferentially directing transcription and translation in embryo tissue to regulate the expression of a synthase may be desired.

In addition, nucleic acid constructs may be designed to decrease expression of endogenous synthase in a plant 35 cell as well. One example is the use of an anti-sense synthase sequence under the control of a promoter capable of expression in at least those plant cells which normally produce the enzyme.

Additionally, one may wish to coordinate expression of a synthase with the expression of other introduced sequences encoding other enzymes related to fatty acid synthesis, for example plant thioesterases, especially 5 medium-chain thioesterases, desaturases, especially  $\Delta$ -9 desaturases, and the like. When nucleic acid constructs encoding such factors are prepared for introduction into a plant cell, the transcriptional initiation regions will most likely be different from each other.

10       Synthase preparations obtained from *R. communis*, substantially free of protein contaminants are described. *R. communis* synthase preparations may be obtained which demonstrate synthase I-type activity and those which demonstrate synthase II-type activity. Enzyme specific 15 activities of up to 16  $\mu\text{mol}/\text{min}/\text{mg}$  protein and 1.7  $\mu\text{mol}/\text{min}/\text{mg}$  protein have been observed for synthase I type and synthase II-type protein preparations, respectively. Proteins or protein preparations displaying such activities, alone or in combination, may be contacted with 20 fatty acid synthesis substrates to drive synthase condensation reactions. The amino acid and nucleic acid sequences corresponding to the various preparations may be deduced and used to obtain other homologously related synthases.

25

#### Detailed Description of the Invention

A plant synthase of this invention includes any sequence of amino acids, polypeptide, peptide fragment or other protein preparation, whether derived in whole or in 30 part from natural or synthetic sources which demonstrates the ability to catalyze a condensation reaction between an acyl-ACP or acyl-CoA having a chain length of C<sub>2</sub> to C<sub>16</sub> and malonyl-ACP in a plant host cell. A plant synthase will be capable of catalyzing a synthase reaction in a plant host 35 cell, i.e., *in vivo*, or in a plant cell-like environment, i.e., *in vitro*. Typically, a plant synthase will be derived in whole or in part from a natural plant source.

In addition, synthase from other sources such as bacteria or lower plants, may also be useful in plants and thus be considered a plant synthase in this invention. For example, the *E. coli* synthase protein encoded by the fab B gene is shown herein to have homology to plant synthase proteins.

Synthase I demonstrates preferential activity towards acyl-ACPs having shorter carbon chains, C<sub>2</sub>-C<sub>14</sub>; synthase II demonstrates preferential activity towards acyl-ACPs having longer carbon chains, C<sub>14</sub>-C<sub>16</sub>. Synthase III demonstrates preferential activity towards acyl-CoAs having very short carbon chains, C<sub>2</sub> to C<sub>6</sub>. Other plant synthases may also find applicability by this invention, including synthase III type activities. Differences between synthases I, II, and III are also observed in inhibition with cerulenin. Synthase I is most sensitive, synthase II less sensitive and synthase III the least sensitive to cerulenin. In Fig. 1, a time course assay of cerulenin effects on synthase I and synthase II activities is provided. It can be seen from these results, that synthase II has some synthase I-type activities.

Synthases include modified amino acid sequences, such as sequences which have been mutated, truncated, increased and the like, as well as such sequences which are partially or wholly artificially synthesized. Synthases and nucleic acid sequences encoding synthases may be obtained by partial or homogenous purification of plant extracts, protein modeling, nucleic acid probes, antibody preparations, or sequence comparisons, for example. Once purified synthase is obtained, it may be used to obtain other plant synthases by contacting an antibody specific to *R. communis* synthase with a plant synthase under conditions conducive to the formation of an antigen:antibody immunocomplex and the recovery of plant synthase which reacts thereto. Once the nucleic acid sequence encoding a synthase is obtained, it may be employed in probes for further screening or used in genetic engineering constructs

for transcription or transcription and translation in host cells, especially plant host cells.

Recombinant constructs containing a nucleic acid sequence encoding a synthase and a heterologous nucleic acid sequence of interest may be prepared. By heterologous is meant any sequence which is not naturally found joined to the synthase sequence. Hence, by definition, a sequence joined to any modified synthase is not a wild-type sequence. Other examples include a synthase from one plant source which is integrated into the genome of a different plant host.

Constructs may be designed to produce synthase in either prokaryotic or eukaryotic cells. The increased expression of a synthase in a plant cell or decreased amount of endogenous synthase observed in a plant cell are of special interest. Moreover, in a nucleic acid construct for integration into a plant host genome, the synthase may be found in a "sense" or "anti-sense" orientation in relation to the direction of transcription. Thus, nucleic acids may encode biologically active synthases or sequences complementary to the sequence encoding a synthase to inhibit the production of endogenous plant synthase. By transcribing and translating a sense sequence in a plant host cell, the amount of synthase available to the plant FAS complex is increased. By transcribing or transcribing and translating an anti-sense sequence in a plant host cell, the amount of the synthase available to the plant FAS is decreased. Ideally, the anti-sense sequence is very highly homologous to the endogenous sequence. Other manners of decreasing the amount of synthase available to FAS may be employed, such as ribozymes or the screening of plant cells transformed with constructs containing sense sequences which in fact act to decrease synthase expression, within the scope of this invention. Other analogous methods may be applied by those of ordinary skill in the art.

Synthases may be used, alone or in combination, to catalyze the elongating condensation reactions of fatty

acid synthesis depending upon the desired result. For example, rate influencing synthase activity may reside in synthase I-type, synthase II-type, synthase III-type or in a combination of these enzymes.

5        Thus, over-expression of synthase I could serve to increase fatty acid yield, and/or the proportion of palmitic acids (C16:0) found in the system. Alternatively, as a critical enzyme in several fatty acid elongation steps, reducing endogenous synthase I might effectively provide low yields of fatty acids. As the last enzyme in the fatty acid elongation pathway, synthase II may be a critical factor to increase production of fatty acids.

10      Increased availability of synthase II to FAS may in effect "drive" the rate of reaction forward and result in a larger pool of long chain fatty acids. In turn, the presence of an increased amount of fatty acids with 18 carbons may result ultimately, in the increased production of triglycerides. In a like manner, the decrease of synthase II may work to decrease one or both of these mechanisms.

15      Because synthase II catalyzes final elongation steps, it may require support from other synthase factors to create the desired effect. In particular, the combined presence of synthase I and synthase II are contemplated for the generation of a high composition of oleic fatty acids

20      and/or increased triglyceride production. In addition, the production of palmitate may be further enhanced by a combination of increased synthase I production and reduction in endogenous synthase II. Thus, various synthase factors may be combined in a like fashion to achieve

25      desired effects.

Other applications for use of cells or plants producing synthase may also be found. For example, potential herbicidal agents selective for plant synthase may be obtained through screening to ultimately provide environmentally safe herbicide products. Especially in that bacterial systems do not have an enzyme equivalent to plant synthase II, they may be particularly useful systems for the screening of such synthase II based herbicides.

The synthase can also be used in conjunction with chloroplast lysates to enhance the production and/or modify the composition of the fatty acids prepared *in vitro*. The synthase can also be used for studying the mechanism of fatty acid formation in plants and bacteria. For these applications, constitutive promoters may find the best use.

- Constructs which contain elements to provide the transcription and translation of a nucleic acid sequence of interest in a host cell are "expression cassettes".
- Depending upon the host, the regulatory regions will vary, including regions from structural genes from viruses, plasmid or chromosomal genes, or the like. For expression in prokaryotic or eukaryotic microorganisms, particularly unicellular hosts, a wide variety of constitutive or regulatable promoters may be employed. Among transcriptional initiation regions which have been described are regions from bacterial and yeast hosts, such as *E. coli*, *B. subtilis*, *Saccharomyces cerevisiae*, including genes such as  $\beta$ -galactosidase, T7 polymerase, trp-lac (lac), trp E and the like.

An expression cassette for expression of synthase in a plant cell will include, in the 5' to 3' direction of transcription, a transcription and translation initiation control regulatory region (also known as a "promoter") functional in a plant cell, a nucleic acid sequence encoding a synthase, and a transcription termination region. Numerous transcription initiation regions are available which provide for a wide variety of constitutive or regulatable, e.g., inducible, transcription of the desaturase structural gene. Among transcriptional initiation regions used for plants are such regions associated with cauliflower mosaic viruses (35S, 19S), and structural genes such as for nopaline synthase or mannopine synthase or napin and ACP promoters, etc. The transcription/translation initiation regions corresponding to such structural genes are found immediately 5' upstream to the respective start codons. Thus, depending upon the intended use, different promoters may be desired.

Of special interest in this invention are the use of promoters which are capable of preferentially expressing the synthase in seed tissue, in particular, at early stages of seed oil formation. Selective modification of seed 5 fatty acid/oils composition will reduce potential adverse effects to other plant tissues. Examples of such seed-specific promoters include the region immediately 5' upstream of a napin or seed ACP genes such as described in EP 0 255 378 (published 2/3/88), desaturase genes such as 10 described in Thompson et al (Proc. Nat. Acad. Sci. (1991) 88:2578-2582), co-pending USSN 494,106 and Figs. 8 and 9, herein, or Bce-4 gene such as described in co-pending USSN 494,722, and Fig. 7 herein. Alternatively, the use of the 15 5' regulatory region associated with the plant synthase structural gene, i.e., the region immediately 5' upstream to a plant synthase structural gene and/or the transcription termination regions found immediately 3' downstream to the plant synthase structural gene, may often be desired. In general, promoters will be selected based 20 upon their expression profile which may change given the particular application.

Sequences found in an anti-sense orientation may be found in cassettes which at least provide for transcription of the sequence encoding the synthase. By anti-sense is 25 meant a DNA sequence in the 5' to 3' direction of transcription which encodes a sequence complementary to the sequence of interest. It is preferred that an "anti-sense synthase" be complementary to a plant synthase gene indigenous to the plant host. Any promoter capable of 30 expression in a plant host which causes initiation of high levels of transcription in all storage tissues during seed development is sufficient. Seed specific promoters may be desired.

In addition, one may choose to provide for the 35 transcription or transcription and translation of one or more other sequences of interest in concert with the expression or anti-sense of the synthase sequence, for example sequences encoding a plant desaturase such as

described in co-pending USSN 494,106 and USSN unassigned, filed on or about 8/13/90 entitled "Plant Desaturases - Compositions and Use", seed or leaf acyl carrier protein such as described in co-pending USSN 437,764, medium-chain 5 plant thioesterase such as described by Pollard, et al., (*Arch. Biochem. Biophys.* (1991) 284:306-312) and in co-pending USSN 514,030, or other sequence encoding an enzyme capable of affecting plant lipids, to affect alterations in the amounts and/or composition of plant oils. The general 10 methods of use and means to determine related sequences and compositions described above as to synthase enzymes may be applied to these enzymes as well.

One may wish to integrate nucleic acids encoding a desaturase sense sequence and synthase sense sequence into 15 the genome of a host cell. A plant desaturase includes any enzyme capable of catalyzing the insertion of a first double band into a fatty acid-ACP moiety, especially  $\Delta$ -9 desaturase. Such a combination may be designed to modify the production of unsaturated fatty acids and thus either 20 lead to significantly lower or higher saturated fat upon the expression of both enzymes in a plant host cell. As desaturase acts upon the longer chain fatty acyl-ACPs, the resulting product of synthase II activity, various 25 applications are possible. Of interest is the combination of an enhanced production of both synthase II and  $\Delta$ -9 desaturase for the production of fatty acids having little or no completely saturated chains. It may also be of interest to provide for the increased production of 30 synthase II and a decreased production of desaturase for the production of high stearate (C18:0) fatty acid compositions. The modified pool of saturated/unsaturated fatty acids may be reflected in the composition of resulting triglycerides. In a different embodiment, it may be desired to combine the increased expression of a 35 synthase, such as synthase I, with a medium-chain plant thioesterase. Plants containing a medium-chain plant thioesterase, an enzyme capable of having preferential hydrolase activity toward one or more medium-chain (C8 to

C14) acyl-ACP substrates, are contemplated for the production of medium chain fatty acids, especially laurate (C12:0). In combination with an increased level of one or more synthases, these effects may be augmented.

When one wishes to provide a plant transformed for the combined effect of more than one nucleic acid sequence of interest, typically a separate nucleic acid construct will be provided for each. The constructs, as described above contain transcriptional or transcriptional and translational regulatory control regions. One skilled in the art will be able to determine regulatory sequences to provide for a desired timing and tissue specificity appropriate to the final product in accord with the above principles set forth as to synthase expression or anti-sense constructs. When two or more constructs are to be employed, whether they are both related to synthase sequences or a synthase sequence and a sequence encoding an enzyme capable of affecting plant lipids, it is desired that different regulatory sequences be employed in each cassette to reduce spontaneous homologous recombination between sequences. The constructs may be introduced into the host cells by the same or different methods, including the introduction of such a trait by crossing transgenic plants via traditional plant breeding methods, so long as the resulting product is a plant having both characteristics integrated into its genome.

Of special interest are synthases which appear to have superior kinetic properties, isolated from protein preparations obtainable from plants such as *Prunus amygdalus*, or more preferred *Ricinus communis*. As shown in Table I, in comparison of crude extracts from *Spinacia oleracea* leaf and some plants with low levels of saturated oils, *R. communis* and *P. amygdalus* show a markedly higher total activity of synthase II activity per gram fresh weight; calculated specific activities are also higher.

Table I  
Synthase II Yields and Substrate Km  
Values in Crude Extracts From Various Sources<sup>1</sup>

5	Source Tissue	Protein mg/g Fr Wt	Activity mU/g Fr Wt	Specific Activity mU/mg Protein	Km (C16-ACP) μM
10	<i>S. oleracea</i> Leaf	7.15	6.61	0.962	14.0
	<i>B. napus</i> Seed	7.62	6.58	0.864	22.0
15	<i>R. communis</i> Endosperm	21.0	346.0	16.5	15.7
	<i>P. amygdalus</i> Embryo	8.07	62.3	7.73	22.4

20

<sup>1</sup>*S. oleracea* leaf extract was prepared according to Shimakata & Stumpf, PNAS 79:5808-5812 (1983). The remaining samples were prepared from ground tissue which had been mixed with two volumes of buffer (2 mg/g fresh meal weight) containing 50 mM potassium phosphate and 2mM dithiothreitol, pH 7.5, of which the supernatant fluid was collected after centrifugation. Protein was assayed by the Bradford method. (Anal. Biochem. (1976) 72:248-254) Synthase II was assayed as described in Example 2 and with the palmitoyl-ACP in varying concentrations.

Tests also compared the sensitivity of the crude extracts to substrate concentration. It was assumed that malonyl-ACP would be proportional to added ACP due to the presence of malonyl transacylase in the crude extracts. The results showed very little differences in Km for palmitoyl-ACP or in sensitivity to ACP/malonyl-ACP between species. Other analogous plant sources may be determined by similar testing.

The exceptionally low level of saturated fat (<1%) and high activity of the synthase II enzyme in crude extracts are qualities which indicate *R. communis* as exemplary of a preferred enzyme source. Of special interest is *R. communis* seed produced by a primary inflorescence or

flower spike, as it usually has a higher oil content and higher synthase II specific activity, than the seed of branches from a secondary or tertiary inflourescence (secondary spikes). A major difficulty with the *R. communis* tissue is the toxicity of the *R. communis* seed storage ricins. Ricin is removed from the extract during the purification of the synthases as discussed in more detail below. Also, the stage at which the seeds are harvested influences the amount of ricin present in the tissue.

"Early" seeds have a very small central opaque core, a predominant translucent tissue, and very low levels of protein and synthase II activity. "Prime" seed tissue, which is found at about 21-28 days after flower opening have a central opaque white core, which contains the deposited seed oil and ricin, surrounded by a translucent white tissue. The seed coat is just beginning to harden and turn from white to a purplish-brown. The translucent tissue gradually disappears and the opaque core increases during maturation. As shown in Table II, the "Prime" tissue from the primary flower spikes have the highest synthase II specific activity; these are a main source of synthase II. The more mature "Late" seeds continue to exhibit high synthase II activity, but the large increase in deposition of ricin dilutes the specific activity. With improved methods of removing ricin, the older seeds may prove to be preferred sources as well.

Table II

## $\beta$ -Ketoacyl-ACP Synthase II Activity in Developing Seeds on Primary and Secondary Flower Spikes of *R. communis*<sup>1</sup>

	Sample	Specific Activity ( $\mu$ Units/mg protein)
35	A	936 $\pm$ 39
	B	2615 $\pm$ 139
	C	10364 $\pm$ 544
	D	9537 $\pm$ 1342
40	E	8386 $\pm$ 261
	F	5034 $\pm$ 171
	G	1735 $\pm$ 134

H	1459	±	4
I	4936	±	87
J	3466	±	30
K	6115	±	193

5           <sup>1</sup>Individual *R. communis* seeds were identified as Early (A,B,G,H), Prime (C,D,I) or Late (E,F,J,K). Seeds A-F were from primary spikes and seeds G-K were from secondary spikes. Each endosperm tissue from seed was ground in two volumes (ml/g fresh weight) of 40 mM potassium phosphate, 20% glycerol (v/v), 1 mM sodium EDTA, 2 mM DTT, pH 7.5, with a pestle in a microcentrifuge tube. The homogenate was clarified by centrifugation at 11,600 x g for 15 minutes. The supernatant was assayed for protein by the Bradford method (*Analy. Biochem.* (1976) 72:248-254) and for synthase II activity as described in Example 2.

10           As demonstrated more fully in the Examples, extraction and purification of synthases I and II from *R. communis* is obtained by ammonium sulfate fractionation (pH 7.5) and then subjecting the supernatant fluid to saturation with 20 ammonium sulfate to precipitate the synthases. The pellet containing synthase activity is resuspended and the activity are bound to Reactive Green-19 Agarose. A column containing the activity bound to the Green-19 Agarose is prepared and the synthase activity is eluted in a high salt 25 wash. The protein associated with fractions of peak activity is partially desalting and then absorbed to an ACP-Sepharose column and eluted with a gradient of 100-250 mM potassium phosphate buffer. The ACP column removes several proteins including a major contaminant which also showed a 30 molecular weight at about 50 kD. Fractions assayed for synthase activity show that a major peak having primarily synthase II-type, but also containing some synthase I-type, activity elutes first and that fractions eluting after the major peak contain primarily synthase I-type activity.

35           When applied to SDS-PAGE analysis, fractions from the major peak having synthase II activity are shown to contain two major bands, one at about 46kD and a second at about 50 kD. Synthase II activity has not been observed separate from protein preparations containing both the 50 kD and a 40 46 kD band. The relationship between the 50 and 46 kD bands is under further investigation, including cerulinin assays and *E. coli* expression studies. Two-dimensional gel analysis separates the 50 kD band into at least two spots.

Fractions eluting after the major peak contain mainly synthase I-type activity and show one distinctive band at about 50kD. Tests with monoclonal antibodies indicate that the 50kD proteins from the two fractions are very similar.

5 Additional work is underway to further characterize these proteins biochemically.

Given the few bands provided in the SDS-PAGE, immediate efforts to obtain the corresponding amino acid and/or nucleic acid sequences thereto are possible in

10 accordance with methods familiar to those skilled in the art. From such sequences, synthase activity may be further confirmed with expression in controlled systems, such as *E. coli*, or by observation of effects of transcription of anti-sense nucleic acid fragments and the like.

15 Amino acid sequences of fragments corresponding to purified protein preparations may be obtained through digestion with a protease, such as trypsin, and sequencing of resulting peptide fragments. Amino acid sequences of peptide fragments derived from the 50 kD protein are shown in Fig. 2

20 and from the 46 kD protein in Fig. 3 (Fig. 4 shows peptide sequences of the 50 kD peptide used to design oligonucleotide by "reverse translation" of peptide fragment amino acid sequences). DNA sequences are chosen for use in Polymerase Chain Reactions (PCR) using *R. communis* endosperm cDNA as a

25 template to obtain longer DNA sequences. The resulting PCR-generated sequences are then used as labeled probes in screening a *R. communis* endosperm cDNA or genomic DNA library. In this manner, the full length clones corresponding to the *R. communis* proteins seen on the SDS-

30 PAGE may be obtained if desired. Figure 5 is a DNA sequence corresponding to the 50kD protein obtained in this manner. Other plant synthase genes may be obtained by screening of cDNA or genomic libraries from other plant sources with probes derived from the synthase cDNA.

35 In figures 6A and 6B we present sequence comparison between the translated amino acid sequence from an isolated cDNA clone which encodes the 50 kD synthase protein and two other known synthase proteins. Comparison to FabB, the

gene encoding  $\beta$ -ketoacyl-ACP synthase I in *E. coli*. in Figure 6A, indicates there is extensive identical homology of amino acids, especially near the active site, amino acids 219-223 of the FabB protein. The 50 kD translated 5 amino acid sequence also has significant identical homology to a polyketide synthase protein in *Streptomyces glaucescens* that is encoded by ORF-1, as shown in Figure 6B. The polyketide synthase protein is homologous to other known synthases, especially at the active site.

10 A DNA sequence of this invention may include genomic or cDNA sequence. A cDNA sequence may or may not contain pre-processing sequences, such as transit peptide sequences. Transit peptide sequences facilitate the delivery of the protein to a given organelle and are 15 cleaved from the amino acid moiety upon entry into the organelle, releasing the "mature" protein (or enzyme). As synthases are part of the FAS pathway of plastid organelles, such as the chloroplast, proplastid, etc., transit peptides may be required to direct the protein(s) 20 to substrate. A transit peptide sequence from any plastid-translocating sources may be employed, such as from ACP, especially seed ACP, small subunit of ribulose bisphosphate carboxylase (RuBC), plant desaturase or from the native sequence naturally associated with the respective synthase.

25 The complete genomic sequence of a plant synthase may be obtained by the screening of a genomic library with a probe and isolating those sequences which hybridize thereto as described more fully below. Regulatory sequences immediately 5', transcriptional and translational 30 initiation regions, and 3', transcriptional and translational termination regions, to the synthase may be obtained and used with or without the synthase structural gene.

Other synthases and/or synthase nucleic sequences are 35 obtainable from amino acid and DNA sequences provided herein. "Obtainable" refers to those plant synthases which have sufficiently similar sequence to that of the native sequence(s) of this invention to provide a biologically

active synthase. One skilled in the art will readily recognize that antibody preparations, nucleic acid probes (DNA and RNA) and the like may be prepared and used to screen and recover synthases and/or synthase nucleic acid sequences from other sources. Thus, sequences which are homologously related to or derivations from either *R. communis* synthase I or II are considered obtainable from the present invention.

"Homologously related" includes those nucleic acid sequences which are identical or conservatively substituted as compared to the native sequence. Typically, a homologously related nucleic acid sequence will show at least about 60% homology, and more preferably at least about 70% homology, between the *R. communis* synthase and the given plant synthase of interest, excluding any deletions which may be present. Homology is determined upon comparison of sequence information, nucleic acid or amino acid, or through hybridization reactions.

Probes can be considerably shorter than the entire sequence, but should be at least about 10, preferably at least about 15, more preferably at least 20 or so nucleotides in length. Longer oligonucleotides are also useful, up to the full length of the gene encoding the polypeptide of interest. Both DNA and RNA can be used.

A genomic library prepared from the plant source of interest may be probed with conserved sequences from a *R. communis* synthase cDNA to identify homologously related sequences. Use of an entire *R. communis* synthase cDNA may be employed if shorter probe sequences are not identified. Positive clones are then analyzed by restriction enzyme digestion and/or sequencing. In this general manner, one or more sequences may be identified providing both the coding region, as well as the transcriptional regulatory elements of the synthase gene from such plant source. cDNA libraries prepared from other plant sources of interest may be screened as well, providing the coding region of synthase genes from such plant sources.

In use, probes are typically labeled in a detectable manner (for example with  $^{32}\text{P}$ -labeled or biotinylated nucleotides) and are incubated with single-stranded DNA or RNA from the plant source in which the gene is sought, 5 although unlabeled oligonucleotides are also useful. Hybridization is detected, typically using nitrocellulose paper or nylon membranes by means of the label after single-stranded and double-stranded (hybridized) DNA or DNA/RNA have been separated. Hybridization techniques 10 suitable for use with oligonucleotides are well known to those skilled in the art. Thus, plant synthase genes may be isolated by various techniques from any convenient plant. Plant genes for synthases from developing seed obtained from other oilseed plants, such as *C. tinctorius*, 15 *seed*, rapeseed, cotton, corn, soybean cotyledons, jojoba nuts, coconut, peanuts, oil palm and the like are desired as well as from non-traditional oil sources, such as *S. oleracea* chloroplast, avocado mesocarp, *Cuphea*, California Bay and *Euglena gracillis*. Synthases, especially synthase 20 I, obtained from *Cuphea* may show specialized activities towards medium chain fatty acids. Such synthase may be of special interest for use in conjunction with a plant medium-chain thioesterase.

Once the desired plant synthase sequence is obtained, 25 it may be manipulated in a variety of ways. Where the sequence involves non-coding flanking regions, the flanking regions may be subjected to resection, mutagenesis, etc. Thus, transitions, transversions, deletions, and insertions 30 may be performed on the naturally occurring sequence. In addition, all or part of the sequence may be synthesized, where one or more codons may be modified to provide for a modified amino acid sequence, or one or more codon mutations may be introduced to provide for a convenient restriction site or other purpose involved with 35 construction or expression. The structural gene may be further modified by employing synthetic adapters, linkers to introduce one or more convenient restriction sites, or the like. For expression, the open reading frame coding

for the plant synthase or functional fragment thereof will be joined at its 5' end to a transcriptional initiation regulatory control region. In some instances, such as modulation of plant synthase via a nucleic acid sequence 5 encoding synthase in an anti-sense orientation, a transcription initiation region or transcription/translation initiation region may be used. In embodiments wherein the expression of the synthase protein is desired in a plant host, a 10 transcription/translation initiation regulatory region, is needed. Additionally, modified promoters, i.e., having transcription initiation regions derived from one gene source and translation initiation regions derived from a different gene source or enhanced promoters, such as double 15 35S CaMV promoters, may be employed for some applications.

As described above, of particular interest are those 5' upstream non-coding regions which are obtained from genes regulated during seed maturation, particularly those preferentially expressed in plant embryo tissue, such as 20 ACP-and napin-derived transcription initiation control regions. Such regulatory regions are active during lipid accumulation and therefore offer potential for greater control and/or effectiveness to modify the production of plant desaturase and/or modification of the fatty acid 25 composition. Especially of interest are transcription initiation regions which are preferentially expressed in seed tissue, i.e., which are undetectable in other plant parts. For this purpose, the transcript initiation region of acyl carrier protein isolated from *B. campestris* seed 30 and designated as "Bcg 4-4" and a gene having an unknown function isolated from *B. campestris* seed and designated as "Bce-4" are also of substantial interest.

Briefly, Bce4 is found in immature embryo tissue at least as early as 11 days after anthesis (flowering), 35 peaking about 6 to 8 days later or 17-19 days post-anthesis, and becoming undetectable by 35 days post-anthesis. The timing of expression of the Bce4 gene closely follows that of lipid accumulation in seed tissue.

Bce4 is primarily detected in seed embryo tissue and to a lesser extent found in the seed coat. Bce4 has not been detected in other plant tissues tested, root, stem and leaves.

5       Bce4 transcript initiation regions will contain at least 1 kb and more preferably about 5 to about 7.5 kb of sequence immediately 5' to the Bce4 structural gene.

10      The Bcg 4-4 ACP message presents a similar expression profile to that of Bce4 and, therefore, also corresponds to lipid accumulation in the seed tissue. Bcg 4-4 is not found in the seed coat and may show some differences in expression level, as compared to Bce4, when the Bcg 4-4 5' non-coding sequence is used to regulate transcription or transcription and translation of a plant  $\Delta$ -9 desaturase of this invention.

15      The napin 1-2 message is found in early seed development and thus, also offers regulatory regions which can offer preferential transcriptional regulation of a desired DNA sequence of interest such as the plant desaturase DNA sequence of this invention during lipid accumulation. Napins are one of the two classes of storage proteins synthesized in developing *Brassica* embryos (Bhatti, et al., *Can J. Biochem.* (1968) 46:1191-1197) and have been used to direct tissue-specific expression when reintroduced into the *Brassica* genome (Radke, et al., *Theor. Appl. Genet.* (1988) 75:685-694).

20      As to regulatory transcript termination regions, these may be provided by the DNA sequence encoding the plant synthase or a convenient transcription termination region derived from a different gene source, especially the transcript termination region which is naturally associated with the transcript initiation region. Typically, the transcript termination region will contain at least about 1 kb, preferably about 3 kb of sequence 3' to the structural gene from which the termination region is derived.

25      In developing the DNA construct, the various components of the construct or fragments thereof will normally be inserted into a convenient cloning vector which

is capable of replication in a bacterial host, e.g., *E. coli*. Numerous vectors exist that have been described in the literature. After each cloning, the plasmid may be isolated and subjected to further manipulation, such as 5 restriction, insertion of new fragments, ligation, deletion, insertion, resection, etc., so as to tailor the components of the desired sequence. Once the construct has been completed, it may then be transferred to an appropriate vector for further manipulation in accordance 10 with the manner of transformation of the host cell.

Normally, included with the DNA construct will be a structural gene having the necessary regulatory regions for expression in a host and providing for selection of transformed cells. The gene may provide for resistance to 15 a cytotoxic agent, e.g. antibiotic, heavy metal, toxin, etc., complementation providing prototrophy to an auxotrophic host, viral immunity or the like. Depending upon the number of different host species into which the expression construct or components thereof are introduced, 20 one or more markers may be employed, where different conditions for selection are used for the different hosts.

The manner in which the DNA construct is introduced into the plant host is not critical to this invention. Any method which provides for efficient transformation may be 25 employed. Various methods for plant cell transformation include the use of Ti- or Ri-plasmids, microinjection, electroporation, liposome fusion, DNA bombardment or the like. In many instances, it will be desirable to have the construct bordered on one or both sides by T-DNA, particularly having the left and right borders, more 30 particularly the right border. This is particularly useful when the construct uses *A. tumefaciens* or *A. rhizogenes* as a mode for transformation, although the T-DNA borders may find use with other modes of transformation.

35 Where *Agrobacterium* is used for plant cell transformation, a vector may be used which may be introduced into the *Agrobacterium* host for homologous recombination with T-DNA or the Ti- or Ri-plasmid present

in the *Agrobacterium* host. The Ti- or Ri-plasmid containing the T-DNA for recombination may be armed (capable of causing gall formation) or disarmed (incapable of causing gall formation), either being permissible, so 5 long as the vir genes are present in the transformed *Agrobacterium* host. The armed plasmid can give a mixture of normal plant cell and gall.

A preferred method for the use of *Agrobacterium* as the vehicle for transformation of plant cells employs a vector 10 having a broad host range replication system, at least one T-DNA boundary and the DNA sequence or sequences of interest. Commonly used vectors include pRK2 or derivatives thereof. See, for example, Ditta et al., PNAS USA, (1980) 77:7347-7351 and EPA 0 120 515, which are 15 incorporated herein by reference. Normally, the vector will be free of genes coding for opines, oncogenes and vir-genes. Included with the expression construct and the T-DNA will be one or more markers, which allow for selection of transformed *Agrobacterium* and transformed plant cells. 20 A number of markers have been developed for use with plant cells, such as resistance to chloramphenicol, the aminoglycoside G418, hygromycin, or the like. The particular marker employed is not essential to this invention, one or another marker being preferred depending 25 on the particular host and the manner of construction.

The vector is used for introducing the DNA of interest into a plant cell by transformation into an *Agrobacterium* having vir-genes functional for transferring T-DNA into a plant cell. The *Agrobacterium* containing the broad host 30 range vector construct is then used to infect plant cells under appropriate conditions for transfer of the desired DNA into the plant host cell under conditions where replication and normal expression will occur. This will also usually include transfer of the marker, so that cells 35 containing the desired DNA may be readily selected.

The expression constructs may be employed with a wide variety of plant life, particularly plant life involved in the production of vegetable oils. These plants include,

but are not limited to rapeseed, peanut, sunflower, *C. tinctorius*, cotton, *Cuphea*, soybean, and corn or palm.

For transformation of plant cells using *Agrobacterium*, explants may be combined and incubated with the transformed 5 *Agrobacterium* for sufficient time for transformation, the bacteria killed, and the plant cells cultured in an appropriate selective medium. Once callus forms, shoot formation can be encouraged by employing the appropriate plant hormones in accordance with known methods and the 10 shoots transferred to rooting medium for regeneration of plants. The plants may then be grown to seed and the seed used to establish repetitive generations and for isolation of vegetable oils.

In addition, synthase I or II produced in accordance 15 with the subject invention can be used in preparing antibodies for assays for detecting plant synthases from other sources. The plant synthases can also be used in conjunction with chloroplast lysates to enhance the production and/or modify the composition of the fatty acids. 20 prepared *in vitro*. The plant synthase can also be used for studying the mechanism of fatty acid formation in plants and bacteria.

The invention now being generally described, it will be more readily understood by reference to the following 25 examples which are included for purposes of illustration only and are not intended to limit the present invention.

#### EXAMPLES

##### **Materials**

30 Commercially available biological chemicals and chromatographic materials, including Reactive Green 19 agarose, Ponceau S, ammonium carbonate, sodium borohydride ( $\text{NaBH}_4$ ), malonyl CoA, free fatty acids,  $\beta$ -mercaptoethanol, and protease inhibitors amino caproic acid, leupeptin, 35 pepstatin, and phenylmethylsulfonyl fluoride are from Sigma (St. Louis, MO). CNBr-activated Sepharose 4B is purchased from Pharmacia (Piscataway, NJ). Proteolytic enzymes, including trypsin and endoproteinase gluC, are sequencing

grade enzymes obtained from Boehringer Mannheim Biochemicals (Indianapolis, IN). Polyvinylidenefluoride (PVDF) membranes are Immobilon-P (Millipore, Bedford, MA). HPLC grade acetonitrile, methanol, chloroform and water are 5 obtained from Burdick and Jackson (Muskegon, MI). Organic solvents including glacial acetic acid and methanol are from J.T. Baker (Phillipsburg, NJ). Tetrahydrofuran, dimethylphenylthiourea (DMPTU), and HPLC grade trifluoroacetic acid (TFA) are from Applied Biosystems 10 (Foster City, CA); all chemicals utilized in the Applied Biosystems 477A Sequencer (see below) are also from Applied Biosystems (ABI). Radiochemicals, including  $^{14}\text{C}$ -malonyl-Coenzyme A, [9,10(n)- $^3\text{H}$ ] oleic acid (10mCi/mmol), and decanoic acid are from New England Nuclear (NEN (Dupont), 15 Boston, MA.). [ $^3\text{H}$ ]-iodoacetic acid is from Amersham, (Arlington Heights, IL).

#### Example 1. FAS Analysis

In this example, the effects of additions of partially purified  $\beta$ -ketoacyl-ACP synthase and/or  $\Delta$ -9 desaturase to FAS systems in cell-free extracts are described.

##### A. Synthase Experiment

###### 1. Purification of *S. oleracea* Leaf Synthase II.

1.1 Assay. Synthase II activity is detected 25 radiometrically as described in Example 2.

1.2 Purification.  $\beta$ -ketoacyl-ACP synthase II is partially purified from *S. oleracea* leaf according to the protocol of Shimakata and Stumpf (*PNAS* (1982) 79:5808-5812), with the following changes.

30 The Sephadryl S300 (Pharmacia) column is 2.5 cm x 100 cm and the flow rate is 18 ml/hour. Synthase I and II activities co-elute in a single peak.

The Affi-gel blue-agarose column (Bio-Rad, Richmond, CA) is 1.5 cm x 14 cm and the flow rate is 10 ml/hour. The 35 synthase II activity requires 300 mM phosphate for elution.

The Whatman (Clifton, NJ) P11 cellulose phosphate column, 1.5 cm x 14 cm, is run at 9 ml/hour. As phosphate

at 50 mM potassium phosphate as was reported by Shimakata and Stumpf (*supra*), the phosphate salt concentration is reduced to 10 mM both in the column buffer and in the applied sample. The synthase I activity does not adsorb to the column even at 10 mM potassium phosphate and is recovered in the flow-through. The synthase II activity is eluted step-wise at 100 mM phosphate.

1.3 Specific Activity. One unit of activity is defined as the amount of protein required for the formation of 1  $\mu$ mol of  $\beta$ -ketoacyl-ACP condensation product per minute. This is measured as incorporation of 1  $\mu$ mole [2- $^{14}\text{C}$ ]malonate, supplied as [2- $^{14}\text{C}$ ]-malonyl-COA, into  $\beta$ -ketoacyl-ACP per minute at 37°C under assay conditions. The recovery of synthase II activity was 164 mU from 30 g S. oleracea leaves, with a specific activity of 31.6 mU/mg protein. The recovery of activity was 35%. Protein is measured by the Bradford method (*Analy. Biochem.* (1976) 72:248-254).

## 2. Substrate Specificity.

The partially purified S. oleracea leaf synthase II activity is twelve times more active with the palmitoyl-ACP substrate than with decanoyl-ACP. In order to show that the small amount of decanoyl-ACP activity observed is from synthase II, the activity is tested for sensitivity to cerulenin, an irreversible inhibitor of synthase I activity. Since the synthase I activity does not adsorb to the cellulose phosphate, the activity in the flow-through from that column is compared to the synthase II activity peak from cellulose phosphate. Each enzyme source is incubated with 5  $\mu\text{M}$  cerulenin for 15 minutes at room temperature before being assayed with each of the acyl-ACP substrates. After incubation with cerulenin, the decanoyl-ACP activity is reduced 99% in the cellulose phosphate flow-through fraction and only 69% in the synthase II fraction. The palmitoyl-ACP activity in the synthase II fraction is not inhibited by the cerulenin treatment.

3. Preparation of Cell-free Extracts.

*Brassica napus* is grown in the greenhouse under a 16-hour photoperiod with temperatures ranging from 76°F (days) to 60°F (nights). The seedpods are collected at 24-28 days after flowering. The seeds are removed from the pods, frozen in liquid nitrogen, and ground with a mortar and pestle. The powder is triturated with two volumes (2 ml/g fresh weight) of buffer containing 50 mM potassium phosphate, 2 mM dithiothreitol, pH 7.5. The sample is mixed by vortex for one minute and clarified by centrifugation at 10,000  $\times$  g for 15 minutes. Soluble protein is measured by the Bradford method (*supra*). A clarified homogenate is made from *S. oleracea* leaves according to the protocol of Shimakata and Stumpf (1982, *supra*) through the step involving centrifugation at 10,000  $\times$  g.

The extracts are assayed for endogenous  $\beta$ -ketoacyl-ACP synthase II activity as described in Example 2. The synthase II activity in the *S. oleracea* leaf extract was 228  $\mu$ U/mg protein. The synthase II activity in the *Brassica* developing seed extract was 1200  $\mu$ U/mg protein.

4. Fatty Acid Synthetase Reaction.

The FAS reaction includes in a 250  $\mu$ l volume 100 mM HEPES-NaOH buffer, pH 8.0, 2 mM dithiothreitol, 400  $\mu$ M each NADH and NADPH, 10.4  $\mu$ M ACP, 12  $\mu$ M acetyl coenzyme A, 5  $\mu$ M [ $2-14$ C]malonyl coenzyme A (NEN, specific activity 55 Ci/mol), .300  $\mu$ g protein from *B. napus* seed or *S. oleracea* leaf cell-free extracts, and varying amounts of partially purified synthase II.

The partially purified synthase II from *S. oleracea* leaf is added to the *S. oleracea* leaf FAS reaction mix at 1-, 2-, and 10-fold excess, and to the *Brassica* seed FAS reaction mix at 0.2-, 0.4-, and 2-fold excess. The reactions are incubated for ten minutes at 33°C and are stopped by the addition of 1 ml of hexane-isopropanol (3:2, v:v) and 667  $\mu$ l sodium sulfate from a 6.67% (w/v) solution. The phases are mixed by vortex for 30 seconds and separated

by centrifugation at 4,500 x g for one minute. The hexane-isopropanol layer is removed by aspiration, and the sample is re-extracted. The hexane-isopropanol extracts are combined and an aliquot is counted in Aquasol (NEN) in a 5 Beckman (Fullerton, CA) LS7800 liquid scintillation counter.

5. Detection.

The hexane-isopropanol is evaporated from the extracts under a stream of nitrogen gas and the lipids are 10 saponified in 200 µl methanol with 100 µM potassium hydroxide for thirty minutes at 80°C. The saponified lipids are cooled to room temperature and titrated to pH 8.5 with 1 N hydrochloric acid in methanol to a phenolphthalein endpoint. The methanol is evaporated under 15 a stream of nitrogen gas. Phenacyl esters of the fatty acids in each sample are prepared by incubation with 100 µl p-Bromophenacyl-8 (Pierce, Rockford, IL) and 300 µl acetonitrile at 80°C for 30 minutes. The sample is cooled to room temperature, 40 µl HPLC-grade water is added, and 20 the solution is clarified by centrifugation at 4,500 x g for five minutes. The supernatant fluid is injected on to an Ultrasphere ODS reverse-phase HPLC column (5 micron particle size, 4.6 mm x 25 cm; Beckman, Fullerton, CA) equilibrated in 80% acetonitrile in water. The fatty acid 25 phenacyl esters are eluted at one ml per minute in 80% acetonitrile in water for 10 min., followed by a one minute gradient of 80-100% acetonitrile in water, and finally, by 100% acetonitrile for 19 min.. Elution of the esters is monitored by UV absorbance and by radioactivity.

30 In both the *S. oleracea* leaf and the *Brassica* developing seed extracts, with an increase in the amount of synthase II added to the FAS system, the percent of radioactivity in palmitic acid decreases with a corresponding increase in the radioactivity detectable in 35 stearic acid. In the table below, the radioactivities in the palmitate and the stearate are expressed as the percent of the total radioactivity recovered in fatty acids.

TABLE III

Effect of *S. oleracea* Leaf  $\beta$ -ketoacyl-ACP  
 Synthase II on the de novo Synthesis of Fatty Acids in  
 Cell-free Extracts of *S. oleracea* Leaf and of Developing  
Seeds of *Brassica napus*

	Synthase II Added (fold excess over endogenous)	C16:0 %	C18:0 %
10	<i>S. oleracea</i> Leaf		
	0	58.4 $\pm$ 2.7	41.6 $\pm$ 2.7
	1X	36.1 $\pm$ 0.0	57.9 $\pm$ 6.1
15	2X	34.3 $\pm$ 1.8	64.0 $\pm$ 0.2
	10X	10.2 $\pm$ 1.0	73.0 $\pm$ 1.5
20	<i>Brassica</i> seed		
	0	48.0 $\pm$ 5.0	48.9 $\pm$ 1.9
	0.2X	37.5 $\pm$ 1.1	59.0 $\pm$ 2.6
	0.4X	37.3 $\pm$ 3.4	59.8 $\pm$ 0.5
	2X	29.9 $\pm$ 1.3	68.2 $\pm$ 0.7

B. Synthase II and Desaturase Experiment

- 25 1. Purification of *S. oleracea* Leaf Synthase II.  
 $\beta$ -ketoacyl-ACP synthase II is partially purified from  
*S. oleracea* leaves as described above. The synthase II  
 activity from the cellulose phosphate column is  
 concentrated in a Centriprep 30 (Amicon Corporation,  
 30 Danvers, MA). During storage at -70°C, the enzyme loses  
 activity. When this experiment was conducted, the  
 preparation had a specific activity of 10.4 mU/mg protein,  
 and the concentration was 42 mU/ml. Protein was measured  
 by the micro-method of Bradford (*supra.*) with BioRad  
 35 Protein Assay Dye Reagent. One unit of activity is defined  
 as the amount of protein required for the incorporation of  
 1  $\mu$ mole [2- $^{14}$ C]malonate into the reduced product per minute  
 at 37°C.

2. Purification of *C. tinctorius* Seed Δ-9 Desaturase.

2.1. Substrate. In each of the following steps, the presence of the enzyme is detected radiometrically by measuring enzyme-catalyzed release of tritium from

5 [9,10(n)-<sup>3</sup>H]stearoyl-ACP, which is prepared and purified from synthesized [9,10(n)-<sup>3</sup>H]stearic acid (synthesis described below) by the enzymatic synthesis procedure of Rock, Garwin, and Cronan (*Methods in Enzymol.* (1981) 72:397-403).

10 [9,10(n)-<sup>3</sup>H]stearic acid is synthesized by reduction of [9,10(n)-<sup>3</sup>H]oleic acid with hydrazine hydrate essentially as described by Johnson and Gurr (*Lipids* (1971) 6:78-84). [9,10(n)-<sup>3</sup>H]oleic acid (2 mCi), supplemented with 5.58 mg unlabeled oleic acid to give a final specific  
15 radioactivity of 100 mCi/mmol, is dissolved in 2 ml of acetonitrile, acidified with 40 μl of glacial acetic acid, and heated to 55°C. Reduction is initiated with 100 μl of 60% (w/w) hydrazine hydrate; oxygen is bubbled through the mixture continuously. After each hour acetonitrile is  
20 added to bring the volume back to 2 ml and an additional 100 μl of hydrazine hydrate is added. At the end of 5 hr. the reaction is stopped by addition of 3 ml of 2M HCl. The reaction products are extracted with three 3-ml aliquots of petroleum ether and the combined ether extracts are washed  
25 with water, dried over sodium sulfate and evaporated to dryness. The dried reaction products are redissolved in 1.0 ml acetonitrile and stored at -20°C. The distribution of fatty acid products in a 15 μl aliquot is determined by preparation of phenacyl esters, which are then analyzed by  
30 thin layer chromatography on C-18 reverse phase plates developed with methanol:water::95:5 (v/v). Usually reduction to [9,10(n)-<sup>3</sup>H]stearic acid is greater than 90%, a small amount of unreacted oleic acid may remain. The analysis is used to establish fraction of the total  
35 radioactivity that is present as stearate, and thereby to determine the exact substrate concentration in the enzyme assay.

2.2 Assay. The assay is performed by mixing 150  $\mu$ l water, 5 ml dithiothreitol (100 mM, freshly prepared in water), 10  $\mu$ l bovine serum albumin (10 mg/ml in water), 15  $\mu$ l NADPH (25 mM, freshly prepared in 0.1 M Tricine-HCl, pH 5.2), 25  $\mu$ l *S. oleacea* ferredoxin (2 mg/ml Sigma Type III in water), 3  $\mu$ l NADPH:ferredoxin oxidoreductase (2.5 units/ml from Sigma), and 1  $\mu$ l bovine liver catalase (800,000 units/ml from Sigma); after 10 min at room temperature, this mixture is added to a 13x100 mm screw-cap test tube containing 250  $\mu$ l sodium 1,4-piperazinediethanesulfonate (0.1 M, pH 6.0). Finally, 10  $\mu$ l of the sample to be assayed is added and the reaction is started by adding 30  $\mu$ l of the substrate, [9,10(n)-<sup>3</sup>H]stearoyl-ACP (100  $\mu$ Ci/ $\mu$ mol, 10  $\mu$ M in 0.1 M sodium 1,4-piperazinediethanesulfonate, pH 5.8). After sealing with a cap, the reaction is allowed to proceed for 10 min. with shaking at 23°C. The reaction is terminated by addition of 1.2 ml of 5.8% tricholoracetic acid and the resulting precipitated acyl-ACPs are removed by centrifugation. The tritium released into the aqueous supernatant fluid by the desaturase reaction is measured by liquid scintillation spectrometry. One unit of activity is defined as the amount of enzyme required to convert one  $\mu$ mol of stearoyl-ACP to oleoyl-ACP, or to release 4  $\mu$ mol of <sup>3</sup>H per minute.

2.3 Source Tissue. Developing *Carthamus tinctorius* (safflower) seeds from greenhouse grown plants are harvested between 16 and 18 days after flowering, frozen in liquid nitrogen and stored at -70°C until extracted.

2.4 Acetone Powder Extract. Approximately 50 g of frozen *C. tinctorius* seeds are ground in liquid nitrogen and sieved to remove large seed coat pieces to provide a fine embryo powder. The powder is washed with acetone on a Buchner funnel until all yellow color is absent from the filtrate. The powder is then air dried and further processed as described below, or may be stored frozen for at least a year at -70°C without loss of enzyme activity. The dried acetone powder is weighed and triturated with ten times its weight of 20 mM potassium phosphate, pH 6.8; the

mixture is then centrifuged at 12,000 x g for 20 minutes and decanted through a layer of Miracloth (Calbiochem, La Jolla, CA).

2.5 Ion Exchange Chromatography. The acetone powder extract is then applied to a DEAE-cellulose column (Whatman DE-52) (1.5 x 12 cm) equilibrated with 20 mM potassium phosphate, pH 6.8. The pass-through and a wash with one column-volume (20 ml) of buffer are pooled.

2.6 Affinity Chromatography. An affinity matrix for purification of the desaturase is prepared by reacting highly purified *E. coli* ACP, with CNBr-activated Sepharose 4B (Sigma). ACP (120 mg) is reduced by treatment with 1 mM dithiothreitol for 30 min on ice, and then desalted on Sephadex G-10 (Pharmacia) equilibrated with 0.1 M sodium bicarbonate, pH 6.0. The treated ACP (20 ml, 6 mg/ml) is then mixed with 20 ml of CNBr-activated Sepharose 4B swollen in 0.1 M sodium bicarbonate, pH 7.0, and the mixture is allowed to stand at 4°C for one day. The gel suspension is then centrifuged, washed once with 0.1 M sodium bicarbonate, pH 7.0, and then treated with 40 ml 0.1 M glycine, pH 8.0, for 4 hours at room temperature to block unreacted sites. The gel is then washed for five cycles with alternating 50 ml volumes of 0.5 M NaCl in 0.1 M sodium acetate, pH 4.0, and 0.5 M NaCl in 0.1 M sodium bicarbonate, pH 6.5, to remove non-covalently bound ligand. The gel is loaded into a column (1.5 x 11.2 cm) and equilibrated in 20 mM potassium phosphate, pH 6.8.

The combined fractions from the DE-52 column are applied to the column, which is subsequently washed with one column volume (20 ml) of the equilibration buffer, and then with 2.5 column volumes (50 ml) of 300 mM potassium phosphate, pH 6.8. Fractions are assayed for protein using the BCA Protein Assay Reagent (Pierce, Rockford, IL) to make sure that all extraneous protein has been eluted. Active Δ-9 desaturase is eluted from the column with 600 mM potassium phosphate, pH 6.8. Active fractions are pooled and concentrated using an Amicon 8400 stirred pressure cell. The protein preparation had a specific activity of

0.131 mU/mg protein, and the concentration was 3.15 mU/ml. The desaturase activity is extremely unstable making it necessary to proceed with the experiment immediately following the final step in the desaturase purification.

5    3. Preparation of cell-free extracts.

Cell-free extracts are prepared from *B. napus* seeds as described in Example 1A. Soluble protein is measured by the micro-method of Bradford (*supra.*) with BioRad Protein Assay Dye Reagent. The *B. napus* extract is assayed for endogenous  $\beta$ -ketoacyl-ACP synthase II activity as described in Example 2, and for endogenous stearoyl desaturase activity as described above. In the *Brassica* developing seed extract, the synthase II activity was 1280  $\mu$ U/mg protein; the desaturase activity was 131  $\mu$ U/mg protein.

15    4. Fatty Acid Synthetase Reaction.

The FAS reaction includes in a 250  $\mu$ l volume 100 mM HEPES-NaOH buffer, pH 8.0, 2 mM dithiothreitol, 400  $\mu$ M each NADH and NADPH, 10.4  $\mu$ M ACP, 12  $\mu$ M acetyl coenzyme A, 5  $\mu$ M [2-<sup>14</sup>C]malonyl coenzyme A (NEN, specific activity 55 Ci/mol), 150  $\mu$ g *Brassica* developing seed protein from cell-free extracts, and *S. oleracea* leaf synthase II and/or *C. tinctorius* seed desaturase.

The partially purified  $\beta$ -ketoacyl-ACP synthase II from *S. oleracea* leaf is added to the *Brassica* seed FAS reaction mix at 2.8- and 12.6-fold excess. The partially purified stearoyl desaturase is added at 2.1- and 9.3-fold excess. The reactions with no exogenous synthase or desaturase contain instead the equivalent volume of the synthase or desaturase buffer. The reactions are incubated for ten minutes at 33°C and stopped by the addition of 1 ml of hexane-isopropanol (3:2, v:v) and 667  $\mu$ l sodium sulfate from a 6.67% (w/v) solution. The phases are mixed by vortex for 30 seconds and then separated by centrifugation at 4500  $\times$  g for one minute. The hexane-isopropanol layer is removed by aspiration, and the sample is re-extracted. The hexane-isopropanol extracts are combined and an aliquot

is counted in Aquasol (NEN) in a Beckman LS7800 liquid scintillation counter.

5. Detection.

The hexane-isopropanol is evaporated from the extract under a stream of nitrogen gas and the lipids are saponified in 200  $\mu$ l methanol with 100  $\mu$ M potassium hydroxide for thirty minutes at 80°C. The saponified lipids are cooled to room temperature and titrated to pH 8.5 with 1 N hydrochloric acid in methanol, to a phenolphthalein endpoint. The methanol is evaporated under a stream of nitrogen gas. Phenacyl esters of the fatty acids in each sample are prepared by incubation with 100  $\mu$ l *p*-Bromophenacyl-8 (Pierce, Rockford IL) and 100  $\mu$ l acetonitrile at 80°C for 30 minutes. The sample is cooled to room temperature, and the solution clarified by centrifugation at 4500  $\times$  g for five minutes. The supernatant fluid is injected to an Ultrasphere ODS reverse-phase HPLC column (5 micron particle size, 4.6 mm  $\times$  25 cm) (Beckman, Fullerton, CA) equilibrated in 82% acetonitrile in water. The fatty acid phenacyl esters are eluted at two ml per minute in 82% acetonitrile in water for 100 minutes, followed by 25 minutes in 100% acetonitrile. Elution of the exters is monitored by UV absorbance and by radioactivity.

25 As shown in the tables below, with increasing amounts of *S. oleracea* leaf synthase II added to the *Brassica* FAS system, the amount of radioactivity in palmitic acid decreases with a corresponding increase in the radioactivity in stearic acid. With increasing amounts of 30 *C. tinctorius* seed desaturase, the amount of radioactivity decreases in saturated fatty acids measured (palmitic acid and stearic acid) with a corresponding increase in the amount of radioactivity incorporated into oleic acid. When the largest volume of desaturase is added to the *Brassica* 35 FAS, the total incorporation of  $^{14}$ C-malonyl-Coenzyme A into fatty acid decreases. This effect is probably due to components of the desaturase buffer interfering with the in

vitro FAS system and therefore limiting the amount of exogenous desaturase that can be added.

TABLE IV

5

Effects of *S. oleracea* Leaf  $\beta$ -ketoacyl-ACP Synthase II and *C. tinctorius* Seed Stearyl Desaturase on the Incorporation of  $^{14}\text{C}$  Malonyl CoEnzyme A into Lipids by a Cell-free Extract of Developing Seeds of *Brassica napus*

10

	Synthase II Added (fold excess over endogenous)	Desaturase Added (fold excess over endogenous)	Incorporation cpm
15	0	0	20,726
	0	2.1	20,971
	0	9.3	10,253
20	2.8	0	20,787
	2.8	2.1	21,329
	2.8	9.3	9,629
25	12.6	0	19,650
	12.6	2.1	19,409
	12.6	9.3	10,736

In the table below, the radioactivities in the individual fatty acids are expressed as the percent of the total radioactivity recovered in fatty acids. The values are averages of duplicate syntheses within one experiment. Replicates were not available for the last two experimental conditions listed in the table.

TABLE V

5           Effects of *S. oleracea* Leaf  $\beta$ -ketoacyl-ACP Synthase II and  
*C. tinctorius* Seed  $\Delta$ -9 Desaturase on the Distribution of Fatty  
Acids Synthesized de novo in a Cell-free  
Extract of Developing Seeds of *Brassica napus*

	Synt.II Added	Desat. Added	C16:0 %	C18:0 %	C18:1 %
10	(fold excess over endogenous)				
	0	0	12.2 $\pm$ 0.4	47.3 $\pm$ 1.2	36.0 $\pm$ 0.8
	0	2.1	11.2 $\pm$ 0.6	40.3 $\pm$ 1.0	45.4 $\pm$ 0.4
	0	9.3	17.4 $\pm$ 1.3	25.6 $\pm$ 3.5	55.6 $\pm$ 3.6
15					
	2.8	0	6.4 $\pm$ 0.3	65.6 $\pm$ 2.0	18.7 $\pm$ 1.3
	2.8	2.1	5.9 $\pm$ 0.1	64.7 $\pm$ 0.1	24.8 $\pm$ 0.3
	2.8	9.3	11.5 $\pm$ 0.3	50.2 $\pm$ 1.1	30.7 $\pm$ 2.0
20					
	12.6	0	7.1 $\pm$ 0.2	75.7 $\pm$ 0.1	6.6 $\pm$ 0.7
	12.6	2.1	6.2	77.5	10.9
	12.6	9.3	9.6	64.8	12.4

#### Example 2. Assay for Synthase Activity

25           In this example, the assay used to detect synthase activity is described. The presence of the synthase activity is detected radiometrically by modification of the method of Garwin et al. (*J. Biol. Chem.* (1980) 255:11949-11956), by measuring synthase-catalyzed condensation of [2-<sup>14</sup>C]malonyl-ACP with either decanoyl-ACP (C10-ACP) or hexadecanoyl-ACP (C16-ACP), which produces  $\beta$ -ketododecanoyl-ACP (C12-ACP) or  $\beta$ -ketoctadecanoyl-ACP (C18-ACP), respectively. Products are reduced to their 1,3,-diol forms for extraction into toluene prior to determining incorporation by scintillation counting.

#### A. Assay

The synthase assay contains 0.2 M potassium phosphate (pH 6.8), 1.25 mM EDTA, 3.1 mM  $\beta$ -mercaptoethanol, 10  $\mu$  Units malonyl CoA-ACP transacylase (MTA) (purification from 40 *E. coli* described below), 50  $\mu$ M ACP (purification from *E.*

*coli* described below), 100 µM [ $2-^{14}\text{C}$ ]malonyl-CoA (20 Ci/mol), 60 µM C16-ACP or C10-ACP, 5% glycerol and enzyme in a total reaction volume of 20 µl.

For maximal activity the MTA and ACP are reduced prior to the enzyme assay by incubation of 1  $\mu$ l of 1 mM ACP and 0.08 ml of MTA (at 129  $\mu$ U/ml) in 0.4  $\mu$ l of 50 mM EDTA, 0.6  $\mu$ l of 20 mM  $\beta$ -mercaptoethanol, 2  $\mu$ l of 1 M potassium phosphate, and 1.12  $\mu$ l of H<sub>2</sub>O for 15 minutes at 37°C. This solution is then added to a 7.3  $\mu$ l solution containing 2  $\mu$ l of 1 M potassium phosphate, 1.3  $\mu$ l of 1 mM malonyl-CoA and 4  $\mu$ l of [2-<sup>14</sup>C]malonyl-CoA (47.8 Ci/mol), and the mixed solution is incubated for 2-5 minutes at room temperature to allow MTA to reach equilibrium. Acyl-ACP, either C16-ACP or C10-ACP, in a total volume of 2.5  $\mu$ l is added to the above solution and the samples are placed at 37°C. The reaction is started by addition of 5  $\mu$ l of enzyme which is in potassium phosphate buffer (pH 7.5), 20% glycerol (V/V), 1mM EDTA, and 10 mM  $\beta$ -mercaptoethanol.

The reaction is stopped after 15 minutes by addition of 400  $\mu$ l of reducing agent containing 0.1 M potassium phosphate, 0.4 M potassium chloride, 30% tetrahydrofuran, and 5 mg/ml NaBH<sub>4</sub>, with the NaBH<sub>4</sub> being added just prior to use. Tubes are vortexed to mix thoroughly after addition of reducing agent and then are incubated for at least 30 minutes (and for up to 3 hours) at 37°C. Toluene, 0.4 ml, is added and samples are again vortexed to mix. Samples are centrifuged for 10 seconds in a microcentrifuge to separate phases. 300  $\mu$ l of the toluene layer (upper phase) is added to 5 ml Aquasol (NEN Research Products (Dupont) Boston, MA) and incorporation of [2-<sup>14</sup>C]malonyl CoA is determined by scintillation counting.

B. Preparation of Assay Components

## Purification of Acyl Carrier Protein from *E. coli*

35      1.1 Assay for ACP. The assay for ACP includes in a volume of 40  $\mu$ l, 100 mM Tris-HCl, pH8.0, 1% Triton X-100 (w/v) (Boehringer Mannheim Biochemicals, Indianapolis, IN), 2 mM dithiothreitol, 5mM adenosine triphosphate, 20 mM MgCl<sub>2</sub>, 300 mM LiCl, 33.5  $\mu$ M [1-<sup>14</sup>C]palmitic acid (NEN

Research Products (Dupont), Boston, MA, specific activity 56 Ci/mol), 32 mU of acyl-ACP synthetase (purified as described below), and 5  $\mu$ l of ACP source to be assayed.

Each assay tube is centrifuged briefly to collect all the liquid into the bottom of the tube, then for three hours at 37°C. From each assay tube 30  $\mu$ l of the 40  $\mu$ l volume is dropped onto a 1  $\text{cm}^2$  piece of filter paper, numbered in pencil and suspended on a straight pin. The filters are allowed to air dry for at least 45 minutes, then are washed two times in chloroform:methanol:acetic acid (3:6:1, v:v:v) at the ratio of 15 ml/filter, in a beaker with stirring. The filters are placed into scintillation vials and counted in 5ml Aquasol in a Beckman LS3801 liquid scintillation counter (Beckman, Fullerton, CA). A one-to-one stoichiometry is assumed between ACP and the 1- $^{14}\text{C}$ -palmitate with the product,  $^{14}\text{C}$ -palmitoyl-ACP, bound to the filter, and the free fatty acid washed into the organic solvent.

1.2 Extraction and Purification of ACP. The acyl carrier protein (ACP) is purified from *E. coli* strain K-12 by a modification of the method of Rock and Cronan, (*Methods in Enzymol.* (1981) 71:341-351). The *E. coli* is obtainable from Grain Processing Corporation (Muscatine, IA) as frozen late-logarithmic phase cells. One kilogram of frozen packed cells of *E. coli* K12 is thawed overnight at 4°C. At room temperature, the cells are combined with 1 L deionized water, 500 mg lysozyme (from chicken egg white, Sigma), and 200 ml lysis buffer containing 1M Tris-HCl, 1M glycine, 250 mM sodium EDTA, pH 8.0. This is stirred at room temperature by a Wheaton overhead stirrer. After two hours, 5 g of Triton X-100 is added and stirring is continued for another hour. The suspension is further homogenized by blending in a 6L Waring Model CB6 Commercial Blender for 60 seconds. Stirring of the homogenate is resumed and 2 L of isopropanol are added from a separatory funnel in a thin stream over twenty minutes to ensure immediate mixing.

Immediately after the addition of the isopropanol, the homogenate is clarified by centrifugation at 10,000 x g for 30 minutes at room temperature. The pH of the supernatant fluid is adjusted to 6.5 with glacial acetic acid and this 5 is combined with 440 ml of a 50% slurry of Whatman DE52 (Whatman, Clifton, NJ) in 10 mM bis[2-hydroxyethyl]imino-tris[hydroxymethyl]-methane hydrochloride (Bis-Tris-HCl) (Sigma, St. Louis, MO), pH 6.5. It is important to sediment the precipitate and combine the supernatant with 10 the DE52 as quickly as possible to prevent clogging of the filters and the column in subsequent steps. The DE52 slurry is allowed to stir overnight or for at least one hour at room temperature, and is then filtered on a sintered glass funnel. The DE52 in the filter funnel is 15 washed five times with 200 ml 10 mM Bis-Tris-HCl, 2 mM DTT, 0.1% (w/v) TX-100, and four times with 200 ml 10 mM Bis-Tris-HCl, 2 mM DTT, 250 mM LiCl. It is resuspended in 200 ml of the last wash buffer and poured into a 4.8 cm x 40 cm column. The flow-through is collected in bulk. The ACP is 20 eluted at 2 ml/min with 10 mM Bis-Tris-HCl, 2 mM DTT, 600 mM LiCl; 6 ml fractions are collected.

After it was determined by the radiometric assay that the ACP fractions also contain a yellow contaminant, the ACP fractions were selected for pooling by their yellow 25 color. The fractions are pooled into a centrifuge bottle and with stirring on ice, the ACP is precipitated by the dropwise addition of 50% ice cold trichloroacetic acid (TCA) to a final concentration of 5% TCA. The protein is quickly sedimented by centrifugation at 10,000 x g for 30 minutes at 4°C.

The pellet is suspended in 10 ml deionized water, and solubilized by the addition of 500 µl aliquots of 1 M Tris base, with homogenization in a hand-held ground glass homogenizer after each addition. At pH 7.0, the solution 35 is clear. The volume is brought to 50 ml with deionized water, and contaminating protein is precipitated by the addition of 26.15 g (80% saturation) solid ammonium sulfate with stirring on ice over 45 minutes. Stirring is

continued for one hour on ice, and the protein is sedimented by centrifugation at 23,700 x g for 45 minutes. The ACP is concentrated by precipitation with trichloroacetic acid and resolubilized with Tris base as described above, keeping the final volume to about 5ml or less. The solution is clarified by centrifugation at 20,000 x g for 20 minutes at 4°C. A typical yield of ACP is 80-100 mg from 1 kg packed cells of *E. coli* K12.

5           2. Purification of Malonyl Coenzyme A:Acyl Carrier Protein  
10          Transacylase (MTA) from *E. coli*.

15          2.1 MTA Assay. The MTA activity is measured at room temperature by modification of the assay of Alberts et al. (*Methods in Enzymol.* (1969) 14:53-56). The reaction mix of 100 µl includes 100 mM potassium phosphate buffer, pH 6.5, 100 µM ACP, 100 µM malonyl coenzymeA (Sigma), 10 nCi [ $2-^{14}\text{C}$ ]malonyl coenzyme A (specific activity 43.1 Ci/mol, NEN), 2 mM  $\beta$ -mercaptoethanol and enzyme in 10 µl. The ACP is incubated with an equal volume of 20 mM  $\beta$ -mercaptoethanol for 15 minutes before being added to the rest of the reaction mix excluding the enzyme. The reaction is started by the addition of enzyme, incubated for 4 minutes at 23°C, and stopped by the addition of 400 µl ice cold 5% perchloric (v/v) acid. The reaction is held on ice for at least 20 minutes. The precipitate is collected on a Millipore HA, 0.45 micron filter on a Millipore filtration manifold (Millipore, Bedford, MA). The precipitate from each assay tube is washed on the filter three times with 5 ml ice cold 5% (v/v) perchloric acid. The filters are dropped into 5 ml Aquasol (NEN) without neutralization or drying, and are counted in a Beckman LS3801 Liquid Scintillation Counter (Beckman, Fullerton, CA). One unit of MTA activity is defined as the conversion of 1 µmole of acid-soluble malonate to acid-precipitable malonate per minute. Protein determinations are by the micromethod of Bradford (*Analy. Biochem.* (1976) 72:248-254), using Bio-Rad Protein Assay Dye Reagent (Bio-Rad, Richmond, CA).

2.2 Extraction and Purification of MTA. The MTA is purified from *E. coli* by a modification of the method of Alberts et al. (*Methods in Enzymol.* (1969) 14:53-56). All steps of the purification are carried out at 4°C.

5 Fractions are routinely stored overnight at 4°C between steps of the protocol. Frozen packed cells (20 g) of *E. coli* K12 available from Grain Processing Corporation (Muscatine, IA) are thawed overnight, then suspended in 20 ml Buffer A which contains 10 mM Tris-HCl, 1 mM sodium EDTA and 10 mM  $\beta$ -mercaptoethanol at pH 7.5. The cells are ruptured by two passes through a French Pressure Cell (American Instrument Company, Silver Spring, MD) at 16,000 psi. The broken cells are diluted with 40 ml of Buffer A and the particulates are sedimented by centrifugation at 16,000  $\times$  g for 30 minutes. The supernatant is combined with streptomycin sulfate (Sigma) from a 20% solution in Buffer A (w/v) for a final concentration of 60 mg streptomycin sulfate per milliliter. The precipitate is sedimented immediately by centrifugation at 17,500  $\times$  g for 15 minutes. The supernatant fluid is diluted with three volumes of Buffer B, which contains 10 mM potassium phosphate, 1 mM sodium EDTA and 10 mM  $\beta$ -mercaptoethanol at pH 7.0, and applied at 360 ml/h to a 4.8 cm  $\times$  11 cm column of DEAE Fast-Flow (Pharmacia, Piscataway, NJ) equilibrated 20 in Buffer B. The column is washed with two bed volumes of Buffer B containing 75 mM LiCl. The MTA activity is eluted 25 with a two-bed volume gradient of Buffer B containing 75-250 mM LiCl.

The fractions containing peak MTA activity, at about 30 240 mM LiCl, are pooled and non-MTA protein is precipitated by the addition of solid ammonium sulfate (29.5 g/100ml.) The suspension is stirred for 30 minutes, then clarified by centrifugation at 16,000  $\times$  g for 30 minutes. The MTA activity is precipitated by the addition of solid ammonium 35 sulfate to the supernatant fluid (19.7 g/100 ml.) which is stirred and sedimented by centrifugation as above. The pellet is suspended with 10 ml Buffer C, containing 20 mM potassium phosphate, 1 mM sodium EDTA and 10 mM  $\beta$ -

mercaptoethanol at pH 7.0 and applied to a 2.5 cm x 40 cm column of Sephadex G-100 (Pharmacia Inc., Piscataway, NJ) equilibrated in Buffer C. The protein is eluted at 60 ml/h. The fractions containing peak MTA activity are 5 pooled and applied at 60 ml/h to a 2.5 cm x 4.7 cm column of DEAE Fast-Flow in Buffer D, which is Buffer C containing 150 mM LiCl. The column is washed with three bed volumes of Buffer D, then a 4-bed volume gradient of Buffer C containing 150-300 mM LiCl is applied. The MTA activity 10 elutes in the 150 mM LiCl wash rather than in the LiCl gradient as was described by Alberts et al. (supra). The fractions containing peak MTA activity are pooled and the protein is precipitated by the addition of ammonium sulfate (61.1 g/100 ml.) The suspension is stirred for one hour 15 and the precipitated MTA activity is collected by centrifugation at 16,000 x g for one hour. The pellet is dissolved in 0.5 ml Buffer C and dialysed overnight against one liter of Buffer C. The dialysate is stored as aliquots in polypropylene tubes at -70°C.

20 About 3.7 units of MTA activity are produced from 20 g of packed cells by this method. When stored at -70°C, as a concentrate of 2.5 U/ml, the MTA retains 100% of its activity for at least 18 months. For the  $\beta$ -ketoacyl-ACP synthase assay, it is diluted into "20 buffer" (described 25 below in Example 3) containing 10 mM  $\beta$ -mercaptoethanol.

3. Purification of Acyl-Acyl Carrier Protein Synthetase. Acyl-ACP synthetase is purified according to the method of Rock and Cronan, 1979, *J. Biol Chem*, Vol 254 No. 15:7116-7122, with the following changes. The heat 30 treatment is eliminated. The fraction from the Blue-Sepharose column is applied at 240 ml/hour to a 2.4 cm x 40 cm column of BioGel P-6DG (Bio-Rad, Richmond, CA) equilibrated in 5 mM Tris-HCl, pH 8.0 with 2% (w/v) Triton X-100. Throughout the purification, protein levels are 35 determined with the Micro BCA Protein Reagent from Pierce (Rockford, IL).

Although quite variable, the yield of acetyl-ACP synthetase is about 55 units from 125 g *E. coli* K12 packed

cells. One unit of activity is described as the amount of protein required to produce 1 nmol of C16:0-ACP from palmitate and ACP per minute. During storage at 4°C, a precipitate is formed that must be suspended before use.

5    4. Synthesis and Purification of Acyl-Acyl Carrier Protein.

The C10:0-ACP and C16:0-ACP substrates are synthesized enzymatically and are purified by the procedure of Rock et al. (*Methods in Enzymol.* (1981) 72:397-403). The acyl-ACP substrates for the  $\beta$ -ketoacyl synthase I and II assays require no radiolabel, but sufficient  $^{14}\text{C}$  or  $^3\text{H}$  may be included to monitor the purification after the enzymatic synthesis. The yield of acyl-ACP is also monitored by the filter assay method described by Rock et al. (*supra*). The synthetic reaction includes, in a 10 ml volume, 4.8  $\mu\text{mol}$  palmitic or decanoic free fatty acid, 800,000 cpm [9,10- $^3\text{H}$ ]palmitic acid (NEN Research Products (Dupont), Boston, MA, specific activity 28.5 Ci/mmol) or [ $1-^{14}\text{C}$ ]decanoic acid (ICN Biomedicals, Inc, Costa Mesa, CA, specific activity 3.6 Ci/mol), 100 mM Tris-HCl pH 8.0, 5 mM adenosine 5'-triphosphate, 2 mM dithiothreitol, 2% Triton X-100 (Boehringer Mannheim Biochemicals, Indianapolis, IN), 400 mM LiCl, 10 mM MgCl<sub>2</sub>, 15 mg ACP and 3 units acyl-ACP synthetase. The mix is incubated at 37°C for three hours and may be stored at room temperature for about 15 hours or at -20°C until purification.

The purification of the acyl-ACP from the synthetic mix is carried out at room temperature according to the procedure of Rock et al. (*supra*) with the following changes. The wash with 2-propanol is omitted as it was found that the free fatty acid does not bind to the DE-52 column. The volume of the wash of the DE-52 with equilibration buffer, however, is increased to ensure removal of the Triton X-100. Some lots of Octyl-Sepharose (Pharmacia Inc., Piscataway, NJ) do not allow adsorption of the acyl-ACP. A test column is therefore run with each new lot of the resin. In most cases, 50% 2-propanol is required for complete recovery of the acyl-ACP. The second

DE-52 column is omitted; instead, the acyl-ACP in 50% 2-propanol is brought to dryness by lyophilization or in a SpeedVac Concentrator (Savant Instruments Inc, Hicksville, NY), and is reconstituted with deionized water. The  
5 substrates are stored at -70°C.

Typical yields are 1.7  $\mu$ mol of palmitoyl-ACP or 0.5  $\mu$ mol of decanoyl-ACP.

**Example 3. Purification of Synthase Proteins**

In this example, purification of  $\beta$ -ketoacyl-ACP synthase from developing seeds of *Ricinus communis* is described. All steps of protein purification are done at 4°C or on ice. Until the ricin, a toxic seed protein, has been removed, all steps are done in a glove box or with appropriate precautions to prevent exposure to the toxin.  
10  
15

A. Extraction

1. Source tissue.

*Ricinus communis* is grown in the greenhouse under the following conditions.

20 : temperature range is 22-32°C  
: lighting is set for a 16-hour day length  
(supplemental lighting is with high pressure sodium lamps)  
: fertilizer is 60ppm nitrogen daily via watering  
The developing seeds are harvested at 21 to 28 days after  
25 the flowers open. The endosperm is removed and frozen in  
liquid nitrogen, and is stored at -70°C for up to 18 months  
until used for purification of synthase activity.

2. Purification Buffers.

The buffers used in the purification of  $\beta$ -ketoacyl-ACP synthases are at pH 7.5, and contain 20% (v/v) glycerol, 1 mM sodium EDTA, 10 mM  $\beta$ -mercaptoethanol, and potassium phosphate at the millimolar concentration that is designated in the buffer name. For example, "20 buffer" contains 20 mM potassium phosphate. The exception is "zero buffer", which is lacking only in the potassium phosphate, and has a pH of approximately 5.  
30  
35

3. Extraction Procedure.

A 200 g batch of frozen tissue is homogenized in an Osterizer blender for 15 seconds at top speed in 400 ml of "40 buffer" which also contains the following protease inhibitors: 1 mM amino caproic acid, 1  $\mu$ M leupeptin, 1  $\mu$ M pepstatin, and 100  $\mu$ M phenylmethylsulfonyl fluoride. Blending is limited to 15 seconds to prevent release of too much of the seed lipid, which if present would interfere with the subsequent ammonium sulfate fractionation. The crude homogenate is clarified by centrifugation at 16,000 x g for one hour. The supernatant fluid, Fraction A, contains the solubilized  $\beta$ -ketoacyl-ACP synthase activity.

B. Ammonium Sulfate Fractionation

Fraction A, is decanted through cheesecloth and Miracloth (CalBiochem, La Jolla, CA) and stirred with ammonium sulfate (40.4 g/100 ml) for one hour. The precipitated protein is sedimented by centrifugation at 16,000 x g for one hour. The supernatant fluid, Fraction B, containing the  $\beta$ -ketoacyl-ACP synthase activity, is stirred with ammonium sulfate (13.4 g/100 ml) for one hour and the protein sedimented by centrifugation at 16,000 x g for one hour. This ammonium sulfate pellet, Fraction D, is suspended in a minimal volume of "20 buffer" and stored at -70°C

C. Reactive Green 19 Agarose Chromatography

Fraction D is diluted with "20 buffer" to a final volume of 1650 ml. Fraction D is then combined with 200 ml (packed bed volume) Reactive Green 19-agarose (Sigma, St. Louis, MO) which has been pre-equilibrated in "20 buffer", and this solution is stirred by an overhead stirrer for two hours. The Green 19-agarose is filtered on a sintered glass funnel and washed with 200 ml of "50 buffer". The washed Green 19-agarose is suspended in an additional 175 ml of "50 buffer" and is poured into a 4.8 cm x 30 cm column. The agarose is packed at 200 ml/hr, until the last of the "50 buffer" reaches the top of the Green 19-agarose

bed. The synthase activity is then eluted with "250 buffer". The synthase activity elutes in the first 100 ml of "250 buffer". The fractions are stored at -20°C until the next step of purification.

5 D. ACP-Affinity Chromatography

An affinity matrix for purification of the synthase activities is prepared by reacting highly purified *E. coli* ACP, with CNBr-activated Sepharose 4B by modification of the procedure of McKeon and Stumpf (*J. Biol. Chem.* (1982) 10 257:12141-12147) as described below.

1. Matrix Preparation.

*E. coli* ACP, 141 mg in a volume of 40 ml, is dialyzed against 3 volumes of 1 liter of 100 mM NaHCO<sub>3</sub>, pH 6.0, for 24 hours in Spectrapor #7 dialysis tubing (molecular weight 15 cutoff = 2000). One millimolar dithiothreitol is included in the second buffer change only, for a total of 3 hours. One hundred milliliters of 1 mM HCl is added to 6.0 g of CNBr-activated Sepharose in a 250 ml polypropylene centrifuge bottle. This is mixed at high speed for 15 minutes at room temperature on a "Rugged Rotator" (Kraft Apparatus, Inc., Mineola, NY) ferris-wheel type mixer. The resulting slurry is poured into a Kontes (Vineland, NJ) 2.5 cm x 20 cm column and is washed with 1.1 liter of 1 mM HCl at 250 ml/hr, at room temperature for the first two hours 20 and then at 4°C. The CNBr-activated Sepharose is then washed in a 60 ml sintered glass funnel five times with 20 ml 100 mM NaHCO<sub>3</sub>, pH 6.0, followed by 5 times with 20 ml 100 mM NaHCO<sub>3</sub>, pH 7.0. The CNBr-activated Sepharose is then resuspended in 40 ml of 100 mM NaHCO<sub>3</sub>, pH 7.0, and 25 transferred to a clean 250 ml polypropylene centrifuge bottle. The dialyzed ACP is added to the CNBr-activated Sepharose slurry and the suspension is mixed for 24 hours at 4°C on the "Rugged Rotator" mixer to couple the ACP to the CNBr-activated Sepharose. The ACP-Sepharose is 30 sedimented by centrifugation for 6 minutes at 100 x g (800 rpm in a Beckman GP tabletop swinging bucket centrifuge) 35 at 4°C. The supernatant fluid is removed and saved for

assay. Fifty milliliters of 1 M ethanolamine at pH 8.0 is added to the ACP-Sepharose and mixed on the "Rugged Rotator" at 4°C for 16 hours to block unused binding sites.

2. Column Packing.

5      The ACP-Sepharose gel is poured into a 2.5 cm x 20 cm column and is washed with 100 ml of 100 mM NaHCO<sub>3</sub>, pH 7.0 containing 500 mM NaCl, followed by another wash with 100 ml of 100 mM sodium acetate, pH 4.0 containing 500 mM NaCl. This washing with alternate buffers is repeated three  
10     times. The gel is then washed with 200 ml of the bicarbonate buffer, and finally with 200 ml of "20 buffer" plus 0.02% sodium azide. The gel is left in this buffer until further use. The unbound fractions were assayed for protein by the method of Bradford (Analy. Biochem. (1976)  
15     72:248-254) and it was calculated that 134 mg of the ACP had bound to the 25 ml CNBr-activated Sepharose. Before application of protein sample, the ACP-Sepharose is packed into a 2.5 cm x 10 cm column and washed with 250 ml "20 buffer". Final volume of the packed bed is 25 ml.

20     3. Sample Preparation.

The fractions from the Green 19-agarose chromatography with synthase activity are combined in an Amicon 8400 stirred pressure cell apparatus with a PM30 membrane (Amicon, Danvers, MA). The emptied fraction tubes are  
25     rinsed with an equal volume of "zero buffer" and the rinse is added to the pooled fractions. Pressure is applied via nitrogen gas until the volume of the concentrate is 10% of the original solution volume. The pressure is then released and the stirring is continued for an additional 5 mins. The concentrate is diluted with "zero buffer" until  
30     the conductivity reaches that of "10 buffer", as measured with a Beckman conductivity meter.

4. Chromatography of Fractions from Green-19 Agarose.

The diluted sample containing synthase activity is  
35     loaded onto the ACP-Sepharose column at a flow rate of 100 ml per hour, and the column is washed with one bed volume

of "20 buffer". The flow-through and the "20 buffer" wash are collected in bulk, and 6 ml fractions are collected during elution. The protein is eluted at 25 ml per hour with five bed volumes of "100 buffer" followed by a ten bed volume gradient of "250 buffer". Following the gradient, the column is washed with additional "500 buffer" until a total of 72 fractions have been collected. The column is regenerated by washing with 10 bed volumes of "500 buffer", followed by 10 bed volumes of "20 buffer". When not in use, the column is stored in "20 buffer" containing 0.02% sodium azide as a preservative.

##### 5. Assay of Fractions for Synthase Activity

The fractions were assayed for both C16-ACP and C10-ACP condensing activities. The major peak of C16-ACP condensing activity eluted in fractions 32-44. A portion of the C10-ACP activity eluted with the major C16-ACP condensing activity peak, but the bulk of the C10-ACP condensing activity eluted after the C16-ACP peak, sometimes as a broad shoulder to the initial peak, and sometimes as a separate peak.

##### E. SDS-PAGE Analysis and Separation of Peptides

The fractions of the ACP-Sepharose column are analyzed by polyacrylamide gel electrophoresis in sodium dodecyl sulfate (SDS-PAGE) by a variation of the method of Laemmli (Nature (1970) 227:680-685). The resolving gel contains only 0.2% bis-acrylamide instead of the standard 0.267%. A Bio-Rad (Richmond, CA) Protean II mini-gel unit is used at 200V. The current is allowed to flow until the tracking dye reaches the end of the gel, and then for an additional 10 minutes. This allows better separation of the two major peptide bands. Fractions in the first peak of synthase activity, which contains the majority of the C16-ACP condensing activity, contain both a 46kD and a 50kD band with approximately equal silver-staining intensities. The bulk of the C10-ACP condensing activity, which elutes after the C16-ACP condensing activity, is associated with a more faintly staining 50 kD band. The synthase fractions are

5 pooled, concentrated and desalting and the proteins are separated in bulk by SDS-PAGE electrophoresis as described. From 200 g, fresh weight, of embryonic seed tissue, approximately 50 µg of each of the 46kD and 50kD proteins is recovered.

F. Purification Table

Protein recovery and synthesize activity at each step of purification are presented in the tables below.

10

TABLE VI  
Purification of *R. communis*  
β-ketoacyl-ACP synthase I

15

	Total Protein (Bradford)	Protein Recovery %	Total Activity mol/min	Activity Recovery %	Specific Activity mol/min/mg	Purification -fold
	mg	%	mol/min	%	mol/min/mg	
20 crude extract	1059.4	100.00	13.3	100.00	.012	1.0
25 0-60% ammonium sulfate (supernatant)	386.6	36.49	33.1	249.12	.086	6.8
30 sat'd ammonium sulfate (pellet)	149.5	14.11	9.7	72.75	.065	5.2
35 Green-19 Agarose	18.3	1.73	.97	7.31	.053	4.2
40 ACP-Sepharose "Peak Two" (affinity chromatography)	0.01*	0.00	.16	1.22	16.2	1290.3

\*rough estimate from Laemmli SDS-PAGE gel

TABLE VII  
Purification of *R. communis*  
 $\beta$ -ketoacyl ACP Synthase II

	Total Protein (Bradford)	Protein Recovery	Total Activity	Activity Recovery	Specific Activity	Purification -fold
	mg	%	mol/min	%	mol/min/mg	
10	crude extract	1059.4	100.00	17.5	100.00	.016
15	0-60% ammonium sulfate (supernatant)	386.6	36.49	12.8	73.35	.033
20	sat'd ammonium sulfate (pellet)	149.5	14.11	10.0	57.26	.067
25	Green-19 Agarose	18.3	1.73	.93	5.29	.051
30	ACP-Sepharose (affinity chromatography)	0.09*	0.01	.15	0.87	1.70
	*rough estimate from Laemmli SDS-PAGE gel					

#### G. Electroblotting from SDS-PAGE

##### 1. Gel Electrophoresis.

Material from the ACP-Sepharose column is applied to a 35 1.5 mm thick SDS reduced cross-linker mini-polyacrylamide gels prepared as described above in Example 3E. The resolving gel is poured the night before the gels are run; the stacking gel is poured the same day. Each ACP-Sepharose column pool contains 40-60  $\mu$ g of protein. The protein is divided between 40 2 gels of 10 wells each, with each lane containing 2-3  $\mu$ g of protein. The gels are run as described above in Example 3E. After electrophoresis, the gels are assembled into a Bio-Rad Mini Trans-Blot module (Bio-Rad, Richmond, CA) and the protein

is electroblotted to either nitrocellulose or polyvinylidenefluoride (PVDF) membranes.

2. Blotting to Nitrocellulose.

When protein is electroblotted to nitrocellulose, the blotting time is 1 hour and the buffer used is 25 mM Tris, 192 mM glycine in 20% methanol. Following electroblotting to nitrocellulose, membranes are stained in 0.1% (w/v) Ponceau S in 1% (v/v) acetic acid for 2 minutes and destained in 2-3 changes of 0.1% (v/v) acetic acid, 2 minutes for each change. Following this, nitrocellulose membranes are stored wet in heat-sealed plastic bags at -20° C. Originally, nitrocellulose membranes were destained in 1% acetic acid and then rinsed with HPLC grade water prior to storage. The stained bands fade rapidly in neutral pH however, so the destain solution was changed to 0.1% acetic acid and membranes were also stored wetted in this solution. If time permits, blots are not frozen but used immediately for digestion to create peptides for determination of amino acid sequence as described below.

20 3. Blotting to PVDF.

When protein is electroblotted to PVDF, the blotting time is 30 minutes and the buffer used is 125 mM Tris/50 mM glycine in 10% (v/v) methanol. Following electroblotting to PVDF, membranes are stained in 0.1% (w/v) Coomassie Blue in 50% (v/v) methanol/10% (v/v) acetic acid for 5 minutes and destained in 2-3 changes of 50% (v/v) methanol/10% (v/v) acetic acid, 2 minutes for each change. Following this, PVDF membranes are allowed to air dry for 30 minutes and are then stored dry in heat-sealed plastic bags at -20° C. Protein blotted to PVDF is used directly to determine N-terminal sequence of the intact protein.

**Example 4. Determination of Amino Acid Sequence**

In this example, a method for the determination of the amino acid sequence of a plant β-ketoacyl-ACP synthase is described.

A. Digestion

Proteins blotted to nitrocellulose are subjected to digestion with proteases in order to obtain peptides for sequencing. The method used is that of Aebersold, et al. 5 (PNAS (1987) 84:6970). Bands of both the 46kD and 50kD proteins, and also an equal amount of blank nitrocellulose to be used as a control, are cut out of the nitrocellulose membrane, chopped into pieces 1 x 2 mm in size, and washed several times with HPLC grade water in order to remove the 10 Ponceau S. The Ponceau S is not always removable if the blot has been frozen, but the presence of the stain apparently has no effect on the digest procedure. Following this wash, 1.0-1.2 ml of 0.5% polyvinylpyrrolidone (PVP-40, Aldrich, Milwaukee, WI) in 0.5% acetic acid is added to the membrane 15 pieces and this mixture is incubated for 30 minutes at 37°C. The PVP-40 is needed to block sites on the nitrocellulose which would bind the protease and/or peptides released by the protease digestion. Following treatment with PVP-40, the membrane pieces are rinsed with several 1.0 ml volumes of HPLC 20 grade water to remove excess PVP-40. The pieces are then suspended in either trypsin digest buffer, 100 mM sodium carbonate pH 8.2, or endoproteinase gluC buffer, 25 mM ammonium carbonate/1 mM EDTA, pH 7.8. Acetonitrile is added to the digest mixture to a concentration of 5% (v/v). 25 Protease, trypson or endoproteinase glu C is diluted in digest buffer and added to the digest mixture in a ratio of 1:10 (w/w) protease to protein. Final volume of the digest mixture is 100 µl. Digests are incubated overnight. Trypsin digests are incubated at 37°C and endoproteinase gluC digests are 30 incubated at room temperature.

B. Separation of Peptides

Following overnight incubation, digest reactions are stopped by the addition of 10µl 10% (v/v) trifluoroacetic acid (TFA). The digest mixture is removed from the nitrocellulose 35 pieces, the nitrocellulose pieces are washed with 1-5 100µl volumes of 0.05% (v/v) TFA, and these volumes are concentrated to a volume of less than 100µl in a Speed-Vac (Savant;

Farmingdale, NY). These concentrates are then injected over a Vydac reverse phase Protein & Peptide C18 column (2.1mm x 100mm) installed in an Applied Biosystems (Foster City, CA) Model 130 High Performance Liquid Chromatograph (HPLC).

5 Mobile phases used to elute peptides were: Buffer A: 0.1mM sodium phosphate, pH2.2; Buffer B: 70% acetonitrile in 0.1mM sodium phosphate, pH2.2. A 3-step gradient of 10-55% buffer B over two hours, 55-75% buffer B over 5 minutes, and 75% buffer B isocratic for 15 minutes at a flow rate of 50 µl/minute is  
10 used. Peptides are detected at 214nm, collected by hand, and then stored at -20° C.

In early digestion experiments, the PVP-40 was incompletely removed and eluted as a broad peak at 50% buffer B. Very few peptides were recovered from these runs. The  
15 PVP-40 peak was collected and then treated with an equal volume of chloroform to extract the PVP-40. The aqueous material was then reapplied to an Applied Biosystems HPLC, as above, except in this case buffer A was 0.1% TFA, buffer B was 0.1% TFA in acetonitrile, and the column used was an Applied  
20 Biosystems (Foster City, CA) reverse phase Spheri-5 RP18 column (1 mm X 50 mm). The gradient and flow rate were as above and the peaks were detected, collected and stored in the same manner.

In later digestion experiments, PVP-40 was thoroughly removed and no chloroform extraction was necessary. In order to remove the PVP-40 completely, nitrocellulose pieces are washed with many volumes of water (8 x 4 ml), checking the absorbance of the washes at 214 nm on a spectrophotometer.  
25 Also, PVP-40 is more easily removed if bands are not cut into small pieces until after PVP-40 treatment and washing. These 30 modifications eliminate interference problems with the PVP-40.

C. Reduction & Alkylation of Cysteine Residues

Digested protein can be reduced with β-mercaptopethanol  
35 and alkylated with <sup>3</sup>H-labelled iodoacetic acid as a method to improve identification of cysteine residues when the peptides are sequenced. The β-mercaptopethanol is added to freshly digested protein at a molar ratio of 20:1 over the assumed

concentration of sulfhydryl groups in the sample and peptides are incubated at room temperature for 30 minutes.  $^3\text{H}$ -labelled iodoacetic acid is then added at a concentration of 1.1 times the concentration of  $\beta$ -mercaptoethanol and the peptides are  
5 incubated in darkness (covered with foil) at room temperature for 60 minutes. To stop the alklylation, more  $\beta$ -mercaptoethanol is added at a concentration of one-tenth of that used to reduce the peptides. Ten  $\mu\text{l}$  of 10% TFA is then added as usual to stop any further action of the protease.  
10 This can not be added prior to the reduction/alkylation as those reactions work best under the basic pH conditions present in the digest mixture. The reduced/alkylated protein is then concentrated in a Speed-Vac prior to separation of the peptides by HPLC, as described above.

15 D. N-terminal Sequencing of Proteins & Peptides

All sequencing is performed by Edman degradation on an Applied Biosystems 477A Pulsed-Liquid Phase Protein Sequencer; phenylthiohydantoin (PTH) amino acids produced by the sequencer are analyzed by an on-line Applied Biosystems 120A PTH Analyzer. Data are collected and stored on to the on-board computer of the sequencer and also on to a Digital Microvax using ACCESS\*CHROM software from PE NELSON, Inc (Cupertino, CA). Sequence data is read from a chart recorder, which receives input from the PTA Analyzer, and is confirmed 25 using quantitative data obtained from the sequencer on-board computer system. All sequence data is read independently by two operators with the aid of the data analysis system.

For peptide samples obtained as peaks off of an HPLC, the sample is loaded on to a Polybrene coated glass fiber filter 30 (Applied Biosystems, Foster City, CA) which has been subjected to 3 pre-cycles in the sequencer. For peptides which have been reduced and alkylated, a portion of the PTA-amino acid product material from each sequencer cycle is counted in a liquid scintillation counter. For protein samples which have 35 been electroblotted to PVDF, the band of interest is cut out and then placed above a Polybrene coated glass fiber filter, pre-cycled as above and the reaction cartridge is assembled according to manufacturer's specifications.

In order to obtain protein sequences from small amounts of sample (5-30 pmoles), the 477A conversion cycle and the 120A analyzer as described by Tempst and Riviere (*Analys. Biochem.* (1989) 183:290).

5       Fragments generated from the trypsin and gluC digestion steps are presented in Fig. 2 and 3. Other proteases may be used to digest the synthase proteins, including but not limited to lysC and aspN. While the individual digest buffer conditions may be different, the  
10 protocols for digestion, peptide separation, purification, and sequencing are substantially the same as those outlined for the digestions with trypsin and gluC. Alternatively, synthases may be digested chemically using cyanogen bromide (*Gross Methods Enzymol* (1967) 11:238-255 or Gross and  
15 Witkop *J. Am. Chem. Soc.* (1961) 83:1510), hydroxylamine (Bornstein and Balian *Methods Enzymol.* (1977) 47:132-745), iodosobenzoic acid (Inglis *Methods Enzymol.* (1983) 91:324-332), or mild acid (Fontana et al., *Methods Enzymol.* (1983) 91:311-317), as described in the respective references.  
20

**Example 5. Methods to Distinguish Synthase Proteins**

In this example, a method to selectively label synthase proteins with cerulenin and a method to express synthase activity in a prokaryote are described.

A. Cerulenin Labeling

1. Distinguishing Synthase I and II using Cerulenin. Cerulenin has been shown to bind to the active sites of synthase I and synthase II. In *S. oleracea*, at a concentration of 5 $\mu$ M, cerulenin reacts readily with the active site of synthase I but not synthase II. Cerulenin will react readily, however with both synthase I and synthase II at concentrations above 50 $\mu$ M (Shimakata and Stumpf, *Proc.Nat.Acad.Sci.* (1982) 79:5805-5812).  
30
- 35   Cerulenin shows similar reaction with synthase I and synthase II of *R. communis* as shown in Figure 1. To differentially radiolabel synthase I and synthase II for subsequent gel analysis and protein sequencing to determine

the active sites,  $^3\text{H}$ -cerulenin is reacted with concentrated post-ACP-sepharose (Example 3) protein containing synthase activity at two different  $^3\text{H}$ -cerulenin concentrations. The samples are then run on Laemmli SDS-PAGE and the molecular weights of the  $^3\text{H}$ -labeled proteins are determined by scintillation counting. Candidate bands, containing both protein and  $^3\text{H}$ -label, are digested with endoproteinase gluC and the peptides are separated and sequenced via Edman chemistry.

10 2. Preparation of Radiolabeled Cerulenin.

[ $^3\text{H}$ ]-Cerulenin (specific activity = 585 Ci/mol) was prepared from unlabeled cerulenin (Sigma) by Amersham (Arlington Heights, IL) tritium labeling service. The material is purified by HPLC.

15 3. Labeling Synthase I.

$^3\text{H}$ -cerulenin is prepared for use by measuring out the required amount of  $^3\text{H}$ -cerulenin solution (in methanol) necessary to make 1.0 mls of 5 $\mu\text{M}$  solution (5nmoles) into a screw-cap microfuge tube. The methanol is then evaporated under a stream of nitrogen, chasing with a diethyl ether to ensure complete evaporation of the methanol. The tube is capped and the dry  $^3\text{H}$ -cerulenin is stored on ice until use (see below).

Material from ACP-Sepharose "Peak One" which contains both the 46kD and 50kD proteins is pooled and concentrated in an Amicon stirred pressure cell with a PM10 43 mm membrane. The concentrate is diluted in the cell with "zero" buffer (described in Example 3 A.2) and reconcentrated to desalt the material. The material is desalting to a phosphate concentration of approximately 20mM. Initial volume of the pooled fractions is 60-66mls and the volume of the final concentrate is 1.0ml or less, which represents a 40-fold or greater concentration.

The concentrated, desalted material is removed from the Amicon stirred cell to the microfuge tube containing the  $^3\text{H}$ -cerulenin and additional "20" buffer (described in Example 3 A.2) is added to a final volume of 1 ml. The

mixture is incubated at 37°C for 20 minutes to allow complete reaction with the synthase I.

4. Labeling Synthase II.

To label Synthase II with  $^3\text{H}$ -cerulenin in a mixture of synthase I and synthase II, synthase I must first be blocked with unlabeled cerulenin. Five nmoles of unlabeled cerulenin is prepared as described above for the  $^3\text{H}$ -cerulenin.  $^3\text{H}$ -cerulenin is prepared as above except a larger concentration is used to ensure binding to synthase II.

The concentrated enzyme is prepared as above and reacted first with 5 $\mu\text{M}$  unlabeled cerulenin for 20 mins at 37°C to block the synthase I from subsequent reaction with the  $^3\text{H}$ -cerulenin. Following this reaction, the sample is placed in the second tube containing the higher concentration of  $^3\text{H}$ -cerulenin and reacted at 37°C for 60 mins. The rest of the procedure is as described above.

5. Gel Analysis of Candidate Protein Fractions.

Laemmli-SDS-PAGE methods are as described in Example 3E, again using the reduced cross-linker formula for the gels. Gel thickness is 0.75mm. Bands from SDS-PAGE are excised and analyzed by scintillation counting to determine the molecular weight of labeled bands, and amino acid sequence of labeled fragments is determined.

25 6. Sequence Determination

The protein is digested with endoproteinase gluC using the method described in Example 4, with the following alteration. The digestion is carried out in solution, therefore the 5% acetonitrile added to previous digests for ease in recovery of peptides off of nitrocellulose is omitted. Reverse-phase HPLC and sequencing of peptides are as described in Example 4.

B. E. coli Expression

1. Expression Vectors.

35 Plasmids for expression of  $\beta$ -ketoacyl-ACP synthase activity in *E. coli* can be constructed using one or more *E.*

coli expression vectors. These expression vectors include pUC120, an *E. coli* expression vector based on pUC118 (Vieira and Messing, *Methods in Enzymology* (1987) 153:3-11) with the lac region inserted in the opposite orientation and an NcoI site at the ATG of the lac peptide (Vieira, J. PhD. Thesis, University of Minnesota, 1988). Other expression vectors which may be used include, but are not limited to, the pET system vectors, in particular pET8C (Studier et al., *Methods in Enzymology* (1990) ed. D.V. Goedel, Vol. 185) which use a T7 RNA polymerase promoter, and pKK223 vector (Pharmacia), which utilizes a trp-lac (lac) bacterial promoter. An example of *E. coli* expression of synthase activity associated with a 50 kD protein using the pUC120 expression system is described below.

## 2. Constructs for Expression of Synthases

A fragment containing regions of a cDNA which encodes the 50 kD protein associated with synthase activity (Ex. 6), can be subcloned into pUC120 using commercially available linkers, restriction endonucleases, and ligase. The subcloned regions will include the coding region of the mature protein, and also possibly 5' and 3'-noncoding sequences, a transit peptide sequence, and a poly(A) tail. The synthase sequences are inserted such that they are aligned in the 5' to 3' orientation with the lac transcription and translation signals. The resulting plasmid can be transformed to an appropriate strain of *E. coli* for analysis.

Constructs containing the cDNA clone for the 46 kD protein (Ex. 6) or containing the cDNAs for both the 46 kD and the 50 kD proteins can be made using the procedures and vectors described above.

## 3. Expression of Synthase Activity in *E. coli*

Single colonies of *E. coli* containing pUC120 or the synthase constructs in pUC120 are cultured in ECLB broth containing 300mg/L penicillin. The lac promoter is induced by the addition of 1mM IPTG. Cells are grown overnight (18 hrs) at 37°C. The overnight cultures of *E. coli* (induced and uninduced) containing pUC120 or the synthase constructs

in pUC120 are centrifuged to pellet the cells. The pelleted cells are resuspended in buffer and broken in a french press at 16,000 psi. Broken cell mixtures are centrifuged and a portion of each supernatant is applied to 5 a G-25 Sephadex gel filtration centrifugal column (Boehringer Mannheim Biochemicals), equilibrated buffer. Columns are centrifuged and effluent is collected and used as enzyme source in the synthase assay. Synthase activity is assayed as described in Example 2. Cerulinin is also 10 reacted with the synthase activity to distinguish synthase I and synthase II activities as described previously in Example 5A.

4. Detection of Synthase Protein in *E. coli*.

Extracts of overnight cultures of *E. coli* containing 15 pUC120 or synthase constructs in pUC120 grown in ECLB containing 300mg/L penicillin induced with 1mM IPTG are prepared as follows. Overnight cultures grown shaking at 37°C are pelleted by centrifugation in 1.5ml Eppendorf tubes. Pellets are resuspended in SDS sample buffer (0.05M 20 Tris-HCl, pH6.8, 1% SDS, 5%  $\beta$ -mercaptoethanol, 10% glycerol and 0.005% bromophenol blue) and boiled for 10 min. Samples are electrophoresed on a 10% polyacrylamide gel (Laemmli, *Nature* (1970) 227:680). Gels are stained in 0.05% Coomassie Brilliant Blue, 25% isopropanol and 10% 25 acetic acid and destained in 10% acetic acid and 10% isopropanol. Bands corresponding to synthase proteins may be detected by comparison of *E. coli* proteins produced in cells containing synthase constructs inserted in pUC120 to those containing the pUC120 vector with no insertion.

30 5. Expression of Synthase Activity in *E. coli* Using a T7 Promoter

A construct for the expression of the 50kD *R. communis* synthase protein in *E. coli* under control of the T7 promoter is prepared as follows. DNA sequence specifying 35 the endonuclease restriction sites *Bam*H I and *Nde*I are inserted into the 50kD synthase cDNA clone, pCGN2765, by in vitro mutagenesis. The sequence is inserted immediately 5'

of the AAC codon specifying the asparagine N-terminal amino acid of the mature synthase protein. DNA sequence specifying the endonuclease restriction sites *Bam*HI and *Pst*I are inserted into the 50kD synthase cDNA clone 5 immediately 3' of the TGA stop codon following the CCC codon specifying the proline C-terminal amino acid. The resulting plasmid is pCGN2773. A fragment of pCGN2773 containing the coding sequence for the mature 50kD synthase protein is subcloned by digestion with *Nde*I and *Bam*HI and 10 ligation into *Nde*I and *Bam*HI digested pET3A, a T7 *E. coli* expression vector (Studier et al., *supra*). The resulting plasmid is pCGN2775.

Similar constructs for the expression of the 46kD *R. communis* synthase protein in *E. coli* are prepared as 15 follows. DNA sequence specifying the endonuclease restriction sites *Bam*HI and *Nde*I are inserted into the 46kD synthase cDNA clone, 1-1A by *in vitro* mutagenesis. The sequence is inserted immediately 5' of the AAT codon specifying the asparagine amino acid located immediately to 20 the amino end of the lysine previously identified as the N-terminal amino acid (Fig. 3) of the mature synthase protein. DNA sequence specifying the endonuclease restriction sites *Bam*HI and *Pst*I are inserted into the 46 kD synthase cDNA clone immediately 3' of the TGA stop codon 25 which follows the TTC codon specifying the lysine C-terminal amino acid. The resulting plasmid is pCGN2774. A fragment of pCGN2774 containing the coding sequence for the mature 46 kD synthase protein is subcloned by digestion with *Nde*I and *Bam*HI and ligation into *Nde*I and *Bam*HI 30 digested *E. coli* expression vector pET3A. The resulting plasmid is pCGN2776. A second construct for expression of the 46 kD synthase is prepared by subcloning the T7 promoter and coding sequence for the mature 46kD synthase protein from pCGN2776 by digestion with *Eco*RV and *Bgl*II 35 (*Eco*RV and *Bgl*II restriction sites supplied by original pET3A vector) and ligation into *Bam*HI and *Eco*RV digested cloning vector pACYC184. The resulting plasmid is pCGN2777.

In addition, a construct for expression of both the 46 kD and 50 kD synthase proteins under the control of the same T7 promoter is constructed as follows. The 50 kD coding region of pCGN2773 is obtained by digestion with 5 *Bam*HI and is ligated into *Bam*HI digested pCGN2776. This inserts the 50 kD coding sequence immediately 3' of the 46 kD coding sequence and results in plasmid pCGN2778.

The 46 kD and 50 kD constructs are transformed into *E. coli* strain BL21 (Studier et al., *supra*). Cultures are 10 grown overnight and cells are harvested by centrifugation. The pelleted cells are resuspended to approximately 1/20 of the original volume in 20mM potassium phosphate buffer and broken using a French press apparatus. The broken cell samples are spun at approximately 12,000xg to remove cell 15 debris and the resulting supernatant is diluted 1:1 in 40% glycerol and assayed for synthase II activity as described in Example 2 using radiolabeled C16:0-ACP as substrate in the assay. Results of these assays are presented in Table VIII.

20

Table VIII  
Synthase Activity in *E. coli* Extracts

	<u>Construct</u>	<u>Protein</u>	<u>Specific Activity (pmol/min/μg)</u>
	pET3a		2.4
	pCGN2775	50 kD	2.4
	pCGN2776	46 kD	2.8
25	pCGN2778	46 kD + 50 kD	4.2
	pACYC184		1.7
	pCGN2777	46 kD	2.2
	pACYC184 + pCGN2775	50 kD	2.2
30	pCGN2777 + pCGN2775	46 kD + 50 kD	5.2

The above results demonstrate that both the 46kD and 50kD proteins, now referred to as "synthase factor A" and "synthase factor B" respectively, are required for synthase II type activity. This is in agreement with protein 5 purification data indicating synthase II type activity primarily in an ACP-sepharose column fraction containing both the 46 and 50kD proteins (Example 3F).

Analysis of *E. coli* extracts for the presence of synthase proteins indicates that synthase factor A 10 comprises approximately 2% of total protein in cells transformed with pCGN2776, roughly 50 times the level of synthase factor B in the pCGN2775 cells. Further, as shown in Figure 12, the *E. coli* synthase I protein shares considerable homology at the amino acid level with plant 15 synthase factor A and B proteins.

Additional analysis of *E. coli* cells containing the synthase constructs and control cells lacking these constructs are conducted to determine the fatty acid composition of these cells. Lipids are extracted from 20 pelleted *E. coli* cells and fatty acids are analyzed by methanalysis and GC (gas-liquid chromatography), essentially as described by Browse et al. (*Anal. Biochem.* (1986) 152:141-145). Results are presented in Table IX.

25

Table IX

Analysis of Fatty Acids in Transformed *E. coli*

	pET3a (Control)	pCGN2775 (50K)	pCGN2776 (46K)	pCGN2775 + pCGN2776
	%	%	%	%
30	12:0	3.5	3.5	3.5
	14:0	5	5	3
	16:0	27	28	21
	16:1	22	23	10
	Cyc17	2	2	2
	18:0	0.5	0.5	5
	18:1	37	37	51
35	18:2	3	3	2
	18:3	0.5	0.5	0.5
	20:0	--	--	0.5
	20:1	tr	--	2
				1.5
40				6
				49
				3
				0.5
				0.5

The above results demonstrate that the percentage of C18 fatty acids in *E. coli* increases upon expression of the plant synthase factor A protein in *E. coli*, either in the presence or absence of plant synthase factor B. When the 5 *E. coli* cells are grown at 30°C instead of 37°C, as in the above experiments, an even greater effect on the *E. coli* lipids is observed. Thus, synthase II type activity may be increased by expression of the factor A protein in host cells as evidenced by increased longer chain fatty acids. 10 In broken cells, however, increased synthase II type activity is only detectable in extracts from cells transformed with both synthase factor A and synthase factor B constructs (Table VIII). These results indicate that synthase factor A is the component which contributes the 15 longer fatty acid substrate specificity to synthase II activity, and that factor B may or may not be required, depending on synthase factors present in the host cells.

**Example 6. Isolation of Synthase Genes**

20 In this example, the preparation of a cDNA libraries, using the methods as described in Alexander, et al. (*Methods in Enzymology* (1987) 154:41-64), and the screening of the cDNA libraries for synthase cDNA clones are described.

25 A. R. communis cDNA Library Construction

A cDNA library may be constructed from poly(A)+ RNA isolated from *R. communis* immature endosperm from seeds collected at approximately 14-21 days post-anthesis. Total RNA is isolated from 10 g of *R. communis* immature endosperm tissue by a method described by Halling, et al. (*Nucl. Acids Res.* (1985) 13:8019-8033). Total RNA is further purified by removing polysaccharides on a 0.25 g Sigma Cell 30 cellulose column. The RNA is loaded onto the column in 1 ml of loading buffer (20 mM Tris-HCl pH 7.5, 0.5 M NaCl, 1 mM EDTA, 0.1% SDS), eluted with loading buffer, and collected in 500 µl fractions. Ethanol is added to the samples to precipitate the RNA. The samples are centrifuged, and the pellets resuspended in sterile

distilled water, pooled, and again precipitated in ethanol. The sample is centrifuged, and the resulting RNA is subjected to oligo(dT)-cellulose chromatography two times to enrich for poly(A)<sup>+</sup> RNA as described by Maniatis et al.

5 (*Molecular Cloning: A Laboratory Manual*, Cold Spring Harbor Laboratory, New York (1982)).

The plasmid cloning vector pCGN1703, derived from the commercial cloning vector Bluescribe M13- (Stratagene Cloning Systems; San Diego, CA), is made as follows. The 10 polylinker of Bluescribe M13- is altered by digestion with *Bam*HI, treatment with mung bean endonuclease, and blunt-end ligation to create a *Bam*HI-deleted plasmid, pCGN1700. pCGN1700 is digested with *Eco*RI and *Sst*I (adjacent restriction sites) and annealed with synthetic 15 complementary oligonucleotides having the sequences 5' CGGATCCACTGCAGTCTAGAGGGCCCGGG 3' and 5' AATTCCCAGGGCCCTCTAGACTGCAGTGGATCCGAGCT 3'. These sequences are inserted to eliminate the *Eco*RI site, move the *Bam*HI site onto the opposite side of the *Sst*I (also, 20 sometimes referred to as "SacI" herein) site found in Bluescribe, and to include new restriction sites *Pst*I, *Xba*I, *Apal*, *Sma*I. The resulting plasmid pCGN1702, is digested with *Hind*III and blunt-ended with Klenow enzyme; the linear DNA is partially digested with *Pvu*II and ligated 25 with T4 DNA ligase in dilute solution. A transformant having the *lac* promoter region deleted is selected (pCGN1703) and is used as the plasmid cloning vector.

Briefly, the cloning method for cDNA synthesis is as follows. The plasmid cloning vector is digested with *Sst*I and homopolymer T-tails are generated on the resulting 3'-overhang sticky-ends using terminal deoxynucleotidyl transferase. The tailed plasmid is separated from undigested or un-tailed plasmid by oligo(dA)-cellulose chromatography. The resultant vector serves as the primer 35 for synthesis of cDNA first strands from mRNA covalently attached to either end of the vector plasmid by their poly(A) tract. The cDNA-mRNA-vector complexes are treated with terminal transferase in the presence of deoxyguanosine

triphosphate, generating G-tails at the ends of the cDNA strands. The extra cDNA-mRNA complex, adjacent to the BamHI site, is removed by BamHI digestion, leaving a cDNA-mRNA-vector complex with a BamHI sticky-end at one end and a G-tail at the other. This complex is cyclized using the annealed synthetic cyclizing linker, 5'-  
5 GATCCGGGCCGCGAATTGGAGCTCCCCCCCCC-3' and  
3'-GCGCCGGCGCTTAAGCTCGA-5',  
which has a BamHI sticky-end and a C-tail end. Following  
10 ligation and repair the circular complexes are transformed into *E. coli* strain DH5 $\alpha$  (BRL; Gaithersburg, MD) to generate the cDNA library. The *R. communis* immature endosperm cDNA bank contains approximately  $2 \times 10^6$  clones with an average cDNA insert size of approximately 1000 base  
15 pairs.

B. Isolation of a *R. communis* cDNA Clone to the 50 kD Synthase Protein

1. Probe production.

1.1 Polymerase Chain Reactions (PCR). Amino acid sequences from two peptides from the 50 kD synthase amino acid sequence (Example 3) with low codon degeneracy, KR4 and KR16 are chosen for production of a probe for the plant 50 kD synthase cDNA. Four sets of mixed oligonucleotides are designed and synthesized for use as forward and reverse primers in the polymerase chain reaction (Saiki et al., Science (1985) 230:1350-1354; Oste, Biotechniques (1988) 6:162-167) for the KR4 sequence, and two sets of mixed oligonucleotides are designed and synthesized for use as forward and reverse primers in the polymerase chain reaction for the KR16 sequence. All oligonucleotides are synthesized on an Applied Biosystems 380A DNA synthesizer.

The KR4 oligonucleotide groups have a redundancy of 128 and contain 20 bases of coding sequence along with flanking restriction site sequences for HindIII (forward primers) or EcoRI (reverse primers). The KR16 oligonucleotide groups have a redundancy of 384 and contain 23 bases of coding sequence along with flanking restriction site sequences for HindIII (forward primers) or EcoRI

(reverse primers). The KR4 forward and KR16 reverse primers are illustrated in Figure 4.

The KR4 oligonucleotide groups are combined so that only two polymerase chain reactions are required to account  
5 for both possible orientations of the KR4 and KR16 peptides in the synthase protein. Using the cDNA library DNA as template and the possible two combinations of the forward and reverse oligonucleotides as primers, polymerase chain reactions are performed in a Perkin-Elmer/Cetus DNA Thermal  
10 Cycler (Norwalk, CT) (thermocycle file 1 min. 94°C, 2 min. 42°C, 2 min rise from 42°-72°C, 3min. 72°C for 15 cycles, followed by the step cycle file without step rises, 1 min. 94°C, 2 min. 42°C, 3 min. 72°C with increasing 15 sec extensions of the 72°C step for 10 cycles, and a final 10  
15 min. 72°C extension).

### 1.2 PCR Product Analysis.

1.2.1 Subcloning. The 283 bp product of the KR4 forward primer and the KR16 reverse primer reaction is gel-purified, digested with *Hind*III and *Eco*RI, and ethanol  
20 precipitated. The resulting fragment is subcloned into pCGN2015, a chloramphenicol resistant version of Bluescript KS+ (Stratagene, La Jolla, CA).

1.2.2 Construction of pCGN2015. pCGN2015 is prepared by digesting pCGN565 with *Hha*I, and the fragment  
25 containing the chloramphenicol resistance gene is excised, blunted by use of mung bean nuclease, and inserted into the *Eco*RV site of Bluescript KS- (Stratagene, La Jolla, CA) to create pCGN2008. pCGN565 is a cloning vector based on pUC12-cm (K. Buckley Ph.D. Thesis, Regulation and expression of the phi  
30 X174 lysis gene, University of California, San Diego, 1985), but contains pUC18 linkers (Yanisch-Perron, et al., Gene (1985) 53:103-119).

The chloramphenicol resistance gene of pCGN2008 is removed by *Eco*RI/*Hind*III digestion. After treatment with  
35 Klenow enzyme to blunt the ends, the fragment is ligated to *Dra*I digested Bluescript KS+. A clone that has the *Dra*I fragment containing ampicillin resistance replaced with the chloramphenicol resistance is chosen and named pCGN2015.

1.2.3 Clone Analysis. Minipreparation DNA (Maniatis et al., *supra*) of two clones, AG-18 and AG-32, was sequenced by Sanger dideoxy sequencing (Sanger et al., *Proc. Natl. Acad. Sci. USA* (1977) 74:5463-5467) using the 5 M13 universal and reverse primers. The clones were shown to have the same DNA sequence. Translation of the DNA sequence results in an amino acid sequence that contains five of the 50 kD synthase peptides (78 amino acid residues) within its 91 amino acid residues. The 10 translated amino acid sequence was shown to have homology to the  $\beta$ -ketoacyl-ACP synthase I gene of *E. coli* which is encoded by fabB (Kauppinen et al., *Carlsberg Res. Commun.* (1988) 53:357-370), and a polyketide synthase gene from 15 *Streptomyces glaucescens* which has been shown to have homology to other  $\beta$ -ketoacyl synthases (Bibb et al., *EMBO J.* (1989) 8:2727-2736).

1.3 Probe Purification. The 283 bp insert in AG-32 was amplified by PCR using the minipreparation DNA as template and the KR4 and KR16 oligonucleotides described 20 above as primers. The resulting fragment was gel-purified for use as a probe in screening cDNA library screening.

## 2. Library Screen.

The *R. communis* immature endosperm cDNA bank is moved 25 into the cloning vector lambda gt22 (Stratagene Cloning Systems, La Jolla, CA) by digestion of total cDNA with *NotI* and ligation to lambda gt22 DNA digested with *NotI*. The titer of the resulting library was approximately  $1.5 \times 10^7$  pfu/ml. The library is then plated on *E. coli* strain Y1090 (Young, R.A. and Davis, R.W., *Proc. Natl. Acad. Sci. USA* 30 (1983) 80:1194 at a density of approximately 15,000 plaques/150 mm NZY ("NZYM" as defined in Maniatis et al. *supra*) agar plate to provide over 60,000 plaques for screening. Duplicate lifts are taken of the plaques using NEN Colony Plaque Screen filters by laying precut filters 35 over the plates for approximately 2 minutes and then peeling them off. The phage DNA is immobilized by floating the filters on denaturing solution (1.5 M NaCl, 0.5 M NaOH) for 1 min., transferring the filters to neutralizing

solution (1.5 M NaCl, 0.5 M Tris-HCl pH 8.0) for 2 min. and then to 2X SSC (1X SSC = 0.15 M NaCl; 0.015 M Na citrate) for 3 min., followed by air drying. The filters are pre-hybridized at 42°C in hybridization buffer consisting of  
5 50% formamide, 10X Denhardt's solution, 5X SSC, 1% SDS, 5 mM EDTA, and 0.1 mg/ml denatured salmon sperm DNA. Filters are hybridized overnight at 42°C in the same buffer solution with added <sup>32</sup>P-labeled (Boehringer Mannheim Random Primed DNA Labeling Kit) AG-32 insert DNA described above.  
10 Filters are washed sequentially at 55°C in 1X SSC, 0.1% SDS for 25 minutes, in 0.5 X SSC, 0.1% SDS for 25 minutes, and finally in 0.1 X SSC, 0.1% SDS for 25 minutes. Filters are exposed to X-ray film at -70°C with a Dupont Cronex intensifying screen for 48 hours.

15 3. Clone Analysis.

Clones are detected by hybridization with the AG-32 <sup>32</sup>P-labeled DNA and plaque purified. Phage DNA is prepared from the purified clones as described by Grossberger (*NAR* (1987) 15:6737) with the following modification. The  
20 proteinase K treatment is replaced by the addition of 10% SDS and a 10 minute incubation at room temperature. Recovered phage DNA is digested with NotI, religated at low concentration, and transformed into *E. coli* mm294 (Hanahan, *J.Mol.Biol.* (1983) 166:557-580) cells to recover plasmids  
25 containing cDNA inserts in pCGN1703. Preliminary nucleotide sequence of the cDNA insert of the longest clone, pCGN2764 (1-3), indicates that the clone does not contain the entire coding sequence for the gene.

4. Screening for Longer Clones.

30 Longer cDNA clones can be obtained by screening the *R. communis* cDNA library with an oligonucleotide from the furthest 5' sequence of this clone.

A 23 base oligonucleotide, #2272, was synthesized which consists of the sequence 5' ACCAGCAACAATGCAATACCTCA  
35 3', which is complementary to nucleotides 24-46 of cDNA clone pCGN2764. Greater than 100,000 clones from the *R. communis* embryo cDNA library in lambda gt22 are plated in

- E. coli strain Y1090 as described above at a density of 20,000 plaques/150mm NZY plate. Phage are lifted onto NEN Colony/Plaque Screen filters as described above. The probe for hybridization is prepared by 5' end-labeling
- 5 oligonucleotide #2272 using BRL 5X buffer and T4 kinase. Filters are prehybridized and hybridized with the probe at 37°C, and washed to remove background hybridization according to the method of Berent et al. (BioTechniques (1985) 3:208-220). Filters are exposed to X-ray film at -
- 10 70°C with a Dupont Cronex intensifying screen overnight.
- 12 clones are detected by hybridization to the oligonucleotide probe and are plaque-purified and recovered as pCGN1703 plasmids as described above. Minipreparation DNA (Maniatis et al., supra) from each of the clones is
- 15 analyzed by restriction digestion and agarose gel electrophoresis. The complete DNA sequence of the longest clone, pCGN2765 (2-8), is presented in Figure 5. DNA sequence is determined by the dideoxy-chain termination method of Sanger et. al, (Proc. Natl. Acad. Sci. USA (1977) 20 24:5463-5467) using the 7-Deaza-dGTP Reagent Kit with Sequenase Version 2 Enzyme (United States Biochemical Corp., Cleveland, OH). The sequence data are analyzed using the IntelliGenetics Suite of molecular programs Gel and SEQ.
- 25 C. Isolation of a R. communis cDNA Clone for the 46 kD Synthase Protein
1. Probe Production.
- 1.1 Polymerase Chain Reactions. A probe to be used in screening for a cDNA clone to the 46 kD protein can be prepared by PCR from oligonucleotides to the 46 kD peptide sequences following the procedures described above in the isolation of a cDNA to the 50 kD protein. Sequences derived from the N-terminal peptide amino acid sequence of the 46 kD protein, **KHPLMKQRRVVVTGMGV**, (sequences used for 30 oligo design indicated in bold letters) are used as the forward primers in four polymerase chain reactions. The reverse primers for these reactions are DNA sequences derived from 46 kD peptides KR2, **EEVNYIAXATSTPAGDL**, and

KR3, VFNDAIEALR. The forward primer has a redundancy of 128 and contains 20 bases of coding sequence along with a flanking HindIII restriction site (AAGCTT). The reverse primers have a redundancy of 128 (KR2) and 64 (KR3) and contain 20 bases of coding sequence along with flanking sequences specifying EcoRI restriction sites (GAATTC).  
5 These restriction sites are useful in cloning the product resulting from PCR. Reactions are performed in a Perkin-Elmer/Cetus DNA Thermal Cycler (Norwalk, CT) (step cycle  
10 file 1 min. 94°C, 2 min. 50°C, 3 min. 72°C for 15 cycles, followed by the step cycle file, 1 min. 94°C, 2 min. 42°C, 3 min. 72°C with increasing 15 sec extensions of the 72°C step for 10 cycles, and a final 10 min. 72°C extension).  
15 PCR using NTERM-B, 5' TTTAAGCTTAAPCAQCCNCTNATGAAPCA3', as forward primer, and KR2-A,  
5' TTTGAATTCTTPATPTAPTTNACQTCQTC3' or KR3-A,  
5' TTTGAATTCGCQTCTATNGCPTCPTTPAA3', as reverse primers,  
where N=A,G,C or T, Q=C or T, and P=A or G, resulted in  
20 production of prominent ~900 bp and ~330 bp bands,  
respectively.

1.2 Analysis of PCR products. A nitrocellulose filter containing PCR product DNA was prepared by the Southern blot technique (Maniatis et al., *supra*) The filter was probed with a synthetic oligonucleotide,  
25 Nterm11, 5' ACNCCCATNCCNGT3' prepared from the 46 kD N-terminal sequence KHPLMKQRVVVTGMGV. Nterm-11 is derived from a different portion of the N-terminal sequence than the oligonucleotide used as forward primer in the reactions. Prehybridization, hybridization, and washing of  
30 the filter is according to Berent et al. (*supra*), the only significant change being in the temperature used for hybridization and prehybridization, which was 25°C. Both the ~900 bp and ~330 bp bands produced by PCR as described above hybridize to this oligonucleotide. Further evidence  
35 that the ~330 bp band is a product specific to a cDNA for the 46 kD protein is obtained by repeating the PCR described above with the Nterm-B and KR3-A oligonucleotides, but using the product from the Nterm-

B/KR2-A PCR as template. The ~330 bp band is again obtained as the predominant product. The ~330 bp PCR product is digested with HindIII and EcoRI and subcloned into pCGN2015 as described above. Minipreparation DNA is prepared and DNA sequence of clones containing the ~330 bp fragment is determined as described above.

5           1.3 Probe Purification. The ~330 bp PCR product is gel-purified for use as probe in screening the cDNA library.

10       2. Library Screen.

The *R. communis* embryo cDNA library described above can be screened for a cDNA to the 46 kD synthase protein using the procedures described above in the isolation of a cDNA to the 50 kD synthase. The ~330 bp DNA fragment described above is  $^{32}\text{P}$ -labeled using a random primed labeling kit (Boehringer Mannheim). Greater than 60,000 clones in lambda gt22 are plated at a density of approximately 15,000/150 mm NZY plate and lifted onto NEN Colony/Plaque Screen filters as described above. Clones are detected by hybridization to the ~330 bp PCR fragment by prehybridization, hybridization, and washing as described above for screening for the cDNA to the 50 kD protein using the AG-32 fragment as probe. Clones are plaque-purified, lambda DNA is isolated, and clones are recovered as *E. coli* clones containing plasmids with inserts in pCGN1703 as described above. DNA sequence of clones is determined as described above.

20       3. DNA Sequence Analysis.

DNA sequence and translated amino acid sequence of a *R. communis* 46kD synthase (synthase factor A) cDNA clone, l-1A, is presented in Figure 10. The mature protein start site is tentatively identified as the lysine residue encoded by nucleotides 365-367. Three possible translation initiation ATG codons, which would account for a transit peptide having 116, 57 or 14 amino acids, are present in the sequence 5' of the mature protein start. Electroporation into isolated plant protoplasts of 46kD

synthase encoding constructs, which start at each of the possible translation initiation codons, is conducted to identify the codon used for initiation of translation of the 46kD synthase protein. As also observed in analysis 5 of peptide sequences of the 50kD and 46kD synthase proteins, the translated amino acid sequences of the 46kD and 50kD synthase cDNAs demonstrate extensive homology in portions of the mature protein.

D. Isolation of Synthase Genes from Other Plant Sources

10 1. *B. campestris* cDNA Library Construction.

Total RNA is isolated from 5 g of *B. campestris* cv. R500 embryos obtained from seeds harvested at days 17-19 post-anthesis. RNA is extracted in 25 mls of 4 M guanidine thiocyanate buffer as described by Colbert et al. (PNAS 15 (1983) 80:2248-2252). Polysaccharides are removed from the RNA sample by resuspending the pellet in 6 ml of 1X TE (10 mM Tris/1 mM EDTA pH 8), adding potassium acetate to a concentration of 0.05 M, and adding one half volume of ethanol. The sample is placed on ice for 60 minutes and 20 centrifuged for 10 minutes at 3000 x g. RNA is precipitated from the supernatant by adding sodium acetate to a concentration of 0.3 M followed by the addition of two volumes of ethanol. RNA is recovered from the sample by centrifugation at 12,000 x g for 10 minutes and yield 25 calculated by UV spectrophotometry. Two mg of the total RNA is further purified by removing polysaccharides as described in Example 6A. The resulting RNA is enriched for poly(A)+ RNA also as described in Example 6A.

A *Brassica campestris* day 17-19 post anthesis embryo 30 cDNA library is constructed in plasmid vector pCGN1703 using 5 µg of poly(A)+ RNA as described in Example 6A. cDNA libraries from other plant sources can be similarly prepared.

2. Genomic Library Construction

35 Genomic libraries can be constructed from DNA from various plant sources using commercially available vectors and published DNA isolation, fractionation, and cloning

procedures. For example, a *B. campestris* genomic library can be constructed using DNA isolated according to Scofield and Crouch (*J.Biol.Chem.* (1987) 262:12202-12208) that is digested with BamHI and fractionated on sucrose gradients 5 (Maniatis et al., *supra*), and cloned into the lambda phage vector LambdaGem-11 (Promega; Madison, WI) using cloning procedures of Maniatis et al. (*supra*).

3. Screening cDNA and Genomic Libraries

cDNA and genomic libraries can be screened for synthase cDNA and genomic clones, respectively, using published hybridization techniques. Screening techniques are described above for screening libraries with radiolabeled oligonucleotides and longer DNA fragments. Probes for the library screening can be prepared by PCR, or 10 from the sequence of the synthase clones provided herein. Oligonucleotides prepared from the synthase sequences may be used, as well as longer DNA fragments, up to the entire synthase clone.

For example, the *B. campestris* embryo cDNA library 20 described above is screened for cDNA clones encoding a synthase factor B protein using a *R. communis* 50 kD synthase factor B cDNA (pCGN2764) as probe. The cDNA library is subcloned into lambda gt10 cloning vector by digestion of total cDNA with EcoRI and ligation to EcoRI 25 digested lambda gt10. Clones are plated in an appropriate *E. coli* host and the resulting plaques lifted to duplicate nylon membrane filters. Filters are prehybridized (Maniatis et al., *supra*) overnight at 42°C. An approximately 600bp fragment of *R. communis* cDNA clone 30 pCGN2764 is prepared by digestion with *Nco*I and gel purification of the resulting fragment. The fragment is radiolabeled (<sup>32</sup>P) by nick-translation and added to prehybridized filters for overnight hybridization at 42°C.

For detection of homologous clones, hybridized filters 35 are washed, 2 X 15 minutes, at 42°C in 2X SSC, 0.1% SDS and subjected to autoradiography. Ten clones are identified as homologous to the *R. communis* 50 kD clone and isolated by plaque purification. Phage DNA is purified, digested with

EcoRI and cDNAs are recovered as plasmid clones in the pCGN1703 cloning vector.

- DNA sequence analysis of the 10 clones indicates that two classes of *Brassica* synthase clones having homology to the *R. communis* 50 kD synthase factor B clone were recovered, each class represented by 5 of the 10 clones. DNA and translated amino acid sequences of pCGN3248, the longest clone are presented in Figure 11A. DNA and translated amino acid sequences of 4A, a member of the second class of *B. campestris* synthase clones, are presented in Figure 11B. The sequences are approximately 94% homologous in the DNA coding region and the translated amino acid sequences are approximately 99% homologous. Comparison of pCGN3248 mature coding sequences and translated amino acid sequence to nucleic acid and translated amino acid sequences of the mature coding region of the *R. communis* synthase factor B cDNA, 2-8, indicates approximately 80% homology at the nucleic acid level and approximately 90% homology at the amino acid level.
- The *Brassica* synthase factor B cDNA, pCGN3248, does not appear to be a full length clone based on comparison to the translated amino acid sequence of *R. communis* factor B clone, 2-8, and lack of an ATG initiation codon 5' of the mature protein coding region. In addition, no full length clones of the 4A sequence class were recovered in the initial screen. Full length clones are isolated by screening cDNA or genomic libraries with 5' oligonucleotides, as described above for the *R. communis* clone, or alternatively using PCR techniques.
- Similar to the isolation of the *Brassica* synthase factor B cDNA, a clone or clones encoding a *Brassica* synthase factor A is isolated from the *B. campestris* embryo cDNA library using the *R. communis* 46kD synthase cDNA (1-1A) sequences as a probe.
- To produce a probe specific for synthase factor A (46kD) sequences as opposed to the related synthase factor B (50kD), a PCR approach may be utilized. Two oligonucleotide primers specific to the *R. communis* 46kD

nucleotide sequence are synthesized from conserved synthase peptide sequences; 5' (forward) primer is a 29bp oligonucleotide corresponding to the nucleotide sequence encoding amino acids 291-300 of the RC46 sequence of Fig. 5 12 and 3' (reverse) primer is a 26bp oligonucleotide complementary to the nucleotide sequence encoding amino acids 396-404 of the RC46 sequence of Fig. 12. The above 29bp and 26bp primers are used in PCR to produce a 340bp synthase fragment using DNA from the *B. campestris* cDNA library as template. Due to homology of the *B. campestris* synthase factor B clone, the PCR generated fragment was also presumed to contain factor B sequences. Taking advantage of two *DdeI* sites in this region in both the *R. communis* and *Brassica* factor B sequences and the lack of 10 these sites in the *R. communis* synthase factor A sequence, the PCR product is digested with *DdeI*. This digestion results in the 340bp synthase factor A sequence and two smaller fragments of approximately 270 and 70 base pairs which represent digested synthase factor B sequences. 15 20 Southern blot analysis of the resulting DNA using a 21bp oligonucleotide probe complementary to the nucleotide sequence encoding amino acids 376-382 of the RC46 sequence of Fig. 12, a region where the factor A and factor B sequences are not homologous, confirms that the 340bp fragment is homologous to the RC46 probe, while the smaller synthase factor B fragments are not homologous. The 340bp factor A specific fragment is gel-purified, radiolabeled and used to screen the *B. campestris* embryo cDNA library as previously described. Thirty four candidates for *Brassica* 25 30 factor A were identified and 32 were confirmed as representing synthase factor A by PCR with the above-described 29bp (5') and 21bp (3') primers.

To identify the longest clones among the *Brassica* synthase-factor A clones, PCR is conducted using a forward 35 primer specific to pCGN1703 vector sequences near the cDNA 5' end cloning site and a 26bp synthetic oligonucleotide complementary to the nucleotide sequence encoding amino acids 38-46 of the RC46 sequence of Fig. 12. Six of the

*Brassica synthase factor A* clones yielded distinct bands from the PCR and were selected for further plaque purification and sequence analysis.

5   **Example 7. Synthase Constructs in Plants**

In this example, constructs containing *R. communis* synthase gene(s) suitable for plant transformation are described.

A.   Expression Cassettes

10   Expression cassettes utilizing 5'-upstream sequences and 3'-downstream sequences of genes preferentially expressed during seed development can be constructed from isolated DNA sequences of genes with an appropriate expression pattern. Examples of genes which are expressed 15 during seed development in *Brassica* are a napin gene, 1-2, and an ACP gene, Bcg4-4, both described in European Patent Publication EP 0 255 378, and a Bce4 gene, as described below. The napin gene encodes a seed storage protein that is preferentially expressed in immature embryos which are 20 actively producing storage proteins. The ACP gene encodes a protein which is an integral factor in the synthesis of fatty acids in the developing embryo and is preferentially expressed during fatty acid synthesis. Bce4 is a gene that produces a protein of unknown function that is 25 preferentially expressed early in embryo development, at about 15-19 days post-anthesis, and is also detectable as early as 11 days post-anthesis. The sequence of Bce4 is shown in Figure 7. The 5' and 3' regulatory sequences are obtainable from a genomic library of *B. campestris*, which 30 can be constructed as described in Example 6D.

DNA sequences that control the expression of these genes can be isolated and sufficient portions of the 5' and 3' regulatory regions combined such that a synthase gene inserted between these sequences will be preferentially 35 expressed early in seed development. This expression pattern will allow the synthase gene to affect fatty acid synthesis, which also occurs early in seed development. For example, a 1.45 kb *Xba*I fragment containing 5' sequence

and a 1.5 kb *Sst*I/*Bgl*II fragment containing 3' sequence of the *Bcg*4-4 ACP gene can be combined in an ACP expression cassette using a variety of available DNA manipulation techniques. Similarly, a napin expression cassette can be prepared that contains approximately 1.725 kb of 5' sequence from an *Eco*RV site to immediately before the ATG start codon and approximately 1.25 kb of 3' sequence from an *Xho*I site approximately 18 bases past the TAG stop codon to a 3' *Hind*III site of a 1-2 napin gene. A *Bce*4 expression cassette can be made by combining approximately 7.4 kb of 5' DNA sequence from an upstream *Pst*I site to immediately before the ATG start codon with approximately 1.9 kb of 3' sequences from immediately after the TAA stop codon to a 3' *Pst*I site.

Variations can be made in these expression cassettes such as increasing or decreasing the amounts of 5' and 3' sequences, combining the 5' sequences of one gene with the 3' sequences of a different gene (for example using the 1.3 kb 5' sequences of napin 1-2 with the 1.5 kb 3' sequences of ACP *Bcg*4-4 in an expression cassette), or using other available 3' regulatory sequences, as long as these variations result in expression cassettes that allow for expression of the inserted synthase gene at an appropriate time during seed development.

- 25 1. Napin Seed Specific Expression Cassettes  
Napin 1-2 pCGN1808 Expression Cassette  
An expression cassette utilizing 5' upstream sequences and 3' downstream sequences obtainable from *B. campestris* napin gene can be constructed as follows.  
30 A 2.7 kb *Xho*I fragment of napin 1-2 (See, Figure 2 of EP 0 255 378, published February 3, 1988) containing 5' upstream sequences is subcloned into pCGN789 (a pUC based vector with the normal polylinker replaced by the synthetic linker which encodes the restriction digestion sites *Eco*RI, *Sal*I, *Bgl*II, *Pst*I, *Xho*I, *Bam*HI, *Hind*III) and results in pCGN940. The majority of the napin coding region of pCGN940 was deleted by digestion with *Sal*I and religation to form pCGN1800. Single-stranded DNA from pCGN1800 was

used in an *in vitro* mutagenesis reaction (Adelman et al., *DNA* (1983) 2:183-193) using a synthetic oligonucleotide which inserted *EcoRV* and *NcoI* restriction site at the junction of the promoter region and the ATG start codon of 5 the napin gene. An appropriate mutant was identified by hybridization to the oligonucleotide used for the mutagenesis and sequence analysis and named pCGN1801.

A 1.7 kb promoter fragment was subcloned from pCGN1801 by partial digestion with *EcoRV* and ligation to pCGN786 (a 10 pCGN566 (polylinker in opposite orientation as pCGN565 described in Example 6 B.1) chloramphenicol based vector with the synthetic linker described above in place of the normal polylinker) cut with *EcoRI* and blunted by filling in with DNA Polymerase I Klenow fragment to create pCGN1802.

15 A 2.1 kb *SalI* fragment of napin 1-2 containing 3' downstream sequences is subcloned into pCGN789 (described above) and results in pCGN941. pCGN941 is digested with *XhoI* and *HindIII* and the resulting approximately 1.6 kb of napin 3' sequences are inserted into *XhoI-HindIII* digested 20 pCGN1802 to result in pCGN1803. In order to remove a 326 nucleotide *HindIII* fragment inserted opposite to its natural orientation, as a result of the fact that there are 2 *HindIII* sites in pCGN1803, the pCGN1803 is digested with *HindIII* and religated. Following religation, a clone is 25 selected which now contains only 1.25 kb of the original 1.6 napin 3' sequence. This clone, pCGN1808 is the napin 1-2 expression cassette and contains 1.725 kb of napin promoter sequences and 1.265 kb of napin 3' sequence with the unique cloning sites *SalI*, *BglII*, *PstI* and *XhoI* in 30 between.

Napin 1-2 pCGN3223 Expression Cassette

Alternatively, pCGN1808 may be modified to contain flanking restriction sites to allow movement of only the expression sequences and not the antibiotic resistance 35 marker to binary vectors such as pCGN1557 (McBride and Summerfelt, *supra*). Synthetic oligonucleotides containing *KpnI*, *NotI* and *HindIII* restriction sites are annealed and ligated at the unique *HindIII* site of pCGN1808, such that

only one *Hind*III site is recovered. The resulting plasmid, pCGN3200 contains unique *Hind*III, *Not*I and *Kpn*I restriction sites at the 3'-end of the napin 3'-regulatory sequences as confirmed by sequence analysis.

5 The majority of the napin expression cassette is  
subcloned from pCGN3200 by digestion with *Hind*III and *Sac*I  
and ligation to *Hind*III and *Sac*I digested pIC19R (Marsh, et  
al. (1984) *Gene* 32:481-485) to make pCGN3212. The extreme  
5'-sequences of the napin promoter region are reconstructed  
10 by PCR using pCGN3200 as a template and two primers  
flanking the *Sac*I site and the junction of the napin 5'-  
promoter and the pUC backbone of pCGN3200 from the pCGN1808  
construct. The forward primer contains *Cla*I, *Hind*III,  
15 *Not*I, and *Kpn*I restriction sites as well as nucleotides  
408-423 of the napin 5'-sequence (from the *Eco*RV site) and  
the reverse primer contains the complement to napin  
sequences 718-739 which include the unique *Sac*I site in the  
5'-promoter. The PCR was performed using a Perkin  
Elmer/Cetus thermocycler according to manufacturer's  
20 specifications. The PCR fragment is subcloned as a blunt-  
ended fragment into pUC8 (Vieira and Messing (1982) *Gene*  
19:259-268) and digested with *Hinc*II to give pCGN3217.  
Sequence of pCGN3217 across the napin insert verifies that  
no improper nucleotides were introduced by PCR. The napin  
25 5-sequences in pCGN3217 are ligated to the remainder of the  
napin expression cassette by digestion with *Cla*I and *Sac*I  
and ligation to pCGN3212 digested with *Cla*I and *Sac*I. The  
resulting expression cassette pCGN3221, is digested with  
*Hind*III and the napin expression sequences are gel purified  
30 away and ligated to pIC20H (Marsh, *supra*) digested with  
*Hind*III. The final expression cassette is pCGN3223, which  
contains in an ampicillin resistant background, essentially  
identical 1.725 napin 5' and 1.265 3' regulatory sequences  
as found in pCGN1808. The regulatory regions are flanked  
35 with *Hind*III, *Not*I and *Kpn*I restriction sites and unique  
*Sac*I, *Bgl*III, *Pst*I, and *Xho*I cloning sites are located  
between the 5' and 3' noncoding regions.

2. Bce4 Expression Cassette

An expression cassette for seed specific expression can also be constructed from Bce4 gene sequences, such as those represented in Figure 7. Genomic clones having regulatory sequences of the Bce4 gene may be isolated from a *Brassica campestris* genomic library using Bce4 sequences as probe. For example, an approximately 20 kb *Bam*HI fragment is isolated and designated as clone P1C1. The approximately 20 kb insert of clone P1C1 is released by *Bam*HI digestion and inserted into the *Bam*HI site of the binary vector pCGN1547 (see below), producing pCGN1853. The *Pst*I fragment of pCGN1853, containing the Bce4 gene, is inserted into the *Pst*I site of pUC18 (Norlander, et al., (1983) *supra*), producing pCGN1857. The plasmid pCGN1857 was deposited with the ATCC, Rockville, MD on March 9, 1990, accession number 68251. The *Cla*I fragment of pCGN1857, containing the Bce4 gene is ligated into *Cla*I digested Bluescript KS+ (Stratagene; La Jolla, CA), producing pCGN1864. Single stranded DNA is made from pCGN1864 and altered by *in vitro* mutagenesis as described by Adelman et al. (*DNA* (1983) 2:183-193) using oligonucleotides having homology to Bce4 sequences 5' and 3' of the translated start and stop codons and also coding for restriction digest sites. The resulting plasmid, pCGN1866, contains *Xho*I and *Bam*HI sites (from BCE45P) immediately 5' to the Bce4 start codon and *Bam*HI and *Sma*I sites (from BCE43P) immediately 3' to the Bce4 stop codon. The *Cla*I fragment of pCGN1866, containing the mutagenized sequences, is inserted into the *Cla*I site of pCGN2016 (described below), producing pCGN1866C. The *Cla*I fragment of pCGN1866C is used to replace the corresponding wild-type *Cla*I fragment of pCGN1867 (described below) to produce pCGN1868. Bce4 coding sequences are removed by digestion of pCGN1868 with *Bam*HI and recircularization of the plasmid to produce pCGN1870. The Bce4 expression cassette, pCGN1870, contains 7.4 kb of 5' regulatory sequence and 1.9 kb of 3' regulatory sequence derived from the Bce4 genomic

clone separated by the cloning sites, *Xba*I, *Bam*HI, and *Sma*I.

pCGN1867

5 The *Bam*HI and *Sma*I sites of pUC18 (Norlander et al., (1983) supra) are removed by *Bam*HI-*Sma*I digestion and recircularization of the plasmid, without repair of the ends, to produce pCGN1862. The *Pst*I fragment of pCGN1857, containing the *Bce4* gene, is inserted into the *Pst*I site of pCGN1862 to produce pCGN1867.

10 pCGN2016

The multiple cloning sites of pUC12-Cm (Buckley, K., Ph.D. Thesis, UCSD, CA (1985)) are replaced by those of pUC18 to produce pCGN565. The *Kha*I fragment of pCGN565, containing the chloramphenicol resistance gene is excised, 15 blunted by use of mung bean nuclease, and inserted into the *Eco*RV site of Bluescript KS- (Stratagene; La Jolla, CA) to create pCGN2008. The chloramphenicol resistance gene of pCGN2008 is removed by *Eco*RI-*Hind*III digestion. After treatment with Klenow enzyme to blunt the ends, the 20 fragment carrying the chloramphenicol resistance gene is inserted into the *Dra*I site of Bluescript KS-, replacing the ampicillin resistance gene of Bluescript KS-, to produce pCGN2016.

B. Synthase Constructs in Plants

25 1. Insertion of Synthase Gene into Expression Cassettes.

Synthase cDNA sequences from isolated cDNA clones can be inserted in the expression cassettes in either the sense or anti-sense orientation using a variety of DNA manipulation techniques. If convenient restriction sites 30 are present in the synthase clones, they may be inserted into the expression cassette by digesting with the restriction endonucleases and ligation into the cassette that has been digested at one or more of the available cloning sites. If convenient restriction sites are not 35 available in the clones, the DNA of either the cassette or the synthase gene(s), can be modified in a variety of ways to facilitate cloning of the synthase gene(s) into the cassette. Examples of methods to modify the DNA include by

PCR, synthetic linker or adaptor ligation, *in vitro* site-directed mutagenesis (Adelman et al., *supra*), filling in or cutting back of overhanging 5' or 3' ends, and the like. These and other methods of manipulating DNA are well known to those of ordinary skill in the art.

For example, the *R. communis* synthase factor A cDNA, 1-1A, is altered by *in vitro* mutagenesis to insert a *Bam*HI restriction site at the 5' end of the cDNA insert and *Xho*I and *Sma*I sites immediately 3' of the translation stop codon. The resulting construct, pCGN2781, is digested with *Bam*HI and *Xho*I and ligated into *Bgl*III and *Xho*I digested pCGN3223, the above described napin expression cassette, resulting in pCGN2785.

The *R. communis* synthase factor B cDNA, pCGN2765 (2-8), is altered by *in vitro* mutagenesis to insert a *Bam*HI restriction site at the 5' end of the cDNA insert and *Xho*I and *Sma*I sites immediately 3' of the translation stop codon. The resulting construct, pCGN2783, is digested with *Bam*HI and *Xba*I and ligated into *Bgl*III and *Xho*I digested pCGN3223, the above described napin expression cassette, resulting in pCGN2786.

Similarly, synthase constructs for expression of anti sense sequences may be prepared. For example, the *Brassica campestris* synthase factor B cDNA clone, pCGN3248, is mutagenized to insert *Sma*I, *Bgl*III and *Sal*I restriction sites approximately 200 bases 3' of the translation stop signal, resulting in pCGN3255. pCGN3255 is digested at the factor B cDNA internal *Sal*I site located approximately 140 bases in from the 5' end of the cDNA and at the 3' *Bgl*III site inserted by mutagenesis. The resulting synthase factor B cDNA fragment is ligated into *Bgl*III and *Sal*I digested pCGN3223, the above described napin expression cassette, resulting in antisense construct pCGN3257. Thus, transcription of the *Brassica* synthase factor B sequence from the napin promoter will result in production of an mRNA strand that is complementary to that of the endogenous *Brassica* synthase factor B gene.

A similar *Brassica synthase factor B antisense construct* is prepared in a *Bce4 expression cassette*. pCGN3255 (described above) is digested with *SalI* to yield a *synthase factor B gene fragment*. This fragment is ligated 5 into *XhoI* digested *Bce4 expression cassette*, pCGN1870 (described above), resulting in antisense construct pCGN3260.

## 2. Binary Vectors for Plant Transformation

The fragment containing the synthase gene in the 10 *expression cassette*, 5' sequences/synthase/3' sequences, can be cloned into a binary vector such as described by McBride and Summerfelt (*Pl. Mol. Biol.* (1990) 14:269-276) for *Agrobacterium* transformation. Other binary vectors are known in the art and may also be used for synthase 15 cassettes.

For example, the antisense *Brassica synthase factor B construct* in a *napin expression cassette*, pCGN3257 is digested with *Asp718* (same recognition sequence as *KpnI*) and cloned into *Asp718* digested pCGN1578 (McBride and 20 Summerfelt, *supra*) yielding binary construct pCGN3259. The antisense *Brassica synthase factor B construct* in a *Bce4 expression cassette*, pCGN3260 is digested with *PstI* and cloned into *PstI* digested pCGN1578 (McBride and Summerfelt, *supra*) yielding binary construct pCGN3261.

25 Similarly, the *R. communis synthase factors A and B constructs* described above are ligated into pCGN1557 (McBride and Summerfelt, *supra*) or a similar construct to yield binary vectors for plant transformation with the synthase factor expression constructs.

30 The binary vector containing the expression cassette and the synthase gene is transformed into *Agrobacterium tumefaciens* strain EHA101 (Hood, et al., *J. Bacteriol.* (1986) 168:1291-1301) as per the method of Holsters, et al., (*Mol. Gen. Genet.* (1978) 163:181-187) for plant 35 transformation as described in Example 9.

3. Analysis of Transformed Plants

Transformed *Brassica campestris* cv. Tobin plants are obtained, as described for *B. napus* in Example 9, by cocultivation with *Agrobacterium* cells containing the 5 binary construct, pCGN3259. Oil analysis of mature single seeds from the resulting plants (Browse et al., *supra*) reveals seed oil with reduced stearate content, thus supporting the contribution of synthase factor B to synthase II type activity.

10 4. Other Methods of Plant Transformation

The binary vectors described above are useful for *Agrobacterium*-mediated plant transformation methods. Other methods for plant transformation, such as the DNA-bombardment technique described in Example 9B, and 15 electroporation may be used as well.

5. Constructs Containing More than One Synthase Gene.

If more than one synthase gene is required to obtain an optimum effect in plants, the genes may be expressed under regulation of two different promoters that are 20 preferentially expressed in developing seeds, such as the napin, ACP, and Bce4 sequences described above, and introduced into plants in the same binary vector, or introduced simultaneously in different binary vectors. Use of more than one binary vector would require the use of 25 additional selectable markers to allow for selection of both genes. Examples of selectable markers that can be used include the nptII gene for kanamycin resistance, which is used in the binary vectors of McBride and Summerfelt (*supra*), the nitrilase gene, bxn, that confers resistance 30 to the herbicide bromoxynil, described by Stalker et al. (*Science* (1988) 242:419-423), and a gene that confers resistance to the antibiotic hygromycin, (van den Elzen et al., *Pl.Mol.Biol.* (1985) 5:299-302). Other selectable 35 markers are also known and can be used in binary vectors for plant transformation. Alternatively, the genes can be introduced into the plant sequentially by transforming a plant expressing one of the desired genes with a construct containing a second desired gene. This method would also

require the use of a different selectable marker for selection of the second gene.

Another alternative for obtaining expression of more than one synthase gene in a transformed plant is to produce 5 by the methods described above, different plants, each of which is expressing one of the synthase genes. A plant expressing both genes can be obtained by back-crossing or other plant breeding techniques.

10 **Example 8. Plants Transformed With Synthase and Desaturase**

In this example constructs containing a desaturase gene isolated from *C. tinctorius* are described. The complete cDNA sequence of the *C. tinctorius* desaturase 15 clone, pCGN2754, is presented in Figure 8.

A. Desaturase Gene in an ACP Expression Cassette

The preparation of an ACP expression cassette containing *C. tinctorius* Δ-9 desaturase in a binary vector suitable for plant transformation is described.

20 An expression cassette utilizing 5'-upstream sequences and 3'-downstream sequences obtainable from *B. campestris* ACP gene can be constructed as follows.

25 A 1.45kb *Xho*I fragment of Bcg 4-4 containing 5'-upstream sequences is subcloned into the cloning/sequencing vector Bluescript+ (Stratagene Cloning Systems, San Diego, CA). The resulting construct, pCGN1941, is digested with *Xho*I and ligated to a chloramphenicol resistant Bluescript M13+ vector, pCGN2015 digested with *Xho*I. pCGN2015 described in Example 6. This alters the antibiotic 30 resistance of the plasmid from penicillin resistance to chloramphenicol resistance. The chloramphenicol resistant plasmid is pCGN1953.

35 3'-sequences of Bcg 4-4 are contained on an *Sst*I/*Bgl*II fragment cloned in the *Sst*I/*Bam*HI sites of M13 Bluescript+ vector. This plasmid is named pCGN1940. pCGN1940 is modified by *in vitro* site-directed mutagenesis (Adelman et al., *DNA* (1983) 2:183-193) using the synthetic oligonucleotide 5'-CTTAAGAAGTAACCCGGGCTGCAGTTTAGTATTAAGAG-

3' to insert *Sma*I and *Pst*I restriction sites immediately following the stop codon of the reading frame for the ACP gene 18 nucleotides from the *Sst*I site. The 3'-noncoding sequences from this modified plasmid, pCGN1950, are moved  
5 as a *Pst*I-*Sma*I fragment into pCGN1953 cut with *Pst*I and *Sma*I. The resulting plasmid pCGN1977 comprises the ACP expression cassette with the unique restriction sites *Eco*RV, *Eco*RI and *Pst*I available between the 1.45kb 5' and 1.5 kb of 3'-noncoding sequences for the cloning of genes  
10 to be expressed under regulation of these ACP gene regions.

Desaturase cDNA sequences from pCGN2754 are inserted in the ACP expression cassette, pCGN1977, as follows. pCGN2754 is digested with *Hind*III (located 160 nucleotides upstream of the start codon) and *Asp*718 located in the  
15 polylinker outside the poly(A) tails. The fragment containing the coding region for desaturase was blunt-ended using DNA polymerase I and ligated to pCGN1977 digested with *Eco*RV. A clone containing the desaturase sequences in the sense orientation with respect to the ACP promoter is  
20 selected and called pCGN1895. The fragment containing the pCGN1895 expression sequences ACP 5'/desaturase/ACP 3' is cloned into a binary vector pCGN1557 (described below) for *Agrobacterium* transformation by digestion with *Asp*718 and *Xba*I and ligation to pCGN1557 digested with *Asp*718 and  
25 *Xba*I. The resulting binary vector is called pCGN1898.

#### B. Desaturase in an Anti-Sense Construct

Cassettes for transcription of antisense constructs include, but are not limited to the seed preferential expression cassettes described in Example 7. An antisense construct is described below which allows for constitutive transcription of a *B. campestris* desaturase cDNA clone in the 5' to 3' orientation of transcription such that the mRNA strand produced is complementary to that of the endogenous desaturase gene.

##### 35 1. Isolation of *B. campestris* Desaturase cDNA.

cDNA clones for desaturase are isolated from the *B. campestris* cDNA library described in Example 6 D.1.

Partial DNA sequence of two clones, pCGN3235 and pCGN3236, are presented in Figure 9A and 9B, respectively. Initial DNA sequence analysis of the 3' regions of these clones indicates that pCGN3235 and pCGN3236 are cDNA clones from 5 the same gene. pCGN3236 is a shorter clone than pCGN3235, which appears to contain the entire coding region of the *B. campestris* desaturase gene.

## 2. Binary Vector Construction.

The *Kpn*I, *Bam*HI, and *Xba*I sites of binary vector 10 pCGN1559 (McBride and Summerfelt, *Pl.Mol.Biol.* (1990) 14: 269-276) are removed by *Asp*718/*Xba*I digestion followed by blunting the ends and recircularization to produce pCGP67. The 1.84 kb *Pst*I/*Hind*III fragment of pCGN986 containing the 15 35S promoter-tml3' cassette is inserted into *Pst*I/*Hind*III digested pCGP67 to produce pCGP291.

The 35S promoter-tml3' expression cassette, pCGN986, contains a cauliflower mosaic virus 35S (CaMV35) promoter and a T-DNA tml 3'-region with multiple restriction sites between them. pCGN986 is derived from another cassette, 20 pCGN206, containing a CaMV35S promoter and a different 3' region, the CaMV region VI 3'-end. The CaMV 35S promoter is cloned as an *Alu*I fragment (bp 7144-7734) (Gardner et. al., *Nucl.Acids Res.* (1981) 9:2871-2888) into the *Hinc*II site of M13mp7 (Messing, et. al., *Nucl.Acids Res.* (1981) 25 9:309-321) to create C614. An *Eco*RI digest of C614 produced the *Eco*RI fragment from C614 containing the 35S promoter which is cloned into the *Eco*RI site of pUC8 (Vieira and Messing, *Gene* (1982) 19:259) to produce pCGN147.

30 pCGN148a containing a promoter region, selectable marker (KAN with 2 ATG's) and 3' region, is prepared by digesting pCGN528 with *Bgl*II and inserting the *Bam*HI-*Bgl*II promoter fragment from pCGN147. This fragment is cloned into the *Bgl*II site of pCGN528 so that the *Bgl*II site is 35 proximal to the kanamycin gene of pCGN528.

The shuttle vector used for this construct, pCGN528, is made as follows: pCGN525 is made by digesting a plasmid containing *Tn*5 which harbors a kanamycin gene (Jorgenson

et. al., *Mol. Gen. Genet.* (1979) 177:65) with *Hind*III-*Bam*HI and inserting the *Hind*III-*Bam*HI fragment containing the kanamycin gene into the *Hind*III-*Bam*HI sites in the tetracycline gene of pACYC184 (Chang and Cohen, J. 5 *Bacteriol.* (1978) 134:1141-1156). pCGN526 was made by inserting the *Bam*HI fragment 19 of pTiA6 (Thomashow et. al., *Cell* (1980) 19:729-739), modified with *Xba*I linkers inserted into the *Sma*I site, into the *Bam*HI site of pCGN525. pCGN528 is obtained by deleting the small *Xba*I 10 fragment from pCGN526 by digesting with *Xba*I and religating.

pCGN149a is made by cloning the *Bam*HI-kanamycin gene fragment from pMB9KanXXI into the *Bam*HI site of pCGN148a. pMB9KanXXI is a pUC4K variant (Vieira and Messing, *Gene* 15 (1982) 19:259-268) which has the *Xba*I site missing, but contains a functional kanamycin gene from Tn903 to allow for efficient selection in *Agrobacterium*.

pCGN149a is digested with *Hind*III and *Bam*HI and ligated to pUC8 digested with *Hind*III and *Bam*HI to produce 20 pCGN169. This removes the Tn903 kanamycin marker. pCGN565 (described in Example 6) and pCGN169 are both digested with *Hind*III and *Pst*I and ligated to form pCGN203, a plasmid containing the CaMV 35S promoter and part of the 5'-end of the Tn5 kanamycin gene (up to the *Pst*I site, Jorgenson et. 25 al., (1979), *supra*). A 3'-regulatory region is added to pCGN203 from pCGN204, an *Eco*RI fragment of CaMV (bp 408-6105) containing the region VI 3' cloned into pUC18 (Yanisch-Perron, et al., *Gene* (1985) 33:103-119) by digestion with *Hind*III and *Pst*I and ligation. The 30 resulting cassette, pCGN206, is the basis for the construction of pCGN986.

The pTiA6 T-DNA *tmr* 3'-sequences are subcloned from the *Bam*19 T-DNA fragment (Thomashow et al., (1980) *supra*) as a *Bam*HI-*Eco*RI fragment (nucleotides 9062 to 12,823, 35 numbering as in Barker et al., *Plant Mol. Biol.* (1982) 2:335-350) and combined with the pACYC184 (Chang and Cohen (1978), *supra*) origin of replication as an *Eco*RI-*Hind*III fragment and a gentamycin resistance marker (from plasmid

PLB41), obtained from D. Figurski) as a *Bam*HI-*Hind*III fragment to produce pCGN417.

The unique *Sma*I site of pCGN417 (nucleotide 11,207 of the *Bam*19 fragment) is changed to a *Sac*I site using linkers 5 and the *Bam*HI-*Sac*I fragment is subcloned into pCGN565 to give pCGN971. The *Bam*HI site of pCGN971 is changed to an *Eco*RI site using linkers. The resulting *Eco*RI-*Sac*I fragment containing the *tml* 3' regulatory sequences is joined to pCGN206 by digestion with *Eco*RI and *Sac*I to give 10 pCGN975. The small part of the Tn5 kanamycin resistance gene is deleted from the 3'-end of the CaMV 35S promoter by digestion with *Sal*I and *Bgl*III, blunting the ends and ligation with *Sal*I linkers. The final expression cassette 15 pCGN986 contains the CaMV 35S promoter followed by two *Sal*I sites, an *Xba*I site, *Bam*HI, *Sma*I, *Kpn*I and the *tml* 3' region (nucleotides 11207-9023 of the T-DNA).

3. Insertion of Desaturase Sequence.

The 1.6 kb *Xba*I fragment from a *B. campestris* desaturase cDNA clone, pCGN3235, which contains the 20 desaturase cDNA is inserted in the antisense orientation into the *Xba*I site of pCGP291 to produce pCGN3234. A desaturase construct is transformed into a desired plant host using any appropriate method, such as described in Example 9.

25 C. Synthase and Desaturase Constructs in Plants

Plants containing both a synthase construct as described in Example 7 and a desaturase construct, such as those described above, may be prepared using any appropriate transformation method, such as those described 30 in Example 9. The constructs may be combined in a common binary vector, when *Agrobacterium* is used for plant transformation, or introduced into a plant simultaneously on different binary vectors using different selectable markers. Also, plants containing synthase and desaturase 35 constructs may be prepared by retransformation of a plant that contains one of the desired sequences, with a construct containing the other desired sequence.

Another alternative for obtaining expression of more than one synthase gene or genes and a desaturase gene in a transformed plant is to produce by the methods described above, different plants, each of which is expressing one of 5 the desired genes. A plant expressing all desired genes can be obtained by back-crossing or other plant breeding techniques.

#### Example 9. Plant Transformation

In this example, an *Agrobacterium*-mediated plant transformation is described and *Brassica napus* is exemplified. Also, a DNA-bombardment plant transformation is described and peanut transformation is exemplified.

##### A. Transformation of B. napus

Seeds of *Brassica napus* cv. Delta are soaked in 95% ethanol for 2 min, surface sterilized in a 1.0% solution of sodium hypochlorite containing a drop of Tween 20 for 45 min., and rinsed three times in sterile, distilled water. Seeds are then plated in Magenta boxes with 1/10th 20 concentration of Murashige minimal organics medium (Gibco) supplemented with pyrodoxine (50 µg/l), nicotinic acid (50 µg/l), glycine (200 µg/l), and 0.6% Phytagar (Gibco) pH 5.8. Seeds are germinated in a culture room at 22°C in a 16 h photoperiod with cool fluorescent and red light of 25 intensity approximately 65 µEinsteins per square meter per second ( $\mu\text{Em}^{-2}\text{s}^{-1}$ ).

Hypocotyls are excised from 7 day old seedlings, cut into pieces approximately 4 mm in length, and plated on feeder plates (Horsch et al. 1985). Feeder plates are 30 prepared one day before use by plating 1.0 ml of a tobacco suspension culture onto a petri plate (100x25 mm) containing about 30 ml MS salt base (Carolina Biological) 100 mg/l inositol, 1.3 mg/l thiamine-HCl, 200 mg KH<sub>2</sub>PO<sub>4</sub> with 3% sucrose, 2,4-D (1.0 mg/l), 0.6% Phytagar, and pH 35 adjusted to 5.8 prior to autoclaving (MSO/1/0 medium). A sterile filter paper disc (Whatman 3 mm) is placed on top of the feeder layer prior to use. Tobacco suspension cultures are subcultured weekly by transfer of 10 ml of

culture into 100 ml fresh MS medium as described for the feeder plates with 2,4-D (0.2 mg/l), Kinetin (0.1 mg/l). All hypocotyl explants are preincubated on feeder plates for 24 h. at 22°C in continuous light of intensity 30  $\mu\text{Em}^{-2}\text{s}^{-1}$  to 65  $\mu\text{Em}^{-2}\text{s}^{-1}$ .

Single colonies of *A. tumefaciens* strain EHA101 containing a binary plasmid are transferred to 5 ml MG/L broth and grown overnight at 30°C. Per liter, MG/L broth contains 5g mannitol, 1 g L-glutamic acid or 1.15 g sodium glutamate, 0.25 g kH<sub>2</sub>PO<sub>4</sub>, 0.10 g NaCL, 0.10 g MGSO<sub>4</sub>·7H<sub>2</sub>O, 1 mg biotin, 5 g tryptone, and 2.5 g yeast extract, and the broth is adjusted to pH 7.0. Hypocotyl explants are immersed in 7-12 ml MG/L broth with bacteria diluted to 1x10<sup>8</sup> bacteria/ml and after 10-20 min. are placed onto feeder plates. After 48 h of co-incubation with *Agrobacterium*, the hypocotyl explants are transferred to B5 0/1/0 callus induction medium which contains filter sterilized carbenicillin (500 mg/l, added after autoclaving) and kanamycin sulfate (Boehringer Mannheim) at concentrations of 25 mg/l.

After 3-7 days in culture at 65  $\mu\text{Em}^{-2}\text{s}^{-1}$  to 75  $\mu\text{Em}^{-2}\text{s}^{-1}$  continuous light, callus tissue is visible on the cut surface and the hypocotyl explants are transferred to shoot induction medium, B5BZ (B5 salts and vitamins supplemented with 3 mg/l benzylaminopurine, 1 mg/l zeatin, 1% sucrose, 0.6% Phytagar and pH adjusted to 5.8). This medium also contains carbenicillin (500 mg/l) and kanamycin sulfate (25 mg/l). Hypocotyl explants are subcultured onto fresh shoot induction medium every two weeks.

Shoots regenerate from the hypocotyl calli after one to three months. Green shoots at least 1 cm tall are excised from the calli and placed on medium containing B5 salts and vitamins, 1% sucrose, carbenicillin (300 mg/l), kanamycin sulfate (50 mg/l) and 0.6% Phytagar) and placed in a culture room with conditions as described for seed germination. After 2-4 weeks shoots which remain green are cut at the base and transferred to Magenta boxes containing root induction medium (B5 salts and vitamins, 1% sucrose, 2

mg/l indolebutyric acid, 50 mg/l kanamycin sulfate and 0.6% Phytagar). Green rooted shoots are tested for NPT II activity.

B. Peanut Transformation

5 DNA sequences of interest may be introduced as expression cassettes, comprising at least a promoter region, a gene of interest, and a termination region, into a plant genome via particle bombardment as described in European Patent Application 332 855 and in co-pending 10 application USSN 07/225,332, filed July 27, 1988.

Briefly, tungsten or gold particles of a size ranging from 0.5 $\mu$ M-3 $\mu$ M are coated with DNA of an expression cassette. This DNA may be in the form of an aqueous mixture or a dry DNA/particle precipitate.

15 Tissue used as the target for bombardment may be from cotyledonary explants, shoot meristems, immature leaflets, or anthers.

The bombardment of the tissue with the DNA-coated 20 particles is carried out using a Biolistics™ particle gun (Dupont; Wilmington, DE). The particles are placed in the barrel at variable distances ranging from 1cm-14cm from the barrel mouth. The tissue to be bombarded is placed beneath the stopping plate; testing is performed on the tissue at distances up to 20 cm. At the moment of discharge, the 25 tissue is protected by a nylon net or a combination of nylon nets with mesh ranging from 10 $\mu$ M to 300 $\mu$ M.

Following bombardment, plants may be regenerated 30 following the method of Atreya, et al., (*Plant Science Letters* (1984) 34:379-383). Briefly, embryo axis tissue or cotyledon segments are placed on MS medium (Murashige and Skoog, *Physiol. Plant.* (1962) 15:473) (MS plus 2.0 mg/l 6-benzyladenine (BA) for the cotyledon segments) and incubated in the dark for 1 week at 25 ± 2°C and are subsequently transferred to continuous cool white 35 fluorescent light (6.8 W/m<sup>2</sup>). On the 10th day of culture, the plantlets are transferred to pots containing sterile soil, are kept in the shade for 3-5 days and finally moved to greenhouse.

The putative transgenic shoots are rooted. Integration of exogenous DNA into the plant genome may be confirmed by various methods known to those skilled in the art.

5       The above results demonstrate the ability to obtain protein preparations with synthases activities, especially synthase I or synthase II, isolate DNA sequences related to such protein preparations and manipulate them. In this manner, the production of transcription constructs and  
10      expression cassettes can be produced which allow for production, especially differentiated cell products, or inhibition of plant synthases. Thus, the phenotype of a particular plant may be modified.

15      A purified *R. communis* synthase is provided and used to obtain nucleic acid sequences. From the protein or the sequences other plant synthases may be obtained.

20      All publications and patent applications mentioned in this specification are indicative of the level of skill of those skilled in the art to which this invention pertains. All publications and patent applications are herein incorporated by referenced to the same extent as if each individual publication or patent application was specifically and individually indicated to be incorporated by reference.

25      Although the foregoing invention has been described in some detail by way of illustration and example for purposes of clarity of understanding, it will be obvious that certain changes and modifications may be practiced within  
30      the scope of the appended claim.

What is claimed is:

1. A plant  $\beta$ -ketoacyl synthase protein preparation obtainable from *R. communis* having preferential activity towards shorter chain length acyl-ACPs as compared to longer chain length acyl-ACPs.
2. The protein preparation of Claim 1 having a specific activity of at least 16  $\mu\text{mol}/\text{min}/\text{mg}$  protein.
3. A plant  $\beta$ -ketoacyl synthase protein preparation having preferential activity towards longer chain length acyl-ACPs as compared to shorter chain length acyl-ACPs.
4. The protein preparation of Claim 3 having a specific activity of at least 1.7  $\mu\text{mol}/\text{min}/\text{mg}$  protein.
5. The protein preparation of Claim 3 wherein said protein is obtainable from *R. communis*.
6. A plant  $\beta$ -ketoacyl synthase protein preparation prepared according to a method comprising the steps of:
  - a. fractionating a homogenate of *R. communis* immature endosperm with an ammonium sulfate solution of about 40% weight per volume and recovering supernatant;
  - b. contacting said supernatant with a higher concentration, as compared to step (a) of ammonium sulfate sufficient to precipitate protein having active synthase protein;
  - c. resuspending the precipitate recovered in step (b) and subjecting the resulting solution to Reactive Green-19 Agarose chromatography and eluting proteins having synthase activity in a high salt wash;
  - d. absorbing partially desalted protein fractions prepared from step (c) onto an ACP-Sepharose column;
  - e. eluting fractions having plant synthase activity with a gradient of 100-250 mM potassium phosphate buffer.
7. The protein preparation of Claim 6 further comprising the step of applying a first major fraction eluted from step (e) to SDS-PAGE analysis and observing at least two major bands of about 50 kD and 46 kD.

8. The protein preparation of Claim 7 wherein said 50 kD protein preparation comprises amino acid sequence shown in Fig. 6.

9. The protein preparation of Claim 6 further comprising the step of applying a later major fraction eluted from step (e) to SDS-PAGE analysis and observing at least one major band of about 50 kD.

10. A cDNA sequence encoding at least a portion of the 50 kD protein of Claim 7.

10. 11. A cDNA sequence encoding at least a portion of the 46 kD protein of Claim 7.

12. A cDNA sequence encoding at least a portion of the 50 kD protein of Claim 9.

13. A nucleic acid sequence encoding a  $\beta$ -ketoacyl synthase obtainable from the cDNA of any one of Claims 10-12 joined to a heterologous sequence.

14. A cDNA sequence encoding at least a portion of a  $\beta$ -ketoacyl-ACP synthase obtainable from the cDNA of any one of Claims 10-12.

20 15. A method of catalyzing the condensation reaction between an acyl-ACP having a chain length of C2 to C16 and malonyl-ACP comprising the steps of

25 contacting said acyl-ACP and said malonyl-ACP with a  $\beta$ -ketoacyl synthase protein preparation obtainable from *R. communis*, wherein said synthase is external to a *R. communis* cell, under conditions which permit the condensation of said acyl-ACP and malonyl-ACP.

30 16. The method of Claim 15 wherein said acyl-ACP has a chain length of C2 to C14 and said synthase has a preferential activity towards shorter acyl-ACP fatty acids as compared to longer acyl-ACP fatty acids.

35 17. The method of Claim 15 wherein said acyl-ACP has a chain length of C14 or C16 and said synthase has a preferential activity towards longer acyl-ACP fatty acids as compared to shorter acyl-ACP fatty acids.

18. The method of Claim 15 wherein said contacting occurs *in vitro*.

19. The method of Claim 15 wherein said contacting occurs *in vivo*.

20. The method of Claim 19 further comprising growing a plant cell having integrated in its genome a 5 expression construct capable of expressing a plant synthase.

21. A recombinant DNA construct comprising at least a portion of a plant synthase protein encoding sequence.

22. The recombinant DNA construct of Claim 21, 10 wherein said plant synthase protein is synthase factor A.

23. The recombinant DNA construct of Claim 21, wherein said plant synthase protein is synthase factor B.

24. The construct of Claim 21 encoding a biologically active plant synthase.

25. The construct of Claim 21 wherein said sequence is joined to a second nucleic acid sequence which is not naturally joined to said first sequence.

26. The construct of Claim 21 wherein said sequence is joined to a label.

27. The construct of Claim 21 wherein said sequence encodes a precursor plant synthase protein.

28. The construct of Claim 21 comprising, in the 5' to 3' direction of transcription, a transcriptional regulatory region functional in a host cell and said 25 sequence.

29. The construct of Claim 28 wherein said sequence is a sense sequence.

30. The construct of Claim 28 wherein said sequence is an anti-sense sequence.

31. The construct of Claim 28 further comprising, a translational regulatory region functional in a host cell immediately 5' to said sequence and a transcriptional/translational termination regulatory region 3' to said sequence.

32. The construct of Claim 21 comprising an expression cassette capable of producing a plant synthase protein in a host cell comprising, in the 5' to 3' direction of transcription, a transcriptional initiation

regulatory region functional in said host cell, a translational initiation regulatory region functional in said host cell, a DNA sense sequence encoding a plant synthase protein, and a transcriptional and translational 5 termination regulatory region functional in said host cell, wherein said plant synthase protein encoding sequence is under the control of said regulatory regions.

33. The construct of Claim 32 wherein said host cell is a plant cell.

10 34. The construct of claim 11 wherein said transcriptional initiation region is obtained from a gene preferentially expressed in plant seed tissue.

15 35. The construct of Claim 21 wherein said plant synthase protein is required for preferential activity toward longer acyl-acyl carrier protein fatty acids.

36. The construct of Claim 21 wherein said plant synthase protein is required for preferential activity toward shorter acyl-acyl carrier protein fatty acids.

20 37. The construct of Claim 21 wherein said sequence is obtainable from *Ricinus communis* or *Brassica*.

38. A host cell comprising a plant synthase protein encoding sequence construct of any one of Claims 21-37.

25 39. The cell of claim 38 wherein said cell is a plant cell.

40. The cell of Claim 39 further comprising a second recombinant DNA construct comprising a portion of a plant sequence encoding an enzyme capable of affecting plant lipids.

30 41. The cell of Claim 40 wherein said enzyme is a desaturase or a thioesterase.

42. The cell of Claim 39 wherein said plant cell is *in vivo*.

43. The cell of Claim 39 wherein said plant cell is a *Brassica* plant cell.

35 44. A transgenic host cell comprising a plant synthase protein expressed from a recombinant DNA sequence.

45. The cell of Claim 44 wherein said host cell is a plant cell.

46. The cell of Claim 45 wherein said plant synthase protein is required for preferential activity toward longer acyl-acyl carrier protein fatty acids.

47. The cell of Claim 45 wherein said plant synthase protein is required for preferential activity toward shorter acyl-acyl carrier protein fatty acids.

48. A method of producing a plant synthase protein in a host cell or progeny thereof comprising  
growing a host cell or progeny thereof  
comprising a construct of any one of Claims 32-34, under  
conditions which will permit the production of said plant synthase protein.

49. The method of Claim 48 wherein said host cell is a plant cell and said construct is integrated into the genome of said plant cell.

50. The method of Claim 49 wherein said plant cell is *in vivo*.

51. A host cell comprising a plant synthase protein produced according to Claim 48.

52. A cell of Claim 51 wherein said host cell is a plant host cell and said construct is integrated into the genome of said plant cell.

53. A method of modifying the fatty acid composition in a plant cell comprising:

growing a plant cell having integrated in its genome a DNA construct, said construct comprising in the 5' to 3' direction of transcription, a transcriptional regulatory region functional in said plant cell and a plant synthase protein encoding sequence, under conditions which will permit the transcription of said plant synthase protein encoding sequence.

54. The method of Claim 53 wherein said plant synthase protein encoding sequence is an anti-sense sequence.

55. The method of Claim 54 wherein said plant synthase protein is a synthase factor B.

56. The method of Claim 53 wherein said construct further comprises a translational regulatory region

functional in said plant cell immediately 5' to said plant synthase protein encoding sequence and a transcriptional/translational termination regulatory region 3' to said sequence and wherein said plant synthase protein encoding sequence is a sense sequence.

57. The method of Claim 53 wherein said plant cell is an oilseed embryo plant cell.

58. A plant cell having a modified free fatty acid composition produced according to the method of any one of 10 Claims 53-57.

59. A plant seed having a modified fatty acid composition as compared to a seed of said plant having a native fatty acid composition, produced according to a method comprising:

15 growing a plant, having integrated into the genome of embryo cells a recombinant DNA sequence comprising at least a portion of a plant synthase protein encoding sequence under the transcriptional control of regulatory elements functional in seed during lipid 20 accumulation, to produce seed under conditions which will promote the activity of said regulatory elements, and harvesting said seed.

60. The seed of Claim 59 wherein said plant is *Brassica napus*.

25 61. The seed of Claim 59 wherein said seed is an oilseed.

62. A method of modifying the fatty acid composition of triglycerides produced from an oilseed crop plant comprising:

30 growing a plant cell having integrated in its genome a DNA construct, said construct comprising in the 5' to 3' direction of transcription, a transcriptional regulatory region functional in said plant cell and a plant synthase protein encoding sequence, under conditions which 35 will permit the transcription of said plant synthase protein encoding sequence.

63. The method of Claim 62 wherein said plant synthase protein encoding sequence is an anti-sense sequence.

64. The method of Claim 62 wherein said construct further comprises a translational regulatory region functional in said plant cell immediately 5' to said plant synthase protein encoding sequence and a transcriptional/translational termination regulatory region 3' to said sequence and wherein said plant synthase protein encoding sequence is a sense sequence.

65. The method of Claim 62 wherein said plant cell is an oilseed embryo plant cell.

66. A plant cell having a modified fatty acid composition of triglycerides produced according to the method of any one of Claims 62-65.

67. The method of any one of Claims 62 to 65 wherein said crop plant is selected from the group consisting of rapeseed, sunflower, safflower, cotton, cuphea, soybean, peanut, coconut, oil palm and corn.

68. A plant seed oil separated from a seed produced according to any one of Claims 58-60.

69. The oil of Claim 68 comprising a *Brassica* oil.

✓  
C16  
C10

## Cerulenin time course




FIG. 1

*H42*

F1: NTTISAPKKR

F2: VVITGTGLVSVFGNxVDTY

F3: LLAGESTIGLID

F4: GFNSQG<sup>Y</sup><sub>W</sub>IDGK

F5: YxIVAGK

F6: ALEHADLGGDK

F7: AGVLVGTGMGGLTVFSDGVQALIxK

F8: ALSQR

F9: NDDPQTASR

F10: DGFVMGEAGVLVMESL

F11: GAPIIAEYLGGAVNCDAYxMTDP

F12: ADGLGVSSCIER

F13: SLEDAGVSPEEVNYINAHATSTLAGDLAEIN

FIG. 2

*3/45*

KR1 : SFSTDGVVAPK

KR2 : EEVNYINAXTSTPAGDL

KR3 : VFNDAIEALR

KR4 : DGFVMGEGAGVLLL

KR7 : VVVTGMGVVxPL

KR8 : SMIGxLLGAAGAVEAIATIEAI

KR10 : GGVxPNINLENPEEGV

KR11 : xGVxKEEVNYINAXATxTPAG

KR12 : xxPNINLENPEEGV

NT : KHPLMKQRRVVVTGMxV

FIG. 3

Partial Amino Acid Sequences		KR4	KR16
From 50 kD	Peptides	N D P Q T A	E E V N Y I N A
		MAT GAT GAT CCN CAA ACN GCN C C C G A	GAA GAA GTN ATN TAT ATT ATT GCN G G C C C A

## Forward Primers

5' GACAAGCTT AAQ GAQ GAQ CCQ CAP ACN GC3'  
 5' GACAAGCTT AAQ GAQ GAQ CCP CAP ACN GC3'

Reverse Primers  
(complements)

665-3

3' CTQ CTQ CAN TTP ATP TAP TTP CG CTTAAGCAG

FIG. 4

1	GGCTTCCCAATTCAATCGTTGGATCGCTTACACTCCGCCACCCACCCATGCAAGGCCCTGC METGlnAlaLeuG	69
70	Pst I.   AGTCCCCGTCTCTCCGACCATCCCCCTCTAACCCCCCTCATAAAAATACTCACAAATGCAGCAAAACGCC InSerProSerLeuArgProSerProLeuThrProLeuThrProLeuHisLysAsnThrHisAsnAlaAlaLysArgP	138
139	CAACTAAAAGGTCTCCTTATCACCGCATCATCAACAAATAACACGACGATTTCAGCTCCAAAGC roThrLysValSerSerPheIleThrAlaSerSerThrAsnAsnAsnThrThrIleSerAlaProLysA	207
208	GAGAGAAAGACCCAGAAAAGGGTAGTCATAACTGGTACGGTTGGTATCTGIGTTGGGAATGATG rgGluLysAspProArgLysArgValValIleThrGlyThrGlyLeuValSerValPheGlyLeuIleAspAsnAspV	276
277	TCGATACTACGATAATTGCTTGGAGAAAGTGGGATCGGACTTATGATAGGTTCGATGCGT aAspThrTyrAspLysLeuLeuAlaGlyGluSerGlyIleGlyLeuIleAspArgPheAspAlaS	345

FIG. 5A - 1

6/4/8

346 C <sup>r</sup> AAGTTCCCTACTAGATTGGGACAGATCAGGGGT <sup>r</sup> TAATTCACTTGGTTATATGATGGGAAA erLysPheProThrArgPheGlyGlnIleArgGlyPheAsnSerLeuGlyTyrIleAspGlyLysA	414	
		SphI
415 ATGATAAGGCCGATTGATGATTGGCTATTGCATTGCTGGTAAAAAGCTCTGAGCATGCTG snAspArgArgLeuAspAspCysLeuArgTyrCysIleValAlaGlyLysLysAlaLeuGluHisAlaA	483	
484 ATCTGGGGATAAAGTTGTCTAACATTGATAAAAGAGCGAGCTGGTGTGCTTGGAACAGGGATGG spLeuGlyGlyAspLysLeuSerLysIleAspLysGluArgAlaGlyValGlyThrGlyMETG	552	
553 GTGGCTTACAGTCCTTCAGATGGTGTCAAGGCCCTAACATTGAAAGGACACAGGAAATTACCCCAT lyGlyLeuThrValPheSerAspGlyValGlnAlaLeuIleGluLysGlyHisArgLysIleThrProp	621	
622 TCITTATTCCCTATGCTATAACAAACATGGGATCTGCCCTTAGCTTATGAACTTGGTCTCATGGTC heFheIleProTyrAlaIleThrAsnMetGlySerAlaLeuLeuGluIleGluGlyLeuMetGlyP	690	

FIG. 5A - 2

6691 CTAATTCAATTCAACTGCTTGTGCTACCTCCAATTATGCTTCATGCTGCCAATCATATTC  
roAsnTyrSerThrAlaCysAlaThrSerAsnTyrCysPhyTyrAlaAlaAsnHisIleA  
759

760 GCAGGGTGAATTGATGATTGGCTGAACTGAAGCCATCATTCMTCGGTTGGAG  
rgArgGlyGluAlaGluLeuME'IleAlaGlyGlyThrGluAlaAlaLeProIleGlyLeuGlyG

829 GTTTGAGCATGTAGGGCCTATCACAAAGGAATTGATCCACAAACTGCCCTCAAGGCCATGGACA  
lyPheValAlaCysArgAlaLeuSerGlnArgAsnAspAspProGlnThrAlaSerArgProTriPaspL  
Nco I

898 ANGATCAGAGATGGCTTTGTTATGGGTGAAGGTGGACTGTTGGAGTTATGGAGAGT 966  
 ysAspArgAspGlyPheValIMETGlyGluGlyAlaGlyValLeuValMetGluSerLeuGluHisAlaM

967 TGAAAGGGCTGCACCAATAATTGCTGAGTACTTGAGGTATGCTGTAAATTGATGCTTATCACATGA 1035  
ETlysArgGlyAlaProIleAlaGluItyLeuGlyGlyAlaValAsnCysAspAlaTyRHisMett  
997

FIG. 5A - 3

*8/48*

1036 CTGATCCAAGGGCTGATGGACTTGGGTCTCTGCATTGAGAGAAAGTCTGAAGATGCCGGTGTGT  
hrAspProArgAlaAspGlyLeuGlyValSerSerCysIleGluArgSerLeuGluAspAlaGlyValS

HpaI

1105 CACCTGAGGAGGTTAACATATAATGCACATGCCACTTCCACTCTGCTGGTGACCTTNCAGAGATAA 1173  
erProGluGluValAsnThrIleAsnAlaThrSerAspIleGlyAspLeu GluIleA  
1119

1174 ATGCTATTAAAAGTATTCAAGAATAACGTCTGACATCAMAATGCAAACCAAGTCATGATAAGGAC 1242  
snAlaIleLysValPheLysAsnThrSerAspIleLysIleAsnAlaThrLysSerMetIleGlyH

1243 ATTGCCTTGGTGTGGAGGTCTGGAAAGCAATTGCCCTGTGTGAAGGCCATTACCAAGGATGGTTGC 1311  
isCysLeuGlyAlaAlaGlyGlyLeuGluAlaIleAlaCysVallysAlaIleThrThrGlyTrpLeuH

1312 ATCCTACAATTAAATCATTAAACCCAGAGCCATCAGTTGAACTGTTGCCAAATANGANGCAGC 1380  
isProThrIleAsnGlnPheAsnProGluProSerValGluPheAspThrValAlaAsnLysLysGlnG

FIG. 5A - 4

9/4/8

1381 AGCACCGAAGTGAATGTTGCCATTCAAAATTCCCTTGATTGGACTGGACACAACTCTGTGGTAGCCTTT  
InHisGluValAsnValAlleSerAsnSerPheGlyPheGlyGlyHisAsnSerValValAlaPheS 1449

1450 CTGCATTAAACCCCTGAGAGCATGGTTTCTGCATTGGGCCGGTCATTACATTACCATGGC 1518  
erAlaPheLysPro .

1519 CTGCATTCTGTAGGAACACTGGAGAGTTGCTTATAGACAGAGTCATCGACATCACTCCCCC 1587

1588 TTTAGCTTTGAGCTGATAGTAGTCAGTTCTCATTCAGTATCAAGTCTATCTTAAGAAGGTC 1656

1657 TTGCTTATTCTTT 1672

FIG. 5A - 5

1 GGCTTCTCCCAATTCATCGTTATCGCTACCACTTCCGCCACCCCCAACACCAGCAAGCCCTG  
LeuLeuProIleHisArgCysTyrArgTyrHisPheArgHisProThrThrMETGlnAlaLeuG  
*1*

69

70 AGTCGGCGTCTCCGACCATCCCCCTCTAACCCCCGCTCCATMAAAATACTCACAAATGCCAGCAAAMACGCC  
InSerProSerLeuArgProSerProLeuThrProLeuHisLysAsnThrHisAsnAlaAlaLysArgP  
*1*

138

139 CAACTAAAAGGTCTCCTTATCACCGCATCATCAACAAATAACAAACACGACGATTCAAGCTTCCAAAGC  
roThrLysValSerPheIleThrAlaSerSerThrAsnAsnThrAsnAsnThrThrIleSerAlaProLysA  
*1*

207

208 GAGAGAAAGACCCAGAAAMGGTAGTCATAACTGGTACGGGTTGGTATCTGTGTTGGGAAATGATC  
rgGluLysAspProArgLysArgValValIleThrGlyThrGlyLeuValSerValPheGlyAsnAspV  
*1*

276

277 TCGATACTTACGATAAAATTGCTTGCTGGAAAGTGGATCGGACTTATGATAGGTTCGATGCGT  
alAspThrTyrTyrAspLysLeuLeuAlaGlyGluSerGlyIleGlyLeuIleAspArgPheAspAlaS  
*1*

345

346 CTAAGTTCCACTAGATTGGACAGATCAGGGGTTTAATTACAAGGTTATATGATGGAAAA  
erLysPheProThrArgPheGlyGlyGlnIleArgGlyPheAsnSerGlnGlyTyrIleAspGlyLysA 414

415 ATGATAAGGCTTGATGATTGAGGTATTGCATTGTTGCTGGTAAAAAGCTCTTGAGCATGGCTG 483  
snAspArgArgLeuAspAspCysLeuArgTyrCysIleValAlaGlyLysLysAlaLeuGluHisAlaA

484 A'CTTGGTGGTATAAGATTGATAAGAGCGAGCTGGTGTGCTGGAAACAGGGATGG 552  
sPheGlyGlyAspLysLeuSerLysIleAspLysGluArgAlaGlyValLeuValGlyThrGlyMetIG

553 GTGGCTTACAGTCTTTCAGATGGTGTGCTAGGCCCTAATTGAAAAGGACACAGGAAMTTACCCCAT 621  
lyGlyLeuThrValPheSerAspGlyValGlnAlaLeuIleGluLysGlyHisArgLysIleThrProP

622 TCTTATTCCCTATGCTATAAACATGGGATCTGCCTTAGCTATTGAACTTGGTCTCATGGGTCh 690  
hePheIleProTyrAlaIleThrAsnMETGlySerAlaLeuAlaIleGluLeuGlyLeuMETGlyP

691 CTAATTATTCAAACTGCTTGCTAACCTCCAAATTATGCTTCTATGCTGCTGCCAATTCATATTC  
roAsnTyrSerIleSerThrAlaCysAlaThrSerAsnTyrCysPheTyrAlaAlaAsnHisIleA 759

FIG. 5B - 2

12/4/8

760 GCAGGGTGAAGCTGAATTGATGATTGCTGGACTGAAGCCCATCATTCCAATCGGTTGGAG 828  
 rgArgGlyGluAlaGluLeuMETIleAlaGlyGlyThrGluAlaAlaIleProIleGlyLeuGlyG

829 GTTTAGCATGTAGGCCTTATCACAAAGGAATGATGATCCACAAACUCCCTCAAGGCCATGGACA 897  
 lyPheValAlaCysArgAlaLeuSerGlnArgAsnAspPheGlnThrAlaSerArgProTrpAspL

898 AGATCGAGATGGCTTGTATGGGTGAGTGMAGGTGCTGGTAATGGAGAGTTGGAACATGCCA 966  
 ysASPArgAspGlyPheValMETHGlyGluGlyAlaGlyValMetGluSerLeuGluHisAlaM

967 TGAAAAGGGGTGACCMATAATTGCTGAGTACTTGGGAGGTGCTGTTAATTGTGATGCTTATCACATGA 1035  
 ETLYsArgGlyAlaProIleAlaGluTyrLeuGlyGlyAlaValAsnCysAspAlaTyrHisMETT

1036 CTGATCCAAGGGCTGATGGACTTGGGTCTCTGCATGTAGAGAAGTCITGAAGATGCCGGTGTGT 1104  
 hrAspPheArgAlaAspGlyLeuGlyValSerSerCysIleGluArgSerLeuGluAspLeuAlaGlyValS

1105 CACCTGAGGGTTAACATATAATGCACATGCAACTTCCACTTGCTGGTGCACCTTGCTGAGATA 1173  
 er:ProGluGluValAsnTyrIleAsnAlaThrSerThrLeuAlaGlyAspLeuAlaGlyValS

FIG. 5B - 3

13/48

1174 ATGCTTAAAGTATTCAAGAATAACGTCTGACATCAAATCAATTGCAACCAAGTCTATGATAAGGAC  
snAlaIleLysValPhelysAsnThrSerAspIleLysIleAsnAlaThrLysSerMetIleGlyH

1243 ATTGCCTGGTGCTGGAGGTCTGGAAGCAATTGCCATTCAAGCCATTGAAATTGCTGTTGAAAGGCCATTACCAAGGATGGTTGC 1311  
isCysLeuGlyAlaAlaGlyGlyLeuGluAlaIleAlaCysVallysAlaIleThrThrGlyTrpLeuH

1312 ATCCTACAATTAAATCAATTAAACCCAGAGCCATTCAAGTGTGAATTGACACTGTTGCCAAATAAGAACGCAGC 1380  
isProThrIleAsnGlnPheAsnProGluProSerValGluPheAspThrValAlaAsnLysLysGlnG

1381 AGCACCGAAGTGAATGTTGCCATTCAAAATTCCCTTGGATTGGACACAACTCTGTGGTAGCCTTT 1449  
lnHisGluValAsnValAlaIleSerAsnSerPheGlyPheGlyGlyHisAsnSerValValAlaPheS

1450 CTGCATTAAACCCCTGAGGCAATGGCCTTCTGCATTGGCATTTACATTACCATGGC 1518  
erAlaPheLysPro

1519 CTGCATTCTGTAGGAACCACTGGAGGTTGCTTGCTTATAGACAGAGTCATCGACATCACTCCCC 1587

FIG. 5B - 4

*17/48*

1588 TTTTAGCTTTGAGCTGCTGATAGTAGTCAGTTCTCATTCAGTATCAAGTCTATCTTAAGAAGGTC 1656

1657 TTGCTTAATTCTTTCAAAATTACCATTTCATTTGTCAATTCCCTTGGAACCTTTAGCTTAAGATCTG 1725

1726 CTGTGATCATGGTTGATTCAAATTAAATTATGTTAGGGATAACGAACAGCAATCATAAAAAGTCT 1794

1795 TTGAAATTAGTAATTACGATAACTGTTATTTCTTTTCAAAAAAAA 1845

FIG. 5B - 5

15/42

FIG. 6A - 1

۱۶ / ۴۵

<pre> 310      320      330      340      350      360 RGAPII<del>A</del>EYLGGAVNC<del>D</del>AYHMTDPRADGLGVSSCIERSLEDAGVSPPEVNYINAHATS       .   RGAHIIYAEIVGYGATSDGADMVAPS<del>G</del>AVRCMKMAMHGVD-----T<del>P</del>IDYLN<del>S</del>HGT<del>S</del> 250      260      270      280      290      300 </pre>	<pre> 370      380      390      390      396 TLAGDLXEINAIIKKVF<del>K</del>NTS<del>D</del>I<del>K</del>INATKSMIGH       .                                     TPVGDVKELAAIREVF<del>G</del>DKS-PAISATKAMTGH 310      320      330      330      333 </pre>
---	---

FIG. 6A - 2

17/48

134	VDH <sup>T</sup> LAVEQLFDYFVPTSI <sup>C</sup> REVAWEAGAEGPVT <sup>V</sup> SIGCTSGLD <sup>A</sup> VGYGTELIRDGR   KGURK <sup>I</sup> TPFFIPYAITNMG <sup>S</sup> ALLI <sup>E</sup> LGMP <sup>N</sup> YSISTACATSN <sup>Y</sup> CFYAA <sup>N</sup> HIRRGE
181	140            150            160            170            180            190 190            200            210            220            230

200	210	220	230	240
ADVVVCGATDAPISPI	TACFDAIKATSANNNDDPAHASRPFDRNRDGFVLGEGS	AVFV		
AELMIAGGTEAAIIPIGLGGFVACRALSQRRNDDPQTASRPWDKDRDG	FVMGE	GAGVLV		
240	250	260	270	280
				290

250	LEELSAARRRGAAHAYAEVVRGFATRSNAFHAMTGLKPDGREMAEAITAALDQARRTGDDL	280	290	300
MESLEHAMKRGAPIIAEYLGAVNCDAYHMTDPRADGLGVSSCIERSLEDAGVSPEEV				
300	310	320	330	340
				350

FIG. 6B - 1

18/48

370	380	390	400	410	420
ΔIEHGVIPPTANYEEPDPECDDYVPNVAREQRVDTVLSVGSGFGQSAAVLARPK					
411	412	413	414	415	416
ΔITTGWLHFTINQFNPEPSVEFDTVANKQQNEVNVAISNSFGGGHNSVVAFSAFK					
420	430	440	450	460	468

FIG. 6B - 2

15/45

- 1 ATGATTACCTGAAAAATAGTATAATTGTATTGAAATTAAAGTGACATTTTG'TGTAACAAATATT 69
- 70 T'RG'TGTAACAAGAATTAAAAAACAGAAAATACTCAGCTTTAAATAATAAAAAAAATTAAAT'TG 138
- 139 AGTTAGAAAATTGTGTACCAATAACAAAAGATTATATGGAATTATAAAATCAACACACAAATAACAC 207
- 208 AAGACTTTTAAAGAATAATAAGCAATAACATAAGAAATCTCAAATTCTCAAATCCCTTA 276
- 277 AAAATCAATCTCCACTATTAAATCCCCTTAGTTAG'TGGTAATGGCAACGTTGTGACTACCGTA 345
- 346 TTGTAACTTTGTCAAAATTGTCATAAATACGTGTCAAACTCTGGTAAAAAATTAGTCTGGCTACAT'CCTGT 414

FIG. 7 - 1

*sc/fc*

415 CTTTATTATAAACACAGCTTTAATCAGAATTGGTTTAAATCAACAAACCTGCACGAAACTTG 483

484 TGTGAGCATATTGGTCTGTTCTGGTTCATGACCTCTCCGCATGATGGCCAAGTGTAAATGCCACT 552

553 TGCAAGAGCGTTCTTCAACGGAGATAAGTCGAACAAATATTGTCCGTTACGGACCACATATAANATCTC  
BglII |  
616 621

622 CCCATCTATATAACCAGCATTCAACCATCATGAAATACCTCAAATCCAAATCTCACAAATACTTC 690

691 AATAAAAAGACCAAAAAATTAAAGCAAAAGAAAAAGCCATTCTTGTGCACAAAAAAAGAAGCCTTGCT 759

6/1/89

760 AGGTTCACGGACATGAAAGTTCAACTACTAATGGTCATCACATTGGTGTATAATGCCATCTCGTCTCC  
MET Lys Phe Thr Leu Met Val Ile Thr Leu Val Ile Ala Ile Ser Ser Pro 828

829 TGTTCAAATTAGGCAACCACGGTTGAAAGTTGGGAGAACATGGTGTGACAGAACT 897  
Val Pro Ile Arg Ala Thr Thr Val Glu Ser Phe Gly Glu Val Ala Gln Ser Cys Val Val Thr Glu Le

898 CGCCCCATGCTTACCAAGCAATGACCACGGCAGGAGACCCGAACACTACAGAATGCTGGACAAACTGGTAGA  
u Ala Pro Cys Leu Pro Ala Met Thr Thr Ala Gly Asp Pro Thr Thr Glu Cys Cys Asp Lys Leu Val Gl 966

967 GCAGAAACCATGCTTGGTTATATTGAAACCCAGCCTATAGTATGTATGTTACTCTCCAAACGG 1035  
u Gln Lys Pro Cys Leu Cys Gly Tyr Ile Arg Asn Pro Ala Tyr Ser Met Ty r Val Thr Ser Pro Asn Gl

1036 TCGCAAAGTCTTAGATTGTAAGGGTTCCTAGTTGTTAAATCTCTCAAGACATTGCTAAGAAA 1104  
y Arg Lys Val Leu Asp Phe Cys Lys Val Pro Phe Pro Ser Cys

FIG. 7 - 3

HindIII  
 BgIII  
 1105 AAATATTAAATAAAGAATCAAACTAGATCTGATGTTAACATGAATCATGTTATGGTGTGAA 1173  
 1136  
 1173

1174 GCTTATAGCTGAAGTGTGATTATATATGTGTGTGTCCTGCTCAATTGAAACAC 1242

1243 ACACGTTCCCTGATTGGATTAAATTAATTTGAGTTAAAAAAGAAAAGATGGAATGCTATT 1311

EcoRV  
 1312 TATACAAAGTTGATGAAAAAGTGGAAAGTACAATTNGATATCTCCWWCACTTAAGAAATGAAACATAAT 1350

FIG. 7 - 4

*23/43*

- Sall |
- 1381 AGACTTCAAAATGAAATACTAAATTGTGACAAATCAACGGTCGATCGACGAGTTATTAA 1449  
1414
- 1450 AAATTGTGAAGGACTAGCAGTTCAACCAAATGATATTGAAACATATACTAACAAATATGATAATC 1518
- 1519 ATAAAAGAGAAATGGGGGGGGTGTGTTACCAAGAAACCCCTTCTCAGCTCGCTAAACCCCTA 1587
- 1588 CCACTAGAGACCTAGCTCTGACCGTGGCTCATGGTGCCGGAGGTAAACCTTTCCCATGACCC 1656
- 1657 GAAACCTCTTCCAACTCAGAAAACCCCTACATCAAAACCTAGCTCCGACCATGGCTCATCGGG 1725

FIG. 7 - 5

*26/6*

ClaI

1726 TGCCGAAGGTGTAAACCTTCNCTCCCCATAGTTCTCGTAAATGAAAGCTAATTGGGCCAATCGATT 1794  
1789

1795 TTTAATGTTAACCATGCCAAGCCATTCTTATAGGACAATTGTCAAATAAGCATCTTTGAGTTT 1863

1864 GCTCAAAAGTGACACTAGAAGAAAAAGTCACAAAAATGACATTCAATTAAAAGTAAATCCCTAA 1932

1933 TACCTTTGGTTAAATTAAAGTAAACAAATAAAATAAAACAAATAAAAATAAAATGA 2001

2002 AAAAGAAATTTTTATAGTTCAAGATTATAAGTTTGAAATTTTTA 2060

FIG. 7 - 6

25/42

HindIII  
 1 GCTCAC~~T~~TGTTGGAGGGAAACAGAACACTCACAAAAGCTTGGACTGCCAAGACAA 69  
 42

70 ACAACAAGATAAGAAGAAGATCAAAAATGGCTCTCGAATCACTCCAGTGACCTGCAA 138  
 METAlaLeuArgIleThrProValThrLeuGln

EcoRV  
 139 TCGGAGAGATATCGTTGTTTCGTTCTAAGAAGGCCATAATCTCAGATCTCCAAATCGCCN<sub>n</sub> 207  
 SerGluArgTyrArgSerPheSerProLysLysProPheAlaMetAla  
 149

BglII  
 HindIII  
 208 TCCACCCTCGGATCATCACACCCGAAGGTGACAATGCCAAGAAGCCCTTTCAACCTCACCAGGGT 276  
 SerThrLeuGlySerSerThrProLysValAspAsnAlaLysLysProPheGlnProProArgGluVal  
 238

FIG. 8 - 1

26/43

277 CAGTCAGGAGACGCCATGCCACTCCATTCAAATCCATCGAGGGTTGGCT  
HisValGlnValThrHisSerMetProProGlnLysIleGluIlePheLysSerIleGluGlyTrpAla 345

346 GAGCAGAACATATTGGTTCACCTAAAGCCAGTGGAGAAATGTGGCAAGCACAGGATTCTTGCCGGAC  
GluGlnAsnIleLeuValHisLeuLysProValGluLysCysTrpGlnAlaGlnAspPheLeuProAsp 414

415 CCTGCATCTGAAGGATTGTGATGAAACAAGTCAAGGAACTAAGGGCAAGAGCAAAAGGAGATTCCCTGATGAT  
ProAlaSerGluGlyPheAspGluGlnValLysGluLeuArgAlaArgAlaLysGluIleProAspAsp 483

484 TACTTGTGTTGGAGATATGATTACAGAGGAGGCCCTACTACTTACCAACATGCTTAT  
TyrPheValValLeuValGlyAspMetIleThrGluGluAlaLeuProThrTyrGlnThrMETLeuAsn 552

553 ACCCTAGATGGTGTACGGTGTGAGACTGGGCTAGCCTTACGCCTGGACTAGGGCTTGG  
ThrLeuAspGlyValArgAspGluThrGlyAlaSerLeuThrProTrpAlaValTrpThrArgAlaTrp 621

FIG. 8 - 2

27/48

27/48


<b>PvuII</b>  622 ACAGCTGAAGAACAGGCATGGGATCTTCCACACCTATCTACTACCTTCTGGGGGTAGACATG ThrAlaGluGluAsnArgHisGlyAspLeuLeuHisThrTyrLeuTyrLeuSerGlyArgValAspMet 626	<b>AccI</b>  690	<b>BamHI</b>  691 AGGCAGATAACAGAAAGACAATTCAAGTATCTCATTGGGTCAAGGAATGGATCCCTCGTACCGAAAACAGCCCC ArgGlnIleGlnLysThrIleGlnTyrLeuIleGlySerGlyMETAspProArgThrGluAsnSerPro 736	760 TACCTTGGGTTCATCACATCGTTCAAGAGCCACATTGTTCTCACGGAAACACGCCAGG TyrLeuGlyPheIleTyrThrSerPheGlnGluArgAlaThrPheValSerHisGlyAsnThrAlaArg 828
---	---	---	--

FIG. 8 - 3

898 CACGAGCCGCTTATACAAAGATACTCGAAAAGCTATTGGAGATCCGATCCTGATGGCACCGTTCTTGCT  
HisGluThrAlaTyrThrLysIleValGluLysLeuPheGluIleAspProAspGlyThrValLeuAla  
942

967 TTGCCGACATGATGAGGAAAAGATCTCGATGCCGCACACTTGATGTACGATGGCGTGAATGACAGC 1035  
 TheAlaAspMetMetArgLysSleSerMetProAlaLisLeuMETTYraspGlyArgLysAspAspAsn  
 BglII      |  
 990

FIG. 8 - 4

29/45

1036 CTCTTGAACATTTCTGGGGTTGCCAAAGACTCGGGTCTACACCGCCAAAGACTACGCCGACATA 1104  
 LeuPheGluHisPheSerAlaValAlaGlnArgLeuGlyValTyrThrAlaLysAspTyrAlaAspIle  
 1077

1105 C<sup>r</sup>GGAATTCTGGTCGGCGGATTGACCCGCCATCTGGTGAAGGGCGTMAGCG 1173  
LeuGluPheLeuValGlyArgTrpLysValAlaAspLeuThrGlyIleSerGlyGluGlyArgLysAla

SacI |  
 1174 CAAGATTATGTTGGGGTTCACCAAGAATCAGAAAGCTGGAGAGAGCTCAAGGGCGAGCAAAG 1242  
 GluAspTyrValCysGlyLeuProArgIleArgArgLeuGluGluArgAlaGlnGlyArgAlaLys 1228

FIG. 8-5

30/45

PvuII      |  
 1243 GAGGACCTGGTGTCCATTCAAGCTGGATTTCGATAGACAGGTGAAGCTGTGAAGAAA  
 GluGlyProValProPheSerTrpIlePheAspArgGlnValLysLeu  
 1266

1312 GCACTGAGTTCGGTTTCGTGGCTTATGGGTAGAGGTAAAACCTATTAGATGCTGTTCGTGT 1380

1381 AATGTGGTTT'TTTCTCTTGAATCTGGTATTGTGTCGTTGAGTTGCCGTGTTGACTTC 1449

TGTGGCTGTGGACATAATTAGAACTCGTTATGCCATTGATGACGGTGGTTATCGTCTCCCTGGT 1518

1519 GTTTTTATTGTT 1533

FIG. 8 - 6

31/48

1 TGAGAGATAAGTGTGAGAGCATTAGCCTTAGAGAGAGAGAGCTTGTCAGAAAGAATCCACAA 69

HindIII

70 ATGGCATGAAAGCTAACCCCTTGGCATCTCAGCCTTACAACCTTCCCT 117  
METAlaLeuLysLeuAsnProLeuAlaSerGlnProTyrAsnPhePro

FIG. 9A

*32/48*

PstI  
|  
1 ACTTCATGGCTATTGGACAAGAGCTTGCAGACTGCAGAACCGAACACGGTGATCTTCAATMAG  
ThrSerTrpAlaIleTrpThrArgAlaTrpThrArgGlnAsnArgHisGlyAspLeuLeuAsnLys  
..

70 TATCTTACTTGTCTGGACATGAGGCAGATTGAAAGACCATTCAGTACTTGTTGGTTCT 138  
TyrLeuTyrLeuSerGlyArgValAspMetArgGlnIleGluLysThrIleGlnTyrLeuIleGlySer

BamHI  
|  
139 GGAATGGATCCTAGAACAGAGAACAAATCCTTACCTCGG 176  
GlyMETAspProArgThrGluAsnAsnProTyrLeuAla

FIG. 9B

1	CCCCGGTGGGGCGTGCATGTCGGTCACGTGCTCAAAGGAGAACAGAACACGGCGTTCTCTCATCGAC ProValAlaCysMETSerValThrCysSerLysGluAsnArgHisAlaPheSerSerSerThr	69
70	ACCGGGCACCCAGCAGTCACAGTCGTAACAGAGGGAGGCCTAAATAATAAGTATCAGCACCCCTGCrProGlyThrThrSerSerHisSerArgThrArgArgProLysTrpAsnSerIleSerThrProAl	138
139	CTCTCAATCTTAAATTCTTATCATCTCTGGATCCGAGTTTCACAATTAAATGTCCTCTTGCTTaaSerGlnSerPheAsnSerLeuSerSerGlySerSerGlySerPheGlnLeuMETSerSerCysLe	207
208	GGCCCTTCGAGGCCCTGTAGTCATTACTACTACAGCTCTAATGGCCTCTTCCATAACACTCCTCTTCCTAAuAlaPheGluProCysSerHistTyrrSerSerAsnGlyLeuPheProAsnThrProLeuLeuProLy	276
277	GCGCCATCCTAGACTCATCGCCTTCCCTCGTTCTGGGAAGCAAATGGCAGTGGCTGTGCACCTGA sArgHisProArgLeuHisHisArgLeuProArgSerGlyGluAlaMetAlaValAlaValGlnProG1	345
346	AAAGGGGGTTGCAACAAATAAGAACCTCTTATGAAAGCMAAGGAGAGTAGTTACTGGATGGGTGT uLysGluValAlaThrAsnLysProLeuMetLysProLeuLysProLeuLysProLeuLysProG1	414

FIG. 10 - 1

34/48

415	TGTTTCACCCCCTGGTCATGATAAGACGTCTATTACAAATCTTGACGGTTCTAGTGCTATTAG IvalSerProLeuGlyHisAspIleAspValTyrrAsnAsnLeuLeuAspGlySerSerGlyIleSe	483
484	TCAGATTGATTCCCTTGACTGTGCCAATTCTACGAGGATTGCTGGAGAGATCAAGTCTTCTCAC rGlnIleAspSerPheAspCysAlaGlnPheProThrArgIleAlaGlyGluIleLysSerPheSerTh	552
553	TGATGGATGGGTTGCACCAACTTCCAAGAGAATGGATAAATTCAATGCTTACATGCTTACTGCTGG rAspGlyTrpValAlaProLysLeuSerLysArgMetAspLysPheMetLeuThrAlaG1	621
622	CAAAAGCCTTGGCAGATGGTGTATTACAGAGGATATGGATGAATTGGATAAAGCTAGATGCTGG yLysLysAlaLeuAlaAspGlyGlyIleThrGluAspMetMetAspGluLeuAspLysAlaArgCysG1	690
691	AGTTTAATTGGTTCTGCAATGGGGCGATGAAGGTTTCAATTGATGCAATTGAAGCATTMGGATCTC yValLeuIleGlySerAlaMetGlyGlyMetLysValPheAsnAspAlaIleGluAlaLeuArgIleSe	759

FIG. 10 - 2

35/44

760 G<sup>t</sup>TAGGAAGATGAATTCCCTTGGTACCC<sup>t</sup>TTGGACTAACAAATATGGGCTCTGCCATGCTTGCAAT 828  
rTyrArgLysMETasnProPheCysValProPheAlaThrThrAsnMETGlySerAlaMETLeuAlaME

829 GGACCC<sup>t</sup>TGGTGGATGGGCCAAACTATCAATAATCTACTGCTTGTGCTACTAGCAATTGGTGTATATT 897  
TAspIleGlyTrpMetGlyProAsnTyrSerIleSerThrAlaCysAlaThrSerAsnPheCysIleLe

898 GAATGCCCAAACCACCATCATTAGAGGCCAAGCTGATATTATGCTTGTGGTGGCICAGATGCAGCAAT 966  
uAsnAlaAlaAsnHisIleIleArgGlyGluAlaAspIleMETLeuCysGlyGlySerAspAlaAlaI

967 TATACTATTGGCTGGGAGGTTTGTGGCATGCAGAGCGCTCTCACAGAGGAATGATGATCCTACAAA 1035  
eileProIleGlyLeuGlyGlyPheValAlaCysArgAlaLeuSerGlnArgAsnAspAspProThrIly

1036 AGCTTCACGACCTGGGATATGAATCGGGATGGATTTGTGATGGGGAAAGGGCTGGTGTCTTCTTT 1104  
sAlaSerArgProTrpAspMetAsnArgAspGlyPheValMETGlyGluGlyAlaGlyValLeuLeuLe

FIG. 10 - 3

36/48

1105 AGAAGAACTAACATGCTAAGAAAAGAGGTGCCAAATTATGGCGAATTTCCTTGAGGAAGCCTTAC 1173  
uGluGluLeuGluHisAlaLysLysArgGlyAlaAsnIleTyrAlaGluPheLeuGlyGlySerPheTh

1174 ATGTGATGCTTATCACATGACTGAACCGCGTCCAGATGGAGTTGGTGTCAATTCTCTGTATAAGAAAAGGC 1242  
rCysAspAlaTyrHisMetThrGluProArgProAspGlyValGlyValleLeuCysIleGluLysAl

1243 ATTAGCGCGATCTGGTGTATCCAGGAGTAAGTAAACTACATAAAATGCACATGCTACGTCTACCCCCAGC 1311  
aLeuAlaArgSerGlyValSerLysGluGluValAsnTyrIleAsnAlaHisAlaThrSerThrProAl

1312 TGGAGACCTTAAAGAATATGAAGCTCTTATGGCCTGTTCAAGCCAAAATCCTGATTGAGAGTGAACTC 1380  
aGlyAspLeuLysGluTyrGluAlaLeuMETArgCysPheSerGlnAsnProAspLeuArgValAsnSe

1381 TACGAAGTCTATGATTGCCATTACTAGGAGCAGCTGGTGTGAGCTATAGCMAAATACAGGC 1449  
rThrLysSerMetIleGlyHisLeuGlyAlaAlaGlyAlaValGluAlaAlaThrIleGlnAl

37/48

1450 GATA CGGACAGGATGGGTTCAT CAAACATCAACTGGAAAACCCAGAAGAAGGCGTGGACACAAGGT 1518  
alle Arg Thr Gly Trp Val His Pro Asn Ile Asn Leu Glu Asn Pro Glu Glu Gly Val Asp Thr Lys Va

1519 GCTGGTTGGCCCAAAGAACGGAGATTGGACATTAAGGTGCTCTGTCACACTCTTGGTTGGGTGG 1587  
Ile Val Gly Pro Lys Glu Arg Leu Asp Ile Lys Val Ala Leu Ser Asn Ser Phe Gly Phe Gly G1

1588 GCACAACTCATCGATCATTTGCTCCGTACAAGTGAAATAAGGGGTACTTCAACTTGGTGTATAAAC 1656  
Y His Asn Ser Ser Ile Phe Ala Pro Tyro Lys

1657 GTGMAAGATGATCTAAATGGAACAAAGATTAGATAACTCTATGGTAGGGAAAGGAATATGCCGAGT 1725

1726 TCACAGAGAGAAACTTCCC GTGAAGATT CCT ACC ATT TCA GT ATT CCT CCG CAT CAT 1794

1795 TGTGGCTTGA TCCATGTTGATCCATCGAATACCA GGT AACAGTGGCCTTATT TAAATT TTGTCCATGTA 1863

38/48

1864 T<sup>A</sup>AGGCA<sup>G</sup>ACGGCTGATCGTTAACAGTCAATTGTAATGAATTGGTGGACAGTTGAGCTGGCTAGG 1932

1933 T<sup>T</sup>ACACTAATGTAATGGTGGTTATGAGCAAAAAA 1969

FIG. 10 - 6

39/48

1	ATGCCAGACGCCAACGAGACGGCTCATTCA AlaArgGlnProThrArgArgSerPheIleSerAlaSerSerAlaValSerAlaProLysA	69
70	GCGAACACAGACCCGAAGAACGGGTCTGTA rgGluThrAspProLysLysArgValValleThrGlyMETGlyLeuValSerValPheGlyAsnAspV	138
139	TCGACGCTTACTACGAGAACGGCTCTCCGG alAspAlaTyrrTyrgLulyLysLeuLeuSerGlyGluSerGlyIleSerIleAspGlyAspAlas	207
208	CCAAAAGTTCCCGACCCGATTCTGGGGACAGATCC erLysPheProThrArgPheGlyGlyGlnIleArgGlyPheSerSerGluGlyTyrIleAspGlyLysA	276
277	ATGAGGGGGCTTGATGATTGCTTGAAGTACTGC snGluArgArgLeuAspAspCysLeuLysTyrCysIleValAlaGlyLysLysAlaLeuGluSerAlaA	345
346	ATCTTGGTGGTATAAGCTAACACGATTGATAAG snLeuGlyGlyAspLysLeuAsnThrIleAspLysGlnLysAlaGlyValLeuValGlyThrGlyMETG	414

FIG. 11A - 1

40/48

415	GTGGCTTGACTGTGTTTCAGACGGTGTCAAGCTCTTATTGAGAAAGGTCACAGGAGGATTTCCTCCCTT lyGlyLeuThrValPheSerAspGlyValGlnAlaLeuIleGluIleGlyHisArgArgIleSerProP	483
484	TCTTTrATTCCCTATGCT'ATTACAAACATGGGTTCTGCTTGTGGCGATTGATCTTGGCTCTATGGGTC hePheIleProTyRAlaIleThrAsnMetGlySerAlaLeuAlaIleAspLeuGlyLeuMETGlyP	
553	CTAACTACTCGATCTCGACGGCTTGTGCCACTTCAACTACTGCTTTACGCTGCTGCGAATCACATTC roAsnTyrSerIleSerThrAlaCysAlaThrSerAsnTyrCysPheTyRAlaAlaAsnHisIleA	621
622	GACGTGGTGAAGCTGAT'ATGATGATAAGCTGGTGGAAACCAGGGCTATTCTCTATTGGTTGGGAG rgArgGlyGluAlaAspMetMetIleAlaGlyGlyThrGluAlaAlaIleProIleGlyLeuGlyG	690
691	GTTTGTGCTGTAGGGCGCTTTCACAGAGAATGATGATGATCCTCAGACGGCTCAAGGCCGTGGATA lyPheAlaCysArgAlaLeuSerGlnArgAsnAspAspProGlnThrAlaSerArgProTrpAspL	759
760	AACAGAGAGATGGGTTTGTCAAGGGTGAAGGAGCTGGTGTCTGGTGAAGCTTGGAAACATGCGA ysGlnArgAspGlyPheValMetGlyGluGlyAlaGlyValLeuValMetGluSerLeuGluHisAlaM	828

FIG. 11A - 2

829 TGAAACGTGGTGCCTCCAATTGTAGCAGAGTATCTGGAGCCGCTGTTAACTCGCATGGCTCATCATATGA  
E<sup>1</sup>IlysArgGlyAlaProIleValAlaGluTyrLeuGlyGlyAlaValAsnCysAspAlaHisHiSMETT 897

898 CTGATCCAAGAGCTGATGGCTGGTGTCTCATGCCATTGAGACTGCCCTTGAAAGATGCTGGTGTAT  
hrAspProArgAlaAspGlyIleGlyValSerSerCysIleGluSerCysLeuGluAspAlaGlyVals 966

967 CACCTGAGGAGGTAATTACATCAATGCCAACATGCCACTGGCTGGTGTCTGGTGAAGATTAA 1035  
erProGluGluValAsnTyrIleAsnAlaHisAlaThrSerThrLeuAlaGlyAspLeuAlaGluIleA

1036 ATGCCATTAAAAGGTATTCAAAGCACTTCAGGGATCAAATCAATGCCACCAAGTCATGATAGGTC 1104  
snAlaIleLysValPhelysSerThrSerGlyIleLysIleAsnAlaThrLysSerMetIleGlyH

1105 ACTGCCTCGGTGCAGCTGGAGGCCATTGCCACCCGTGAAGGCTATCAACACGGGATGGCTGC 1173  
isCysIleGlyAlaAlaGlyGlyLeuGluAlaIleAlaThrValLysAlaIleAsnThrGlyTrpLeuH

1174 ATCCCTCTATCAACCAATTAAACCCAGCMACCAGCAGTGGACTTTGATAACGGTCGAAACGAGAAGAGGC 1242  
isProSerIleAsnGlnPheAsnProGluProAlaValAspPheAspThrValAlaAsnGluLysLySG

FIG. 11A - 3

1243 AGCATGAGGTGAATGTTGCCATTACAAACTCGTTGGGTTCGGTGGACATAACTCAGTGGTCGCTTTCT 1311  
In His Glu Val Asn Val Ala Ile Ser Asn Ser Phe Gly Phe Gly His Asn Ser Val Val Ala Phe S

1312 CTGCCCTCAACCCCTGATTCCCTCAGACCCTTAGATCCTCTGGTCATCTGTAGATCACCCATCA 1380  
er Ala Phe Lys Pro

1381 TCTTCTTCGAGCTTCTGGTTACAAAGTTGAGGCCCTTTCAGCTTTTGTCTTATGGTC 1449

1450 ATTGTAAATTTCGCTCAACTCTTATTGGTCATTGAGGTGTAAGAGAATCCAGATTGCTTCTACAAATC 1518

1519 TGTGTACGGAAATGTTGTATCTTCGTTTATGTTGCCAAATTAAAC 1573

43/48

1 AACCAACATTGCCGTGGGAAAGCTGATATGATTGCTGGTGGAAACCGAGGCTGCCATTATTCCATT  
AsnHisIleArgArgGlyGluAlaAspMetMetIleAlaGlyGlyThrGluAlaAlaIleProlle 69

70 GGGTGGGAGGGTTGCTGGGGCCTTCGGAGAGGAATGATGACCCTAAACCGCTTCGAGG 138  
GlyLeuGlyGlyPheValAlaCysArgAlaLeuSerGlnArgAsnAspAspProLysThrAlaSerArg

139 CCTTGGATAAACAGAGAGATGGCTTGTAAATGGGTGAGGAGCTGGTGTCTGGTGATGGAAAGCTTG 207  
ProTrpAspLysGlnArgAspGlyPheValMetGlyGluGlyAlaGlyValLeuValMetGluSerLeu

208 GAAACATGGATGAAAGCGTGGTGGCCAATAGTAGCAGAGTATCTTGGAGGGTCTGTAAACTGTGATGCT 276  
GluHisAlaMetIlySargGlyAlaProIleValAlaGluTyrlLeuGlyGlyAlaValAsnCysAspAla

277 CATCATATGACTGATCCAAGAGGCTGACGGGCTTGGTGTCTCATGCATTGAGAGCTGGCTTGAAAGAT  
HisHisMetThrAspProArgAlaAspGlyLeuGlyValSerSerCysIleGluSerCysLeuGluAsp 345

346 GCTGGTGGTCAACCGAGGGTAAATTACATCAATGCCATGCCAACCTTCCACACTGGTGGATCTI 414  
AlaGlyValSerProGluGluValAsnTyrlLeasnAlaHisAlaThrSerThrLeuAlaGlyAspIle

FIG. 11B - 1

44/48

415 GCTGAGATTATGCCATTAAAGGTATTCAAGAGCACTGGTGGATCAAATCAATGCCAACAGTCT  
AlaGlyIleAsnAlaIleLysValPheLysSerThrAlaGlyIleLysIleAsnAlaThrLysSer 483

484 ATGATAGGTCACTGCCTCGGTGCAGGTCTTGAGGCCATTGGCACTGTGAAGGCTATAACACT  
METIleGlyHisCysLeuGlyAlaAlaGlyGlyLeuGluAlaIleAlaThrValLysAlaIleAsnThr 552

553 GGATGGCTCATCCCTCAATCAACCAATTaaCCAGAACCAGCCGGTGGACTTTGACACGGTGGCAAAAC  
GlyTrpLeuHisProSerIleAsnGlnPheAsnProGluProAlaValAspPheAspThrValAlaAsn 621

622 GAGAAGCAGGCATGAGGTGAACGTTGCTTATCAAATTCGTTGGTTGGACACMACTCAGTT  
GluLysLysGlnHisGluValAsnValAlaIleSerAsnSerPheGlyPheGlyGlyHisAsnSerVal 690

691 GTGGCCTCTCTGCCTCAAACCTGATCCTTCAAAGACCTTCTCCAACTAT'TACA  
ValAlaPheSerAlaPheLysPro 759

760 TCACCAACCATCATCCAGGCATCATCTTCCTTGAGCTTCTTGTTCCACGAGTTGAGCTCTT'CCT'CTT 828

FIG. 11B - 2

45/48

829 TGGCGTTTACGTTCCATTCAACATTGTCTTATGTGAGATTCAAATTTGCTCTCAATCG 897

898 TAAGAAATGTTGTATCTGTATCTGAGTCGTTTCATATTCTAAATTAACAGAACCA 966

967 ATAATCTTGTAGCAATGATGTTATTCAAGAGTTCTCAATCTT 1007

FIG. 11B - 3

RC46	RRVVVTGMGVVSPPLGHDIDVYYNNLLDGSSGISQIDSFDCQAQFPTRIAGEIKSFSSTD	57
RC50	KRVVITGTGLSVFVGNDVDTYYDKLLAGESIGLIDRFDASKFPTRGQQIRGFNSQ	57
BC50	KRVVITGMGLSVFVGNDVDAYEKLLSGESEGISLIDRFDASKFPTRGQQIRGFSSSE	57
fabB	MKRAVITGLGIVSIGNNQQEVLASLREGRSGI	57

FIG. 12 - 1

*47/48*

RC46	AANHIIIRGEADIMLCGGSDAAIIPIGLGGFVACRAL S	QRNDDPTKASRPWDMNRDGF	229
RC50	AANHIIIRGEAEILMIAAGGTEAAIIPIGLGGFVACRAL S	QRNDDPQTASRPWDKDRDGF	230
BC50	AANHIIIRGEADMIAAGGTEAAIIPIGLGGFVACRAL S	QRNDDPQTASRPWDKORDGF	230
fabB	AVEQIQLGKQDIVFAGG GEELCWEMACEFDAMGALSTKYNDTPEKASRTYDAHRDGF		229
RC46	VMGEGAGVLLLEEHAKKRGANIYAE FLGGSFTCDAYHMTEPRPDGVGVLICIEKA		286
RC50	VMGEGAGVLMESLEHAMKRGAPIIAE YLGGAVNCDAYHMTDPRADGLGVSSCIERS		287
BC50	VMGEGAGVLMESLEHAMKRGAPIVAE YLGGAVNCDAHHMTDPRADGLGVSSCIESC		287
fabB	VIAGGGMVVVEELHALARGAHIIYAEIVGYGA TSDGADMVAPSSEGAVRCMK		282
RC46	LARSGVSKREEVNYINAHATSTPAGDLKEYEALMRCSQNPDLRVNSTKSMIGHLLGAA		344
RC50	LEDAGVSPEEVNYINAHATSTLAGDLAEINAIIKKVFKNNTSDIKINATKSMIGHCLGAA		345
BC50	LEDAGVSPEEVNYINAHATSTLAGDLAEINAIIKKVFKNSTSGIKINATKSMIGHCLGAA		345
fabB	MAMHGV DTPIDYLNSHGTSVPVGDVKELAIAIREVF GDKSPAISATKAMTGHSLGAA		338

FIG. 12 - 2

48/48

RC46	GAVEAIATIQAIRTGWHPNINLENPE	EGVDTKVLVGPKKERLDIKVALSNSFGFGG	401
RC50	GLEAIAACVKAITTGWLHPTINQFNPE	PSVEFDTVAN KKQQHEVNVAISNSFGFGG	401
BC50	GLEAIAATVKAINNTGWLHPSINQFNPE	PAVDFFDTVANEKKQ HEVNVAISNSFGFGG	401

RC46	HNSIIIFAPYK	412
RC50	HNSVVAFSAFKP	413
BC50	HNSVVAFSAFKP	413

FIG. 12 - 3

# INTERNATIONAL SEARCH REPORT

International Appln No PCT/US91/05801

## I. CLASSIFICATION OF SUBJECT MATTER (If several classification symbols apply, indicate all):

According to International Patent Classification (IPC) or to both National Classification and IPC  
 IPC(5): C12P 7/64; C12N 5/00; C07K 15/00; C07H 15/12  
 U.S.C1.: 435/134, 240.4; 530/ 377; 536/27

## II. FIELDS SEARCHED

Classification System	Minimum Documentation Searched?	
		Classification Symbols
U.S.	435/ 134, 240.4; 530/377 536/27; 800/ 205, Dig. 26, Dig. 69 935/60, 64, 67	
- Documentation Searched other than Minimum Documentation to the Extent that such Documents are Included in the Fields Searched.		

USPTO Automated Patent System. Dialog files: Biotech, Patents  
 See attachment for search terms.

## III. DOCUMENTS CONSIDERED TO BE RELEVANT:

Category	Citation of Document, if with indication, where appropriate, of the relevant passages	Relevant to Claim No
Y	EP, A, 0, 255, 377 (KRIDL et al) 03 February 1988, See entire document.	21-34, 37-39 42-45, 51-52

### \* Special categories of cited documents:

- "A" document defining the general state of the art which is not considered to be of particular relevance
- "E" earlier document but published on or after the international filing date
- "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- "O" document referring to an oral disclosure, use, exhibition or other means
- "P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art

"Z" document member of the same patent family

## IV. CERTIFICATION

Date of the Actual Completion of the International Search

07 JANUARY 1992

Date of Mailing of this International Search Report

28 JAN 1992

International Searching Authority

ISA/US

Signature of Authorized Officer

P. Rhodes

III DOCUMENTS CONSIDERED TO BE RELEVANT (CONTINUED FROM THE SECOND SHEET)		
Category	Citation of Document, with indication, where appropriate, of the relevant passages	Relevant to Claim No
Y	US, A, 4,394,443 (WEISSMAN et al) 19 July 1983, See entire document.	21-34, 37-39 42-45, 51-52
Y	Trends in Biotechnology, Volume 5, Issued 1987, Knauf, "The application of genetic engineering to oilseed crops", pages 40-47. See entire document.	1, 2, 15-16, 18, 21-34 37-39, 42-45 51-52
X	The Plant Cell, Volume 2, Issued April 1990, Napoli et al, "Introduction of a chimeric chalcone synthase gene into petunia results in reversible co-suppression of homologous genes in trans", pages 279-289. See entire document.	21, 24, 28-33 38-39, 42, 44-45, 51-52
Y	Plant Molecular Biology: Proceedings NATO ASI series (Plenum Press), Volume 140, Issued 1987, Slabas et al, "Molecular structure of plant fatty acid synthesis enzymes", pages 265-277. See entire document.	1, 2, 15-16, 18, 21-34 37-39, 42-45 51-52
X	Carlsberg Research Communication, Volume 53, Issued 1988, Kauppinen et al, "B-ketoacyl-ACP synthase I of Escherichia coli: nucleotide sequence of the fabB gene and identification of the cerulenin binding residue", pages 357-370. See entire document.	21, 23, 25, 26 28-29, 31, 38
Y	Proceedings of the National Academy of Sciences USA, Volume 75, Issued October 1982, Shimakata et al, "Isolation and function of spinach leaf B-ketoacyl-[acyl-carrier-protein] synthases", pages 5808-5812. See entire document.	21-22, 24-34 37-39, 42-45 51-52
Y	Biochimica et Biophysica Acta, Volume 1002, Issued March 1989, MacKintosh et al, "A new assay procedure to study the induction of B-ketoacyl-ACP synthase I and II, and the complete purification of B-Ketoacyl-ACP synthase from developing seeds of oilseed rape (Brassica napus)", pages 114-124. See entire document.	1-2, 15-16 18, 21, 23-34 37-39, 42-45 51-52

ATTACHMENT TO FORM PCT/ISA/210:

Part VI. Observations (continued, page 3 of 3)

IX. Claims 53, 57, 62, 65, and 67, drawn to a method of modifying fatty acid composition of plants, classified in Class 435, subclass 172.1, for example.

Note that the following are independent and distinct species pertinent to the invention of Group IX where t) is the first species and will be searched with claims 53, 57, 62, 65, and 67 in the event that no other fees are paid. Note that a search of any other additional species within Group IX requires payment of additional fees.

t) where the encoding sequence is an antisense sequence (claims 54-55 and 63);

u) where the encoding sequence is a sense sequence (claims 56 and 64).

X. Claims 58-61 and 66, drawn to plant cells and seeds having a modified fatty acid composition, classified in Classes 435 and 800, subclasses 240.4 and 250, respectively, for example.

XI. Claims 68-69, drawn to oil, classified in Class 426, subclass 601, for example.

ATTACHMENT TO FORM PCT/ISA/210:

Part VI. Observations (continued, page 2 of 3)

VI. Claims 21, 24-34, 37-39, 42-45, and 51-52 drawn to a recombinant DNA construct encoding a plant synthase and the transgenic plant cells containing same, classified in Classes 435 and 536, subclasses 240.4 and 27, respectively, for example.

Note that the following are independent and distinct species pertinent to the invention of Group VI where h) is the first species and will be searched with claims 21, 24-34, 37-39, 42-45, and 51-52 in the event that no other fees are paid. Note that a search of any other additional species within Group VI requires payment of additional fees.

- h) where the encoded synthase is factor A (claim 22);
- i) where the encoded synthase is factor B (claim 23);
- j) where the encoded synthase is required for longer chain fatty acids (claims 35 and 46);
- k) where the encoded synthase is required for shorter chain fatty acids (claims 36 and 47).

VII. Claim 40, drawn to a second transgenic plant cell comprised of a first DNA construct and a second DNA construct, classified in Class 435, subclass 240.4, for example.

Note that the following are independent and distinct species pertinent to the invention of Group VII where l) is the first species and will be searched with claim 40 in the event that no other fees are paid. Note that a search of any other additional species within Group VII requires payment of additional fees.

- l) where the first component is factor A (claim 22) and the second component is desaturase (claim 41);
- m) where the first component is factor A (claim 22) and the second component is thioesterase (claim 41);
- n) where the first component is factor B (claim 23) and the second component is desaturase (claim 41);
- o) where the first component is factor B (claim 23) and the second component is thioesterase (claim 41);
- p) where the first component is required for longer chain fatty acids (claim 35) and the second component is desaturase (claim 41);
- q) where the first component is required for longer chain fatty acids (claims 35) and the second component is thioesterase (claim 41);
- r) where the first component is required for shorter chain fatty acids (claims 36) and the second component is desaturase (claim 41);
- s) where the first component is required for shorter chain fatty acids (claims 36) and the second component is thioesterase (claim 41);

VIII. Claims 48-50, drawn to a method of making protein, classified in Class 435, subclass 69.1, for example.

ATTACHMENT TO FORM PCT/ISA/210:

**Part VI. Observations Where Unity of Invention is lacking.**

These claims present a plurality of mutually exclusive independent inventions as follows:

I. Claims 1-2 and 15-16, drawn to a first protein product and process of use to make short chain fatty acids, classified in Classes 435 and 530, subclasses 134 and 377, respectively, for example.

Note that the following are independent and distinct species pertinent to the invention of Group I where a) is the first species and will be searched with claims 1-2 and 15-16 in the event that no other fees are paid. Note that a search of any other additional species within Group I requires payment of additional fees.

- a) an in vitro process (claim 18);
  - b) an in vivo process (Claims 19-20);

III. Claims 3-4, drawn to a second protein product, classified in Class 530, subclass 377, for example.

III. Claim 6, drawn to a third protein product, classified in Class 350, subclass 377, for example.

Note that the following are independent and distinct species pertinent to the invention of Group III where c) is the first species and will be searched with claim 6 in the event that no other fees are paid. Note that a search of any other additional species within Group III requires payment of additional fees.

- c) the product where the preparation is from a first major fraction (claims 7-8);
  - d) the product where the preparation is from a later major fraction (claim 9).

IV. Claims 13-14, drawn to a nucleic acid sequence, classified in Class 536, subclass 27, for example.

Note that the following are independent and distinct species pertinent to the invention of Group IV where e) is the first species and will be searched with claims 13-14 in the event that no other fees are paid. Note that a search of any other additional species within Group IV requires payment of additional fees.

- e) the product where the sequence encodes a 50 kd protein of the first major fraction (claim 10);
  - f) the product where the sequence encodes a 46 kd protein of the first major fraction (claim 11);
  - g) the product where the sequence encodes a 50 kd protein of the later major fraction (claim 12).

V. Claim 17, drawn to a process of use for the product of Group II to make long chain fatty acids, classified in Class 435, subclass 134, for example.

FURTHER INFORMATION CONTINUED FROM THE SECOND SHEET

V.  OBSERVATIONS WHERE CERTAIN CLAIMS WERE FOUND UNSEARCHABLE:

This international search report has not been established in respect of certain claims under Article 17(2) (a) for the following reasons:

1.  Claim numbers ..... because they relate to subject matter<sup>12</sup> not required to be searched by this Authority, namely:

2.  Claim numbers ..... because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out<sup>13</sup>, specifically:

3.  Claim numbers ..... because they are dependent claims not drafted in accordance with the second and third sentences of PCT Rule 6.4(a).

VI.  OBSERVATIONS WHERE UNITY OF INVENTION IS LACKING:

This International Searching Authority found multiple inventions in this international application as follows:

see attachment

1.  As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims of the international application.
2.  As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims of the international application for which fees were paid, specifically claims:

1-2, 15-16, 18, 21-34, 37-39, 42-45, 51-52

..... as instructed in the response received 16 December 1991.

3.  No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claim numbers:

4.  As all searchable claims could be searched without effort justifying an additional fee, the International Searching Authority did not invite payment of any additional fee.

Remark on Protest:

- The additional search fees were accompanied by applicant's protest.
- No protest accompanied the payment of additional search fees.

PCT/US91/05801

ATTACHMENT TO FORM PCT/ISA/210  
Part II. FIELDS SEARCHED TERMS

ketoacyl; synthase or synthetase; fatty acid; synthesis or biosynthesis; plant? or seed; spinach or brassica or soybean or ricinus